<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Propionyl‐L‐carnitine for intermittent claudication - Kamoen, V - 2021 | Cochrane Library</title> <meta content="Propionyl‐L‐carnitine for intermittent claudication - Kamoen, V - 2021 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010117.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Propionyl‐L‐carnitine for intermittent claudication - Kamoen, V - 2021 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010117.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD010117.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Propionyl‐L‐carnitine for intermittent claudication" name="citation_title"/> <meta content="Victor Kamoen" name="citation_author"/> <meta content="Ghent University" name="citation_author_institution"/> <meta content="Robert Vander Stichele" name="citation_author"/> <meta content="Ghent University" name="citation_author_institution"/> <meta content="Laurence Campens" name="citation_author"/> <meta content="Dirk De Bacquer" name="citation_author"/> <meta content="Ghent University" name="citation_author_institution"/> <meta content="Luc Van Bortel" name="citation_author"/> <meta content="Ghent University" name="citation_author_institution"/> <meta content="Tine LM de Backer" name="citation_author"/> <meta content="tine.debacker@ugent.be" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="12" name="citation_issue"/> <meta content="10.1002/14651858.CD010117.pub2" name="citation_doi"/> <meta content="2021" name="citation_date"/> <meta content="2022/12/26" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010117.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010117.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010117.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Ankle Brachial Index; Carnitine [therapeutic use]; *Intermittent Claudication [drug therapy]; *Peripheral Arterial Disease [complications]; Randomized Controlled Trials as Topic; Walking" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010117.pub2&amp;doi=10.1002/14651858.CD010117.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010117.pub2&amp;doi=10.1002/14651858.CD010117.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010117.pub2&amp;doi=10.1002/14651858.CD010117.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010117.pub2&amp;doi=10.1002/14651858.CD010117.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010117.pub2&amp;doi=10.1002/14651858.CD010117.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010117.pub2&amp;doi=10.1002/14651858.CD010117.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010117.pub2&amp;doi=10.1002/14651858.CD010117.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010117.pub2&amp;doi=10.1002/14651858.CD010117.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010117.pub2&amp;doi=10.1002/14651858.CD010117.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010117.pub2&amp;doi=10.1002/14651858.CD010117.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010117.pub2&amp;doi=10.1002/14651858.CD010117.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010117.pub2&amp;doi=10.1002/14651858.CD010117.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010117.pub2&amp;doi=10.1002/14651858.CD010117.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010117.pub2&amp;doi=10.1002/14651858.CD010117.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010117.pub2&amp;doi=10.1002/14651858.CD010117.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010117.pub2&amp;doi=10.1002/14651858.CD010117.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010117.pub2&amp;doi=10.1002/14651858.CD010117.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010117.pub2&amp;doi=10.1002/14651858.CD010117.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010117.pub2&amp;doi=10.1002/14651858.CD010117.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010117.pub2&amp;doi=10.1002/14651858.CD010117.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010117.pub2&amp;doi=10.1002/14651858.CD010117.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010117.pub2&amp;doi=10.1002/14651858.CD010117.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010117.pub2&amp;doi=10.1002/14651858.CD010117.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="afU96cMv";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD010117\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD010117\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010117\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010117\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","fa","fr","ms"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD010117.pub2",title:"Propionyl\\u2010L\\u2010carnitine for intermittent claudication",firstPublishedDate:"Dec 26, 2021 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Vascular Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=afU96cMv&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010117.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010117.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD010117.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD010117.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010117.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD010117.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD010117.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD010117.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD010117.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD010117.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>1239 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD010117.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010117.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010117.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010117.pub2/full#CD010117-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010117.pub2/full#CD010117-sec-0066"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010117.pub2/full#CD010117-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010117.pub2/full#CD010117-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010117.pub2/full#CD010117-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010117.pub2/full#CD010117-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010117.pub2/full#CD010117-sec-0039"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010117.pub2/full#CD010117-sec-0060"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010117.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010117.pub2/appendices#CD010117-sec-0071"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010117.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010117.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/table_n/CD010117StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/table_n/CD010117StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010117.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010117.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010117.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010117.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010117.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD010117.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2021 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Propionyl‐L‐carnitine for intermittent claudication</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010117.pub2/information#CD010117-cr-0004">Victor Kamoen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010117.pub2/information#CD010117-cr-0005">Robert Vander Stichele</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010117.pub2/information#CD010117-cr-0006">Laurence Campens</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010117.pub2/information#CD010117-cr-0007">Dirk De Bacquer</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010117.pub2/information#CD010117-cr-0008">Luc Van Bortel</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010117.pub2/information#CD010117-cr-0009"><i class="icon corresponding-author fa fa-envelope"></i>Tine LM de Backer</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/information/en#CD010117-sec-0077">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 26 December 2021 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD010117.pub2">https://doi.org/10.1002/14651858.CD010117.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD010117-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010117-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010117-abs-0011">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010117-abs-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD010117-abs-0008">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD010117-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD010117-abs-0001" lang="en"> <section id="CD010117-sec-0001"> <h3 class="title" id="CD010117-sec-0001">Background</h3> <p>Peripheral arterial disease (PAD) is a manifestation of systemic atherosclerosis. Intermittent claudication is a symptomatic form of PAD that is characterized by pain in the lower limbs caused by chronic occlusive arterial disease. This pain develops in a limb during exercise and is relieved with rest. Propionyl‐L‐carnitine (PLC) is a drug that may alleviate the symptoms of PAD through a metabolic pathway, thereby improving exercise performance. </p> </section> <section id="CD010117-sec-0002"> <h3 class="title" id="CD010117-sec-0002">Objectives</h3> <p>The objective of this review is to determine whether propionyl‐L‐carnitine is efficacious compared with placebo, other drugs, or other interventions used for treatment of intermittent claudication (e.g. exercise, endovascular intervention, surgery) in increasing pain‐free and maximum walking distance for people with stable intermittent claudication, Fontaine stage II. </p> </section> <section id="CD010117-sec-0003"> <h3 class="title" id="CD010117-sec-0003">Search methods</h3> <p>The Cochrane Vascular Information Specialist searched the Cochrane Vascular Specialised Register, CENTRAL, MEDLINE, Embase, and CINAHL databases and the World Health Organization International Clinical Trials Registry Platform and the ClinicalTrials.gov trials register to July 7, 2021. We undertook reference checking and contact with study authors and pharmaceutical companies to identify additional unpublished and ongoing studies. </p> </section> <section id="CD010117-sec-0004"> <h3 class="title" id="CD010117-sec-0004">Selection criteria</h3> <p>Double‐blind randomized controlled trials (RCTs) in people with intermittent claudication (Fontaine stage II) receiving PLC compared with placebo or another intervention. Outcomes included pain‐free walking performance (initial claudication distance ‐ ICD) and maximal walking performance (absolute claudication distance ‐ ACD), analyzed by standardized treadmill exercise test, as well as ankle brachial index (ABI), quality of life, progression of disease, and adverse events. </p> </section> <section id="CD010117-sec-0005"> <h3 class="title" id="CD010117-sec-0005">Data collection and analysis</h3> <p>Two review authors independently selected trials, extracted data, and evaluated trials for risk of bias. We contacted study authors for additional information. </p> <p>We resolved any disagreements by consensus. We performed fixed‐effect model meta‐analyses with mean differences (MDs) and 95% confidence intervals (CIs). We graded the certainty of evidence according to GRADE. </p> </section> <section id="CD010117-sec-0006"> <h3 class="title" id="CD010117-sec-0006">Main results</h3> <p>We included 12 studies in this review with a total number of 1423 randomized participants. A majority of the included studies assessed PLC versus placebo (11 studies, 1395 participants), and one study assessed PLC versus L‐carnitine (1 study, 26 participants). We identified no RCTs that assessed PLC versus any other medication, exercise, endovascular intervention, or surgery. Participants received PLC 1 grams to 2 grams orally (9 studies) or intravenously (3 studies) per day or placebo. </p> <p>For the comparison PLC versus placebo, there was a high level of both clinical and statistical heterogeneity due to study size, participants coming from different countries and centres, the combination of participants with and without diabetes, and use of different treadmill protocols. We found a high proportion of drug company‐backed studies. The overall certainty of the evidence was moderate. </p> <p>For PLC compared with placebo, improvement in maximal walking performance (ACD) was greater for PLC than for placebo, with a mean difference in absolute improvement of 50.86 meters (95% CI 50.34 to 51.38; 9 studies, 1121 participants), or a 26% relative improvement (95% CI 23% to 28%). Improvement in pain‐free walking distance (ICD) was also greater for PLC than for placebo, with a mean difference in absolute improvement of 32.98 meters (95% CI 32.60 to 33.37; 9 studies, 1151 participants), or a 31% relative improvement (95% CI 28% to 34%). Improvement in ABI was greater for PLC than for placebo, with a mean difference in improvement of 0.09 (95% CI 0.08 to 0.09; 4 studies, 369 participants). Quality of life improvement was greater with PLC (MD 0.06, 95% CI 0.05 to 0.07; 1 study, 126 participants). Progression of disease and adverse events including nausea, gastric intolerance, and flu‐like symptoms did not differ greatly between PLC and placebo. </p> <p>For the comparison of PLC with L‐carnitine, the certainty of evidence was low because this included a single, very small, cross‐over study. Mean improvement in ACD was slightly greater for PLC compared to L‐carnitine, with a mean difference in absolute improvement of 20.00 meters (95% CI 0.47 to 39.53; 1 study, 14 participants) or a 16% relative improvement (95% CI 0.4% to 31.6%). We found no evidence of a clear difference in the ICD (absolute improvement 4.00 meters, 95% CI ‐9.86 to 17.86; 1 study, 14 participants); or a 3% relative improvement (95% CI ‐7.4% to 13.4%). None of the other outcomes of this review were reported in this study. </p> </section> <section id="CD010117-sec-0007"> <h3 class="title" id="CD010117-sec-0007">Authors' conclusions</h3> <p>When PLC was compared with placebo, improvement in walking distance was mild to moderate and safety profiles were similar, with moderate overall certainty of evidence. Although In clinical practice, PLC might be considered as an alternative or an adjuvant to standard treatment when such therapies are found to be contraindicated or ineffective, we found no RCT evidence comparing PLC with standard treatment to directly support such use. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD010117-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010117-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010117-abs-0012">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010117-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD010117-abs-0009">Français</a> </li> <li class="section-language"> <a class="" href="full/ms#CD010117-abs-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD010117-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD010117-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD010117-abs-0002" lang="en"> <h3>Propionyl‐L‐carnitine for intermittent claudication</h3> <p><b>Background</b> </p> <p>Peripheral arterial disease (PAD), most often due to systemic atherosclerosis, affects 4% to 12% of the population aged 55 to 70 years and up to 20% of people over 70 years of age. Peripheral arterial disease tends to be more common in men overall, but woman have more asymptomatic PAD. Approximately 10% to 35% of those affected with PAD report intermittent claudication. Intermittent claudication is characterized by pain in the legs or buttocks that occurs with exercise and subsides with rest. Compared with age‐matched controls, people with intermittent claudication have a six‐fold increased risk of cardiovascular mortality. Treatment should include all measures of prevention for cardiovascular disease, which include cessation of smoking, exercise, and treatment for hypertension, diabetes, and cholesterol. Antiplatelet medications and statins are given to reduce the risk of cerebrovascular and coronary events. </p> <p>To improve symptoms of claudication, regular (supervised) exercise and smoking cessation are the mainstay in the management of intermittent claudication. Drug treatments can include, besides antiplatelets and lipid‐lowering agents, vasoactive agents to improve blood flow, reduce pain, and improve walking distance. A minority of people with intermittent claudication undergo endovascular intervention or vascular surgery. Many pharmacological agents have been advocated for treating intermittent claudication, but none have gained worldwide acceptance. Few show some mild to moderate improvement in walking performance and are prudently proposed in the guidelines. Propionyl‐L‐carnitine (PLC) is a drug that may alleviate symptoms of PAD through a metabolic pathway, thereby improving exercise performance. </p> <p><b>Key results</b> </p> <p>A search for relevant articles on propionyl‐L‐carnitine for treatment of intermittent claudication identified 12 relevant trials that matched our inclusion criteria (current until July 2021). In 11 studies, participants received either 1 gram to 2 grams oral PLC (9 studies) or intravenous propionyl‐L‐carnitine (3 studies) per day or placebo. One study compared propionyl‐L‐carnitine with L‐carnitine. Studies comparing PLC against other interventions such as exercise, other medication, endovascular intervention, or vascular surgery were not identified. </p> <p>Maximum walking distance (or absolute claudication distance (ACD)) is the distance walked during a standardized test at which the participant stops walking due to muscular cramps. Pain‐free walking distance (or initial claudication distance (ICD)) is the distance walked during a standardized test until the start of pain. ACD and ICD were the outcomes of the review parameters and showed moderate improvement: for ACD, participants on propionyl‐L‐carnitine walked 50.86 meters or 26% farther than participants on placebo; for ICD, participants on propionyl‐L‐carnitine walked 32.98 meters or 31% farther than participants on placebo. Propionyl‐L‐carnitine participants showed improvement in ankle brachial index of 0.09 over placebo participants. Improvement in quality of life was also greater in the propionyl‐L‐carnitine group; however, this was based on the findings of only one study. Adverse events of propionyl‐L‐carnitine were similar to those of placebo and mainly consisted of nausea, gastric intolerance, and flu‐like symptoms. Propionyl‐L‐carnitine seemed to be a well‐tolerated and safe drug. </p> <p>In the single propionyl‐L‐carnitine versus L‐carnitine study, participants on propionyl‐L‐carnitine showed significantly greater improvement in walking performance compared to those receiving L‐carnitine (ACD and ICD). This study did not report on the other outcomes of this review. </p> <p><b>Certainty of the evidence</b> </p> <p>Overall certainty of the evidence was moderate (for propionyl‐L‐carnitine compared with placebo) or low (for propionyl‐L‐carnitine compared with L‐carnitine) because of differences between studies such as participants coming from different countries and centres, participants with and without diabetes, use of different treadmill protocols, small numbers of participants, and short follow‐up times, respectively. </p> <p><b>Conclusion</b> </p> <p>When propionyl‐L‐carnitine was compared with placebo, improvement in walking distance was mild to moderate and safety profiles were similar, with overall moderate certainty of the evidence. Although in clinical practice, propionyl‐L‐carnitine might be considered a useful alternative medicine or addition to standard treatment when such therapies are contraindicated or ineffective, we found no clinical trial evidence comparing propionyl‐L‐carnitine with standard treatment to directly support such use. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD010117-sec-0066" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD010117-sec-0066"></div> <h3 class="title" id="CD010117-sec-0067">Implications for practice</h3> <section id="CD010117-sec-0067"> <p>For symptomatic PAD, treatment includes maximal risk modification, exercise, and, when indicated, invasive treatment consisting of balloon angioplasty with or without stenting and/or bypass surgery. Additionally, several pharmacological substances have been tested to determine if they improve walking capacity. The efficacy of many of these drugs is controversial. Based on results of this review, PLC appears to have some potential in the treatment of IC in the studied population. The participant pool from this review, with average baseline ACD, ICD, and ABI of 189 meters, 120 meters, and 0.69 meters, respectively, is already in an advanced stage of IC (Fontaine class IIb). One study tested participants with a baseline ACD greater than 250 meters, but PLC was not effective in this population (<a href="./references#CD010117-bbs2-0004" title="BrevettiG , DiehmC , LambertD . European multicenter study on propionyl-l-carnitine in intermittent claudication. Journal of American College of Cardiology1999;34(5):1618-24. ">Brevetti 1999</a>). So, treatment with PLC in clinical practice might be considered for patients with IC with a rather advanced limitation of their walking performance when classic treatments are not sufficient or feasible. The increase in ABI was statistically significant, but the net effect size is probably too small to detect differences in clinical practice. </p> <p>PLC has no place in standard treatment. PLC treatment might be considered in practice adjuvant to exercise and other conservative interventions, when these seem insufficient for symptom relief. In cases where endovascular procedures or invasive surgery is not indicated or contraindicated, PLC might be considered for symptomatic treatment on a patient‐by‐patient basis; however no RCT evidence was found comparing PLC with standard treatment to directly support such use. </p> <p>In terms of adverse events, overall, no remarkable differences were seen between intervention arms. Mainly gastric and intestinal problems were observed, occurring evenly in all arms. The tolerance and safety of this drug appear to be acceptable. PLC could be given to IC patients as try‐out medicine. When the intervention does not bring improvement in symptoms after a certain period (e.g. three to six months), it can easily be stopped. It should be emphasized that this review did not assess the effectiveness of PLC for mortality or other hard endpoints, and there is no evidence that it slows down the evolution of PAD. PLC may be considered only potential symptomatic treatment to improve quality of life by improving walking performance. </p> </section> <h3 class="title" id="CD010117-sec-0068">Implications for research</h3> <section id="CD010117-sec-0068"> <p>In the past 25 years, several PLC trials on people with IC have been conducted. In these studies, outcomes were mainly the primary and secondary outcomes of this review (ACD, ICD, ABI). Future trials should systematically include a robust quality of life assessment. Walking performances are essential in the evaluation of IC; however evidence could be stronger if psychosocial effects and the global well‐being of a drug intervention are also evaluated. Following up on "fate of the claudicant limb" in longitudinal studies and cost‐effectiveness of the drug treatment, whoever is the payer, could also be useful outcomes. </p> <p>All but one of the studies included in this review were studies on the efficacy of PLC versus placebo. More research with this medication could be done, such as head‐to‐head comparisons with other vasoactive drugs. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD010117-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD010117-sec-0008"></div> <div class="table" id="CD010117-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Propionyl‐L‐carnitine compared to placebo for intermittent claudication</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Propionyl‐L‐carnitine compared to placebo for intermittent claudication</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with intermittent claudication<br/><b>Setting:</b> outpatient setting<br/><b>Intervention:</b> propionyl‐L‐carnitine<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo/control</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with propionyl‐L‐carnitine</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute claudication distance (MWD + PWT) (in meters)</p> <p>Follow‐up: 3 weeks to 1 year</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean change in ACD in placebo group was 59.89 m</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 50.86 m higher<br/>(50.34 higher to 51.38 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1121<br/>(9 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Initial claudication distance (PFWD + COT) (in meters)</p> <p>Follow‐up: 90 days to 1 year</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean change in ICD in placebo group was 32.24 m</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 32.98 m higher<br/>(32.6 higher to 33.37 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1151<br/>(9 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean change in QoL score in placebo group was 0.01</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.06 higher<br/>(0.05 higher to 0.07 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Progression of disease (to Fontaine stage III or IV, or necessity for intervention (endovascular or surgery)) </p> <p>Follow‐up: 1 year</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>1 study evaluated progression of disease: 5/242 (2%) PLC participants evolved from Fontaine stage II to stage III (rest pain) vs 10/243 (4%) placebo participants; 2/242 (0.8%) PLC participants evolved to Fontaine stage IV (critical ischemia) vs 0/243 (0%) placebo participants </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>485</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low</b><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Side effects of propionyl‐L‐carnitine regimen</p> <p>Follow‐up: 6 months to 1 year</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><a href="./references#CD010117-bbs2-0003" title="BrevettiG , PernaS , SabbaC , MartoneVD , CondorelliM . Propionyl-L-carnitine in intermittent claudication: double-blind, placebo-controlled, dose titration, multicenter study. Journal of American College of Cardiology1995;26(6):1411-6. BrevettiG , PernaS , SabbaC , MartoneVD , Di IorioA , BarlettaG . Effect of propionyl-L-carnitine on quality of life in intermittent claudication. American Journal of Cardiology1997;79(6):777-80. ">Brevetti 1995</a>: 7 AEs in placebo group and 5 AEs in PLC group not requiring drug discontinuation. Nausea and gastric pain were the most frequent side effects; 11 AEs resulting in drug discontinuation occurred in the PLC group, and 3 in the placebo group. According to study authors, medical problems requiring drug discontinuation in the PLC group were unrelated to study medication </p> <p><a href="./references#CD010117-bbs2-0004" title="BrevettiG , DiehmC , LambertD . European multicenter study on propionyl-l-carnitine in intermittent claudication. Journal of American College of Cardiology1999;34(5):1618-24. ">Brevetti 1999</a>: 27 PLC participants discontinued the study because of the occurrence of serious AEs (mainly cardiac and peripheral vascular). In the placebo group, 30 AEs required study discontinuation. 38 AEs not requiring drug discontinuation occurred in the PLC group vs 98 in the placebo group; flu syndrome was the most frequent AE without a difference in occurrence between arms </p> <p><a href="./references#CD010117-bbs2-0005" title="CotoV , D'AlessandroL , GrattarolaG , ImparatoL , LingettiM , ManciniM , et al. Evaluation of the therapeutic efficacy and tolerability of levocarnitine propionyl in the treatment of chronic obstructive arteriopathies of the lower extremities: a multicentre controlled study vs. placebo. Drugs under Experimental and Clinical Research1992;18(1):29-36. ">Coto 1992</a>: 3 AEs requiring study interruption in the PLC group and 6 in the placebo group. The most common AE was abdominal pain </p> <p><a href="./references#CD010117-bbs2-0008" title="HiattWR , RegensteinerJG , CreagerMA , HirschAT , CookeJP , OlinJW , et al. Propionyl-L-carnitine improves exercise performance and functional status in patients with claudication. American Journal of Medicine2001;110(8):616-22. ">Hiatt 2001</a> and <a href="./references#CD010117-bbs2-0009" title="HiattWR , CreagerMA , AmatoA , BrassEP . Effect of propionyl-L-carnitine on a background of monitored exercise in patients with claudication secondary to peripheral arterial disease. Journal Cardiopulmonary Rehabilitation Prevention2011;31(2):125-32. [NCT00399919]">Hiatt 2011</a>: no mention of important differences in side effects between 2 intervention arms: 70% of PLC participants and 68% of placebo participants experienced 1 or more AEs; AEs that affected more than 5% of participants in either group with a ratio &gt; 1.5 PLC vs placebo included nausea, diarrhea, bronchitis, and back pain </p> <p><a href="./references#CD010117-bbs2-0012" title="SignorelliSS , FatuzzoP , RapisardaF , NeriS , FerranteM , Oliveri ContiG , et al. A randomised, controlled clinical trial evaluating changes in therapeutic efficacy and oxidative parameters after treatment with propionyl-L-carnitine in patients with peripheral arterial disease requiring hemodialysis. Drugs and Aging2006;23(3):263-70. SignorelliSS , FatuzzoP , RapisardaF , NeriS , FerranteM , Oliveri ContiG , et al. Propionyl-L-carnitine therapy: effects on endothelin-1 and homocysteine levels in patients with peripheral arterial disease and end-stage renal disease. Kidney &amp; Blood Pressure Research2006;29(2):100-7. ">Signorelli 2006b</a>: no AEs </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1303</p> <p>(6 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p><b>moderate</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall, PLC appears to be a safe and well‐tolerated drug, as no significant differences with placebo can be found in studies with follow‐up from 6 months to 1 year </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ankle brachial index (ABI)</p> <p>Follow‐up: 4 months to 1 year</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Mean ABI in control group was ‐0.02</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>MD 0.09 higher<br/>(0.08 higher to 0.09 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>369<br/>(4 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p><b>moderate</b><sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>ABI:</b> ankle brachial index; <b>ACD:</b> absolute claudication distance; <b>AE:</b> adverse event; <b>CI:</b> confidence interval; <b>COT:</b> claudication onset time; <b>ICD:</b> initial claudication distance; <b>MD:</b> mean difference; <b>MWD:</b> maximum waking distance; <b>PFWD:</b> pain‐free walking distance; <b>PLC:</b> propionyl‐L‐carnitine; <b>PWT:</b> peak walking time; <b>QoL:</b> quality of life. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by one level due to high heterogeneity between studies. Furthermore, the overall estimate of effect reflects mainly results of the studies of Brevetti (largest numbers of participants); however in these studies, subgroups were not reported (?publication bias) and there was a marked center effect. Overall results were relatively consistent among studies. The same remarks apply for all outcomes.<br/><sup>b</sup>Downgraded by one level because this was investigated in only one study.<br/><sup>c</sup>Downgraded by two levels because this outcome was investigated in only one study and the absolute number of events in this study was low.<br/><sup>d</sup>Downgraded by one level because causal relationship of different adverse events was not fully explained.<br/><sup>e</sup>Downgraded by one level because this outcome was investigated in a small number of studies (four studies). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010117-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Propionyl‐L‐carnitine compared to L‐carnitine for intermittent claudication</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Propionyl‐L‐carnitine compared to L‐carnitine for intermittent claudication</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with intermittent claudication<br/><b>Setting:</b> outpatient setting<br/><b>Intervention:</b> propionyl‐L‐carnitine<br/><b>Comparison:</b> L‐carnitine </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with L‐carnitine</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with propionyl‐L‐carnitine</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute claudication distance (in meters)</p> <p>Follow‐up: 4 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean ACD in control group was 36.00 m</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 20 m higher<br/>(0.47 higher to 39.53 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Initial claudication distance (in meters)</p> <p>Follow‐up: 4 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean ICD in control group was 23.00 m</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 4 m higher<br/>(9.86 lower to 17.86 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>See comments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The single included study in this comparison did not report this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Progression of disease (to Fontaine stage III or IV or necessity for intervention (endovascular or surgery)) </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>See comments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The single included study in this comparison did not report this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Side effects of propionyl‐L‐carnitine regimen</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>See comments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The single included study in this comparison did not report this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ankle brachial index</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>See comments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The single included study in this comparison did not report this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>ACD:</b> absolute claudication distance; <b>CI:</b> confidence interval; <b>ICD:</b> initial claudication distance; <b>MD:</b> mean difference. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by two levels because results are based on a single study with borderline or no statistically significant results. Moreover, this study is a cross‐over study with few participants and limited follow‐up time (four days), as well as several risk of bias issues. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD010117-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD010117-sec-0009"></div> <p>Abbreviation list: see <a href="./appendices#CD010117-sec-0072">Appendix 1</a>. </p> <section id="CD010117-sec-0010"> <h3 class="title" id="CD010117-sec-0010">Description of the condition</h3> <p>Atherosclerosis is a common form of sclerosis in arteries, including those in the legs. Atheromas containing cholesterol, lipoid material, and lipophages are formed within the intima and the inner media of large and medium‐sized arteries, causing arterial narrowing and reducing blood flow to the lower limbs, at rest or during exercise. Peripheral arterial disease (PAD) is defined as occlusive atherosclerosis of the lower extremity arteries or the arteries distal to the aortic bifurcation (<a href="./references#CD010117-bbs2-0045" title="HiattWR , GoldstoneJ , SmithS , McDermottM , MonetaG , OkaR , NewmanA , PearceWH . Atherosclerotic Peripheral Vascular Disease Symposium II. Nomenclature for vascular diseases. Circulation2008;118(25):2826–9.">Hiatt 2008</a>). </p> <p>A widely accepted international classification of PAD is Fontaine’s classification (<a href="./references#CD010117-bbs2-0038" title="FontaineVR , KimM , KienyR . Surgical treatment for peripheral vascular disease [Die chirurgische Behandlung der peripherern Durchblutungsstorungen]. Helvetica Chirurgica Acta1954;5/6:499-533.">Fontaine 1954</a>); asymptomatic patients are stage I, those with intermittent claudication (IC) are stage II, with rest pain stage III, and with trophic lesions stage IV. It is estimated that PAD occurs in approximately 12% of the adult population, and the prevalence increases with advancing age, such that almost 20% of people over 70 years of age have the disease (<a href="./references#CD010117-bbs2-0043" title="HiattWR , HoagS , HammanRF . Effect of diagnostic criteria on the prevalence of peripheral arterial disease. The San Luis Valley Diabetes Study. Circulation1995;91(5):1472-9.">Hiatt 1995</a>). In the United Kingdom, one in five of the late middle‐aged (65 to 75 years) population has evidence of PAD on clinical examination, although only a quarter of them have symptoms (<a href="./references#CD010117-bbs2-0039" title="FowkesFG , HousleyE , CawoodEH , MacIntyreCC , RuckleyCV , PrescottRJ . Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. International Journal of Epidemiology1991;20(2):384-92.">Fowkes 1991</a>). In a Swedish population‐based point‐prevalence study, women are reported to have higher prevalence of asymptomatic PAD and severe limb ischemia, but for intermittent claudication, there are no sex differences (<a href="./references#CD010117-bbs2-0053" title="SigvantB , Wiber-HedmanK , BergqvistD , RolandssonO , AndersonB , PerssonE , et al. A population-based study of peripheral arterial disease prevalence with special focus on critical limb ischemia and sex differences. Journal of Vascular Surgery2007;45(6):1185-91.">Sigvant 2007</a>). </p> <p>The evolution from asymptomatic to symptomatic disease, the severity of symptoms in IC, and the transition to stages III and IV are influenced by the extent of anatomical narrowing of affected vessel(s) and the existence of a collateral circulation. </p> <p>Intermittent claudication, stage II of Fontaine’s classification, is defined by leg muscle pain, cramping, and fatigue that are evoked by exercise and are relieved on rest. The overall incidence rate of IC is 6.4 per 1000 person‐years (<a href="./references#CD010117-bbs2-0048" title="MeijerWT , CostB , BernsenRM , HoesAW . Incidence and management of intermittent claudication in primary care in The Netherlands. Scandinavian Journal of Primary Health Care2002;20(1):33-4.">Meijer 2002</a>). The prevalence of IC appears to increase from about 3% in patients aged 40 years to 6% in patients aged 60 years (<a href="./references#CD010117-bbs2-0051" title="NorgrenL , HiattWR , DormandyJA , NehlerMR , HarrisKA , FowkesFG , et al. Inter-society consensus for the management of peripheral arterial disease (TASC II). European Journal of Vascular and Endovascular Surgery2007;33 (Suppl 1):1-75.">Norgren 2007</a>). Intermittent claudication is a cardinal symptom of lower extremity PAD. It is caused by atherosclerosis in the peripheral arteries of the legs, leading to an insufficient blood supply during exercise, which causes anaerobic metabolism in the muscles with production of lactic acid and other metabolites. When PAD becomes more severe, the worsening ischemia leads to rest pain, ulceration, gangrene, and tissue loss. Intermittent claudication is indicative of systemic atherosclerosis, representing an independent risk factor for cardiovascular morbidity and mortality. The annual overall major cardiovascular event rate (myocardial infarction, ischemic stroke, and vascular death) in patients with IC is approximately 5% to 7% (<a href="./references#CD010117-bbs2-0051" title="NorgrenL , HiattWR , DormandyJA , NehlerMR , HarrisKA , FowkesFG , et al. Inter-society consensus for the management of peripheral arterial disease (TASC II). European Journal of Vascular and Endovascular Surgery2007;33 (Suppl 1):1-75.">Norgren 2007</a>). One to three per cent of patients with IC will need major amputation within five years (<a href="./references#CD010117-bbs2-0051" title="NorgrenL , HiattWR , DormandyJA , NehlerMR , HarrisKA , FowkesFG , et al. Inter-society consensus for the management of peripheral arterial disease (TASC II). European Journal of Vascular and Endovascular Surgery2007;33 (Suppl 1):1-75.">Norgren 2007</a>). </p> <p>Strategies for management of symptomatic as well as asymptomatic PAD consist of conservative treatment with risk factor modification and exercise. For symptomatic PAD, treatment includes maximal risk factor modification, exercise, and, when indicated, invasive treatment consisting of balloon angioplasty with or without stenting and bypass surgery. Additionally, for symptomatic treatment, several pharmacological agents have been tested to improve walking capacity. The pharmacological management of IC is yet to be precisely defined. To date, drugs with proven efficacy for prevention of major cardiovascular and cerebrovascular events include antiplatelets, angiotensin‐converting enzyme (ACE) inhibitors, and lipid‐lowering drugs (mainly statins, which also have proven benefit for walking distance). Several oral vasoactive drugs claim to increase walking capacity among patients with IC, but robust data are lacking (<a href="./references#CD010117-bbs2-0050" title="MoherD , PhamB , AusejoM , SaenzA , HoodS , BarberGG . Pharmacological management of intermittent claudication: a meta-analysis of randomized trials. Drugs2000;59(5):1057-70.">Moher 2000</a>). No single drug has gained full acceptance for its use in IC. Only oral naftidrofuryl and cilostazol have evidence (documented by Cochrane analyses) of moderately increased walking capacity (<a href="./references#CD010117-bbs2-0031" title="BrownT , ForsterRB , CleanthisM , MikhailidisDP , StansbyG , StewartM . Cilostazol for intermittent claudication. Cochrane Database of Systematic Reviews2021, Issue 6. Art. No: CD003748. [DOI: 10.1002/14651858.CD003748.pub5]">Brown 2021</a>; <a href="./references#CD010117-bbs2-0032" title="De BackerTLM , Vander SticheleR , De BuyzereM , De BackerG , Van BortelL . Silence of the limbs: pharmacological symptomatic treatment of intermittent claudication. Current Vascular Pharmacology2010;8(3):383-7.">De Backer 2010</a>; <a href="./references#CD010117-bbs2-0033" title="deBackerTLM , Vander SticheleR , LehertP , Van BortelL . Naftidrofuryl for intermittent claudication. Cochrane Database of Systematic Reviews2012, Issue 12. Art. No: CD001368. [DOI: 10.1002/14651858.CD001368.pub4]">De Backer 2012</a>). </p> </section> <section id="CD010117-sec-0011"> <h3 class="title" id="CD010117-sec-0011">Description of the intervention</h3> <p>Vasoactive drugs may have a place in the pharmacological management of symptomatic PAD, in addition to lifestyle modification and basic cardiovascular pharmacotherapy, when revascularization is not indicated, when exercise therapy is not feasible, or when benefit is insufficient despite maximal treatment. In the current review, propionyl‐L‐carnitine is tested as a pharmacological agent for use in PAD. </p> <p>Treatment should achieve improvement in functional capacity, that is, an increase in walking distance, reduced symptoms, enhanced quality of life, inhibition of the progression of atherosclerotic lesions, and reduction in cardiovascular and cerebrovascular morbidity and mortality. In keeping with European and American regulatory guidelines, improvement in functional capacity is assessed by measuring improvement in walking distance among patients. </p> </section> <section id="CD010117-sec-0012"> <h3 class="title" id="CD010117-sec-0012">How the intervention might work</h3> <p>Propionyl‐L‐carnitine is an acyl derivative, the propionyl ester of levo‐carnitine (L‐carnitine). Levo‐carnitine is an endogenous quaternary amine that is synthesized in the liver and kidneys. </p> <p>Propionyl‐L‐carnitine has been postulated to improve walking capacity in patients with PAD by causing: </p> <p> <ul id="CD010117-list-0001"> <li> <p>an increase in total carnitine content in ischemic muscle, improvement in muscle metabolism and stimulation of oxidative phosphorylation, and a decrease in plasma lactate concentration on exercise; </p> </li> <li> <p>improvement in endothelial function; and</p> </li> <li> <p>improvement in the micro‐architecture of the micro‐vascularization.</p> </li> </ul> </p> <p>Under normal metabolic conditions, fuel substrates such as fatty acids and carbohydrates are converted to acyl–coenzyme A (CoA) intermediates to be used in Krebs’ cycle for complete oxidation. These CoA‐coupled intermediates are linked to the cellular carnitine pool through the reversible transfer of acyl groups between carnitine and CoA. One function of carnitine is to serve as a buffer to the acyl‐CoA pool by the formation of acylcarnitines (<a href="./references#CD010117-bbs2-0044" title="HiattWR . Carnitine and peripheral arterial disease. Annals of the New York Academy of Sciences2004;1033:92-8.">Hiatt 2004</a>). Hence, during conditions of metabolic stress, incomplete oxidation or incomplete utilization of acyl‐CoA will lead to its accumulation (<a href="./references#CD010117-bbs2-0044" title="HiattWR . Carnitine and peripheral arterial disease. Annals of the New York Academy of Sciences2004;1033:92-8.">Hiatt 2004</a>). L‐carnitine plays a crucial role in transporting fatty acids, which are coupled with acyl‐CoA, from the cytosol to the mitochondrial matrix for oxidative metabolism (<a href="./references#CD010117-bbs2-0037" title="EvansAM , FornasiniG . Pharmacokinetics of L-carnitine. Clinical Pharmacokinetics2003;42(11):941-67.">Evans 2003</a>). </p> <p>Propionyl‐L‐carnitine has several actions.</p> <p> <ul id="CD010117-list-0002"> <li> <p>It increases total carnitine content in ischemic muscle, improves muscle metabolism and stimulates oxidative phosphorylation, and decreases plasma lactate concentration on exercise. </p> </li> </ul> </p> <p> <ul class="plain" id="CD010117-list-0003"> <li> <ul id="CD010117-list-0004"> <li> <p>Pharmacodynamic studies in patients with PAD show that propionyl‐L‐carnitine facilitates fatty acid oxidation by increasing intracellular levels of L‐carnitine, adenosine, and adenosine‐5'‐triphosphate (ATP) (<a href="./references#CD010117-bbs2-0030" title="BrevettiG , FaninM , De AmicisV , CarrozzoR , Di LelloF , MartoneVD , et al. Changes in skeletal muscle histology and metabolism in patients undergoing exercise deconditioning: effect of propionyl-L-carnitine. Muscle and Nerve1997;20(9):1115-20.">Brevetti 1997</a>). Maintaining the rate of fatty acid oxidation would permit glucose utilization to decrease, thus preserving muscle glycogen content and ensuring maximal rates of oxidative ATP production. Depletion of muscle glycogen has been linked to fatigue, thus glycogen preservation might be inherently performance enhancing (carnitine study; <a href="./references#CD010117-bbs2-0028" title="BrassEP , HiattWR . The role of carnitine and carnitine supplementation during exercise in man and in individuals with special needs. Journal of the American College of Nutrition1998;17(3):207-15.">Brass 1998</a>). </p> </li> </ul> <ul id="CD010117-list-0005"> <li> <p>Within mitochondria, free carnitine, acting as an acetyl group buffer, reduces the acetyl‐CoA/CoA ratio with the formation of acylcarnitine, thus stimulating pyruvate dehydrogenase activity, because acetyl‐CoA is an end‐product inhibitor of pyruvate dehydrogenase. This acyl scavenging process, which requires adequate availability of carnitine, becomes crucial under conditions of limited oxygen availability when deficiency of free CoA limits the mitochondrial oxidation of both pyruvate and α‐ketoglutarate (and thus continuation of the pyruvate dehydrogenase complex and Krebs' cycle). The concurrent accumulation of CoA esters results in inhibition of the enzymes involved (<a href="./references#CD010117-bbs2-0028" title="BrassEP , HiattWR . The role of carnitine and carnitine supplementation during exercise in man and in individuals with special needs. Journal of the American College of Nutrition1998;17(3):207-15.">Brass 1998</a>). Accumulation of acetylcarnitine itself provides a store of acetyl groups, which are readily available for transacetylation back to acetyl‐CoA for utilization by Krebs’ cycle. Increased levels of short‐chain acylcarnitines, most often acetylcarnitine, occur in muscle and plasma of normal individuals performing maximal exercise. In patients with PAD stage II of Fontaine's classification, increased carnitine esterification with accumulation of acylcarnitines may occur even at rest (<a href="./references#CD010117-bbs2-0018" title="BrevettiG , di LisaF , PernaS , MenabóR , BarbatoR , MartoneVD , et al. Carnitine-related alternations in patients with intermittent claudication: indication for a focused carnitine therapy. Circulation1996;93(9):1685-9. ">Brevetti 1996</a>). The more severe the ischemic disease, the higher the accumulation of CoA esters in affected tissues, and consequently, the greater the amount of carnitine required for their removal. For such patients, carnitine supplementation restores normal carnitine homeostasis, improves the efficiency of oxidative phosphorylation, and lessens symptoms of claudication with concomitant improvement in walking capacity (<a href="./references#CD010117-bbs2-0018" title="BrevettiG , di LisaF , PernaS , MenabóR , BarbatoR , MartoneVD , et al. Carnitine-related alternations in patients with intermittent claudication: indication for a focused carnitine therapy. Circulation1996;93(9):1685-9. ">Brevetti 1996</a>; <a href="./references#CD010117-bbs2-0004" title="BrevettiG , DiehmC , LambertD . European multicenter study on propionyl-l-carnitine in intermittent claudication. Journal of American College of Cardiology1999;34(5):1618-24. ">Brevetti 1999</a>; <a href="./references#CD010117-bbs2-0054" title="StephensFB , Constantin-TeodosiuD , GreenhaffPL . New insights concerning the role of carnitine in the regulation of fuel metabolism in skeletal muscle. Journal of Physiology2007;581(Pt 2):431-44.">Stephens 2007</a>). Several studies have shown that administration of propionyl‐CoA increases glycogen (by blocking its utilization or promoting glycogen synthesis). Propionyl‐CoA is a gluconeogenesis substrate; thus it can generate glucose‐6‐phosphate, which can become glycogen. On the other hand, propionyl‐CoA can, by entering into Krebs’ cycle as succinyl‐CoA, provide additional substrates for energy metabolism with formation of ATP, thus leading to a glycogen‐sparing effect (<a href="./references#CD010117-bbs2-0030" title="BrevettiG , FaninM , De AmicisV , CarrozzoR , Di LelloF , MartoneVD , et al. Changes in skeletal muscle histology and metabolism in patients undergoing exercise deconditioning: effect of propionyl-L-carnitine. Muscle and Nerve1997;20(9):1115-20.">Brevetti 1997</a>). </p> </li> </ul> </li> </ul> </p> <p> <ul id="CD010117-list-0006"> <li> <p>Propionyl‐L‐carnitine improves endothelial cell function by reducing oxidative stress and reducing leucocyte activation and endothelial adhesion molecule expression (<a href="./references#CD010117-bbs2-0049" title="MilioG , NovoG , GenovaC , AlmasioP , NovoS , PintoA . Pharmacological treatment of patients with chronic critical limb ischemia: L-propionyl-carnitine enhances the short-term effects of PGE-1. Cardiovascular Drugs and Therapy2009;23(4):301-6.">Milio 2009</a>), and by providing protection against damage induced by ischemia and reperfusion, leading to maintenance of its regulatory role in vascular dynamics (<a href="./references#CD010117-bbs2-0027" title="AndreozziGM . Propionyl-l-carnitine: intermittent claudication and peripheral arterial disease. Expert Opinion on Pharmacotherapy2009;10(16):2697-707.">Andreozzi 2009</a>; <a href="./references#CD010117-bbs2-0028" title="BrassEP , HiattWR . The role of carnitine and carnitine supplementation during exercise in man and in individuals with special needs. Journal of the American College of Nutrition1998;17(3):207-15.">Brass 1998</a>). </p> </li> <li> <p>Propionyl‐L‐carnitine improves the micro‐architecture of the micro‐vascularization, leading to improvement in the quality of micro‐vascular activity. </p> </li> </ul> </p> <p>In studies included in the current review, PLC is administered as a tablet or by infusion.</p> </section> <section id="CD010117-sec-0013"> <h3 class="title" id="CD010117-sec-0013">Why it is important to do this review</h3> <p>A review assessing the evidence for efficacy of propionyl‐L‐carnitine in treatment of IC is warranted to determine whether the mechanisms described above translate into clinical benefit beyond the placebo effect. The bioavailability of L‐carnitine is uncertain. Therapy with L‐carnitine is not yet standardized, and results of existing studies are variable. In addition, propionyl‐L‐carnitine is an old drug, and its effectiveness remains unproven. Therefore, the question as to whether it is worthwhile to continue to use and further promote propionyl‐L‐carnitine for this indication should be raised. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD010117-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD010117-sec-0014"></div> <p>The objective of this review is to determine whether propionyl‐L‐carnitine is efficacious compared with placebo, other drugs, or other interventions used for treatment of intermittent claudication (e.g. exercise, endovascular intervention, surgery) in increasing pain‐free and maximum walking distance for people with stable intermittent claudication, Fontaine stage II. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD010117-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD010117-sec-0015"></div> <section id="CD010117-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD010117-sec-0017"> <h4 class="title">Types of studies</h4> <p>Double‐blind randomized controlled trials (RCTs) evaluating the efficacy of propionyl‐L‐carnitine in improving walking capacity among people with IC compared with placebo or versus other pharmacological or non‐pharmacological interventions were considered. Studies that failed on the risk of bias assessment, that is, studies that were judged to be at high risk of bias in one or more domains, were excluded from the review. See <a href="#CD010117-sec-0029">Assessment of risk of bias in included studies</a> for more information on risk of bias. </p> </section> <section id="CD010117-sec-0018"> <h4 class="title">Types of participants</h4> <p>People of either sex and of any age in whom IC (Fontaine stage II) due to atherosclerotic disease has been diagnosed by an expert clinician on clinical or investigative assessment (ankle brachial pressure index (ABI), exercise testing, duplex scanning, or angiography) (<a href="./references#CD010117-bbs2-0038" title="FontaineVR , KimM , KienyR . Surgical treatment for peripheral vascular disease [Die chirurgische Behandlung der peripherern Durchblutungsstorungen]. Helvetica Chirurgica Acta1954;5/6:499-533.">Fontaine 1954</a>). Studies of people with asymptomatic lower limb atherosclerosis identified by testing were excluded. People with symptoms of critical limb ischemia (rest pain, skin ulcers, or gangrene) or who have undergone previous surgical intervention or percutaneous catheter interventions were not included. </p> </section> <section id="CD010117-sec-0019"> <h4 class="title">Types of interventions</h4> <p>All types of propionyl‐L‐carnitine regimens versus placebo or versus some other pharmacological or non‐pharmacological intervention were included. Non‐pharmacological interventions might consist of exercise (including pneumatic compression), endovascular intervention, or surgery. </p> </section> <section id="CD010117-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>The effect of propionyl‐L‐carnitine on walking capacity. Walking capacity can be assessed by two parameters: maximal walking distance (MWD) and pain‐free walking distance (PFWD). The primary outcome was MWD, and PFWD was a secondary outcome measure. </p> <section id="CD010117-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD010117-list-0007"> <li> <p>MWD, or absolute claudication distance (ACD) ‐ the distance walked during a standardized test at which the participant stops walking due to muscular cramps (maximum distance walked). Another parameter used for this is peak walking time (PWT) </p> </li> </ul> </p> </section> <section id="CD010117-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD010117-list-0008"> <li> <p>PFWD, or initial claudication distance (ICD) ‐ the distance walked during a standardized test (usually on a treadmill) until the onset of pain </p> </li> <li> <p>Quality of life (QoL)</p> </li> <li> <p>Progression of disease (to Fontaine stage III or IV or necessity for intervention (endovascular or surgical)) </p> </li> <li> <p>Side effects of propionyl‐L‐carnitine regimen</p> </li> </ul> </p> <p> <ul class="plain" id="CD010117-list-0009"> <li> <ul id="CD010117-list-0010"> <li> <p>We assessed side effects using the same methods and eligibility criteria as were used for beneficial effects as described in Chapter 14.2.1 of the <i>Cochrane Handbook for Systematic Reviews for Interventions</i> (<a href="./references#CD010117-bbs2-0046" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). In addition, we checked the Primary Safety Update Reports (PSURs) via the European Medicines Agency (EMA) and the database of individual patient experience (DIPEx) registry for information on side effects. </p> </li> </ul> </li> </ul> </p> <p> <ul id="CD010117-list-0011"> <li> <p>Ankle brachial index, if available. ABI is considered a measure of the underlying hemodynamic severity of disease </p> </li> </ul> </p> </section> </section> </section> <section id="CD010117-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <p>We applied no restriction on language, publication year, or publication status.</p> <section id="CD010117-sec-0024"> <h4 class="title">Electronic searches</h4> <p>The Cochrane Vascular Information Specialist first searched the following databases for relevant trials on March 22, 2017. </p> <p> <ul id="CD010117-list-0012"> <li> <p>Cochrane Vascular Specialised Register.</p> </li> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; 2017, Issue 5), in the Cochrane Library (<a href="http://www.cochranelibrary.com" target="_blank">www.cochranelibrary.com</a>). </p> </li> </ul> </p> <p>See <a href="./appendices#CD010117-sec-0073">Appendix 2</a> for details of the search strategy used to search CENTRAL. </p> <p>The Information Specialist also searched the following trial registries for details of ongoing and unpublished studies using the search term 'propionyl' on March 22, 2017. </p> <p> <ul id="CD010117-list-0013"> <li> <p>World Health Organization International Clinical Trials Registry <a href="http://apps.who.int/trialsearch/" target="_blank">who.int/trialsearch/</a>. </p> </li> <li> <p>ClinicalTrials.gov (<a href="http://clinicaltrials.gov/" target="_blank">clinicaltrials.gov/</a>). </p> </li> <li> <p>Current Controlled Trials (<a href="http://www.controlled-trials.com/" target="_blank">controlled-trials.com/</a>). </p> </li> </ul> </p> <p>The Cochrane Vascular Information Specialist subsequently conducted systematic top‐up searches of the following databases. </p> <p> <ul id="CD010117-list-0014"> <li> <p>Cochrane Vascular Specialised Register via the Cochrane Register of Studies (CRS‐Web) (searched from March 23, 2017, to July 7, 2021). </p> </li> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL), Cochrane Register of Studies Online (CRSO; 2021, Issue 7). </p> </li> <li> <p>MEDLINE (Ovid MEDLINE® Epub Ahead of Print, In‐Process &amp; Other Non‐Indexed Citations; Ovid MEDLINE® Daily; and Ovid MEDLINE®) (searched from January 1, 2017, to July 12, 2021). </p> </li> <li> <p>Embase Ovid (searched from January 1, 2017, to July 12, 2021).</p> </li> <li> <p>Cumulative Index to Nursing and Allied Health Literature (CINAHL) Ebsco (searched from January 1, 2017, to July 12, 2021). </p> </li> <li> <p>Allied and Complementary Medicine Database (AMED) Ovid (searched from January 1, 2017, to July 12, 2021). </p> </li> </ul> </p> <p>The Information Specialist modelled search strategies for the listed databases on the search strategy designed for CENTRAL. When appropriate, they were combined with adaptations of the highly sensitive search strategy designed by Cochrane for identifying RCTs and controlled clinical trials (as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions,</i> Chapter 6; <a href="./references#CD010117-bbs2-0047" title="LefebvreC , ManheimerE , GlanvilleJ . Chapter 6. Searching for studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Lefebvre 2011</a>). Search strategies for major databases are provided in <a href="./appendices#CD010117-sec-0074">Appendix 3</a>. </p> <p>The Information Specialist also performed top‐up searches of the following trials registries on July 12, 2021. </p> <p> <ul id="CD010117-list-0015"> <li> <p>World Health Organization International Clinical Trials Registry Platform (<a href="http://who.int/trialsearch" target="_blank">who.int/trialsearch</a>). </p> </li> <li> <p>ClinicalTrials.gov (<a href="http://clinicaltrials.gov/" target="_blank">clinicaltrials.gov/</a>). </p> </li> </ul> </p> </section> <section id="CD010117-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We reviewed all reference lists of identified studies and handsearched relevant bibliographies. In addition, we contacted study authors, trialists, and pharmaceutical companies marketing propionyl‐L‐carnitine for details on unpublished and ongoing trials and unpublished data. Given the fact that it is impossible to contact more than 50 suppliers worldwide, we restricted our first contact to one well‐known company in Italy (Pomezia) ‐ Sigma Tau ‐ which we contacted to request potential additional data. </p> <p>In addition, we checked the PSURs via the EMA and the DIPEx registry for information on side effects (<a href="http://www.ema.europa.eu/ema" target="_blank">ema.europa.eu/ema</a>; <a href="http://www.healthtalkonline.org" target="_blank">healthtalkonline.org</a>). </p> </section> </section> <section id="CD010117-sec-0026"> <h3 class="title" id="CD010117-sec-0026">Data collection and analysis</h3> <section id="CD010117-sec-0027"> <h4 class="title">Selection of studies</h4> <p>The above search strategy yielded a set of potentially relevant articles. Two review authors (TDB and VK) independently selected RCTs on propionyl‐L‐carnitine for IC for inclusion in the review. Publications were selected based on the abstracts of retrieved articles or, if necessary, the original publication. Differences were resolved by consensus. </p> </section> <section id="CD010117-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>TDB and VK independently collected information from each included trial using data collection forms designed by Cochrane Vascular. We collected information on trial design, participant characteristics, inclusion and exclusion criteria, interventions and controls used, treatment periods, methods of assessment, and results of MWD and PFWD. We also collected data on QoL, progression of disease, side effects of the propionyl‐L‐carnitine regimen, and ABI. When necessary, we sought information from the authors of primary studies. </p> </section> <section id="CD010117-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>TDB and VK independently assessed the risk of bias of included studies according to guidelines provided in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010117-bbs2-0046" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). The original reports of all selected trials were transformed into structured abstracts. We evaluated studies for methods of randomization, concealment of allocation, blinding, description of withdrawals and dropouts in each group (internal validity), incomplete outcome data, and selective reporting. We assessed the risk of bias of selected studies by using the checklist for quality assessment from Cochrane Vascular. When necessary, in case of differences, a third assessor (RVS) or a fourth assessor (LVB) was involved, and consensus was reached. Studies that failed on the risk of bias assessment, that is, studies that we judged to be at high risk of bias in one or more domains, were excluded from the review. </p> </section> <section id="CD010117-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>We measured the main treatment effect using the mean difference (MD) of the walking distances (expressed in meters) (outcome data = continuous data (numerical quantity)). For studies using peak walking time, results were converted to distance using the velocity of the constant‐load treadmill settings. However, some studies use peak walking time on a graded treadmill, which is not comparable to MWD on a constant‐load treadmill. To resolve this problem and to be able to combine the data from studies with different treadmill protocols, we based the data on the treatment effect of the ratio (or percent change) of benefit of propionyl‐L‐carnitine relative to the benefit of placebo or control (or other active). Treatment effects are reported with a 95% confidence interval (CI). </p> </section> <section id="CD010117-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of the analysis was the individual participant.</p> <p>Placebo‐controlled studies included in the review were parallel‐group RCTs. The L‐carnitine controlled study was a cross‐over study, which we included after analysis. </p> </section> <section id="CD010117-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>Types of missing data can be missing studies, missing outcomes, missing summary data, missing individual results, or missing study level characteristics. We considered the reasons why data were missing. We considered missing data as either 'missing at random' or 'not missing at random'. </p> <p>When possible, we contacted the original investigators to ask for any missing data. We planned to impute missing data with replacement values as if they were observed. For example, for missing main endpoint data, we contacted study authors and asked for available data or for the worst case value attributed to participants who interrupted the trial early for a reason related to PAD (progression to stages III and IV, aggravation of the disease, hospitalization, or surgery). For all other randomized participants who stopped for a reason unrelated to PAD, we used the last observation carried forward (LOCF), similar to most PAD trials. However, for sensitivity analysis purposes, we planned to carry out an alternative analysis by using summary statistics (mean of intermediate, non‐missing post‐baseline values) when at least two intermediate observations were available. </p> <p>If missing data could not be retrieved, we analyzed only available data when the data could be assumed to be missing at random. If the data were not missing at random, we considered imputing the missing data with replacement values, or imputing the missing data (with uncertainty), or using specific statistical models that allowed for missing data, after consulting with and in consensus with our statistician. </p> <p>When dealing with missing data, we also addressed the impact of the missing data on results when preparing the <a href="#CD010117-sec-0060">Discussion</a> section of the review. </p> </section> <section id="CD010117-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed clinical heterogeneity by clinical judgement. We judged study design, participants, interventions, comparators, and outcomes, and stated whether or not trial data should be combined. This was the first step in determining whether a meta‐analysis was possible. </p> <p>We identified statistical heterogeneity by using the I² statistic. I² describes the percentage of variability in point estimates that is due to heterogeneity rather than to sampling error. To explore any issues concerning heterogeneity, we considered several statistical models (including random‐effects and fixed‐effect models), as well as sensitivity analyses (described below). </p> </section> <section id="CD010117-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>We planned to assess possible publication bias through simple funnel plots; however this was not possible because of an insufficient number of studies (<a href="./references#CD010117-bbs2-0046" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a> suggests to make funnel plots if more than 10 studies are included in the meta‐analysis). A funnel plot is a simple scatter plot of intervention effect estimates from individual studies against some measure of each study's size or precision. The name 'funnel plot' arises from the fact that precision of the estimated intervention effect increases as the size of the study increases (<a href="./references#CD010117-bbs2-0046" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). When visual presentation of the funnel plot suggests a possible publication bias, we planned to calculate the correlation between effect size and sample size (<a href="./references#CD010117-bbs2-0036" title="EggerM , Davey SmithG , SchneiderM , MinderC . Bias in meta-analysis detected by simple, graphical test. BMJ1997;315(7109):629-34.">Egger 1997</a>). </p> </section> <section id="CD010117-sec-0035"> <h4 class="title">Data synthesis</h4> <p>We pooled data on MWD and on PFWD from each trial to arrive at an overall estimate of the effectiveness of pharmacological interventions. We calculated the percentage change in walking distance before and after the interventions. We then calculated the mean difference with variance of the propionyl‐L‐carnitine group compared with the control group. If feasible, we conducted a fixed‐effect model meta‐analysis with extracted results. </p> </section> <section id="CD010117-sec-0036"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We carried out subgroup analysis, according to the participant characteristic diabetes versus non‐diabetes. </p> <p>We planned to perform subgroup analyses for treatment duration, dose (for propionyl‐L‐carnitine, a wide dose range exists, ranging from 1 gram daily to 4 grams daily), and route of administration (orally or intravenously). </p> </section> <section id="CD010117-sec-0037"> <h4 class="title">Sensitivity analysis</h4> <p>Studies at high risk of bias were excluded from the review.</p> <p>Depending on study selection, we planned to also test the stability of results by comparing results while (1) using all available included trials, (2) excluding trials contributing large weight to the analyses, and (3) considering full intention‐to‐treat (ITT) analysis versus per‐protocol (PP) analysis in trials. </p> <p>As described above, in the <a href="#CD010117-sec-0032">Dealing with missing data</a> section, we planned to carry out an alternative analysis by using summary statistics (mean of intermediate, non‐missing post‐baseline values) when at least two intermediate observations were available. </p> <p>As a post‐hoc measure, we performed an additional sensitivity analysis to explore more fully the high heterogeneity that was evident in many analyses. This sensitivity analysis included only the three studies contributing the largest weights to the fixed‐effect model. </p> </section> <section id="CD010117-sec-0038"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We presented the overall certainty of evidence for each outcome according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach (<a href="./references#CD010117-bbs2-0041" title='GuyattGH , OxmanAD , VistGE , KunzR , Falck-YtterY , SchünemannHJ . GRADE: what is "quality of evidence" and why is it important to clinicians?BMJ (Clinical Research Ed.)2008;336(7651):995-8.'>Guyatt 2008</a>), which takes into account the following five criteria: risk of bias, inconsistency, imprecision, publication bias, and directness of results. For each comparison, we rated the certainty of evidence for each outcome as 'high', 'moderate', 'low', or 'very low' using <a href="./references#CD010117-bbs2-0040" title="McMaster University (developed by Evidence Prime)GRADEpro GDT. Version accessed April 13, 2018. Hamilton (ON): McMaster University (developed by Evidence Prime). Available at gradepro.org.">GRADEpro GDT</a>. We presented a summary of evidence for main outcomes in a 'Summary of findings' table, which provides key information about the best estimate of the magnitude of effect in relative terms and absolute differences for each relevant comparison of alternative management strategies; numbers of participants and studies addressing each important outcome; and the rating of overall confidence in effect estimates for each outcome (<a href="./references#CD010117-bbs2-0042" title="GuyattG , OxmanAD , AklEA , KunzR , VistG , BrozekJ . GRADE guidelines: 1. Introduction - GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology2011;64(4):383-94.">Guyatt 2011</a>; <a href="./references#CD010117-bbs2-0052" title="SchünemannHJ , OxmanAD , VistGE , HigginsJP , DeeksJJ , GlasziouP , et al. Chapter 12. Interpreting results and drawing conclusions. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Schünemann 2011</a>). When meta‐analysis was not possible, we presented results in a narrative manner. </p> <p>We included in the 'Summary of findings' table data for the following outcomes: absolute claudication distance, initial claudication distance, quality of life, progression of disease (to Fontaine stage III or IV or necessity for intervention (endovascular or surgery)), side effects of the propionyl‐L‐carnitine regimen, and ABI. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD010117-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD010117-sec-0039"></div> <section id="CD010117-sec-0040"> <h3 class="title">Description of studies</h3> <section id="CD010117-sec-0041"> <h4 class="title">Results of the search</h4> <p>See <a href="#CD010117-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD010117-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD010117-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/image_n/nCD010117-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <p>In total, we assessed 50 full‐text papers for inclusion. We included 12 studies (15 reports) and excluded 14 studies (14 reports). We assessed the remaining 21 reports as not relevant. </p> </section> <section id="CD010117-sec-0042"> <h4 class="title">Included studies</h4> <p>See <a href="./references#CD010117-sec-0083" title="">Characteristics of included studies</a>. </p> <p>We included 12 studies (15 reports) that fulfilled all inclusion criteria (<a href="./references#CD010117-bbs2-0001" title="AndreozziGM , LeoneA , LaudaniR , MartiniR , DeiniteG , CataldiV . Levo-propionyl-carnitine improves the effectiveness of supervised physical training on the absolute claudication distance in patients with intermittent claudication. Angiology2008;59(1):84-9. ">Andreozzi 2008</a>; <a href="./references#CD010117-bbs2-0002" title="BrevettiG , PernaS , SabbaC , RossiniA , Scotto di UccioV , BerardiE , et al. Superiority of L-propionylcarnitine vs L-carnitine in improving walking capacity in patients with peripheral vascular disease: an acute, intravenous, double-blind, cross-over study. European Heart Journal1992;13(2):251-5. ">Brevetti 1992</a>; <a href="./references#CD010117-bbs2-0003" title="BrevettiG , PernaS , SabbaC , MartoneVD , CondorelliM . Propionyl-L-carnitine in intermittent claudication: double-blind, placebo-controlled, dose titration, multicenter study. Journal of American College of Cardiology1995;26(6):1411-6. BrevettiG , PernaS , SabbaC , MartoneVD , Di IorioA , BarlettaG . Effect of propionyl-L-carnitine on quality of life in intermittent claudication. American Journal of Cardiology1997;79(6):777-80. ">Brevetti 1995</a>; <a href="./references#CD010117-bbs2-0004" title="BrevettiG , DiehmC , LambertD . European multicenter study on propionyl-l-carnitine in intermittent claudication. Journal of American College of Cardiology1999;34(5):1618-24. ">Brevetti 1999</a>; <a href="./references#CD010117-bbs2-0005" title="CotoV , D'AlessandroL , GrattarolaG , ImparatoL , LingettiM , ManciniM , et al. Evaluation of the therapeutic efficacy and tolerability of levocarnitine propionyl in the treatment of chronic obstructive arteriopathies of the lower extremities: a multicentre controlled study vs. placebo. Drugs under Experimental and Clinical Research1992;18(1):29-36. ">Coto 1992</a>; <a href="./references#CD010117-bbs2-0006" title="Dal LagoA , De MartiniD , FloreR , GaetaniE , GasbarriniA , GerardinoL , et al. Effects of propionyl-L-carnitine on peripheral arterial obliterative disease of the lower limbs: a double-blind clinical trial. Drugs under Experimental and Clinical Research1999;25(1):29-36. ">Dal Lago 1999</a>; <a href="./references#CD010117-bbs2-0007" title="GrecoAV , MingroneG , BianchiM , GhirlandaG . Effect of propionyl-L-carnitine in the treatment of diabetic angiopathy: controlled double-blind trial versus placebo. Drugs under Experimental and Clinical Research1992;18(2):69-80. ">Greco 1992</a>; <a href="./references#CD010117-bbs2-0008" title="HiattWR , RegensteinerJG , CreagerMA , HirschAT , CookeJP , OlinJW , et al. Propionyl-L-carnitine improves exercise performance and functional status in patients with claudication. American Journal of Medicine2001;110(8):616-22. ">Hiatt 2001</a>; <a href="./references#CD010117-bbs2-0009" title="HiattWR , CreagerMA , AmatoA , BrassEP . Effect of propionyl-L-carnitine on a background of monitored exercise in patients with claudication secondary to peripheral arterial disease. Journal Cardiopulmonary Rehabilitation Prevention2011;31(2):125-32. [NCT00399919]">Hiatt 2011</a>; <a href="./references#CD010117-bbs2-0010" title="LuoT , LiJ , LiL , YangB , LiuC , ZhengQ , et al. A study on the efficacy and safety assessment of propionyl-L-carnitine tablets in treatment of intermittent claudication. Thrombosis Research2013;132(4):427-32. NCT00809497. A clinical study on efficacy &amp; safety profile of propionyl-L-carnitine tablets for peripheral arterial diseases. clinicaltrialsgov/show/NCT00809497 (first received December 17, 2008). ">Luo 2013</a>; <a href="./references#CD010117-bbs2-0011" title="SignorelliSS , NeriS , Di PinoL , MarcheseG , FerranteM , OliveriCG , et al. Effect of PLC on functional parameters and oxidative profile in type 2 diabetes-associated PAD. Diabetes Research and Clinical Practice2006;72(3):231-7. ">Signorelli 2006a</a>; <a href="./references#CD010117-bbs2-0012" title="SignorelliSS , FatuzzoP , RapisardaF , NeriS , FerranteM , Oliveri ContiG , et al. A randomised, controlled clinical trial evaluating changes in therapeutic efficacy and oxidative parameters after treatment with propionyl-L-carnitine in patients with peripheral arterial disease requiring hemodialysis. Drugs and Aging2006;23(3):263-70. SignorelliSS , FatuzzoP , RapisardaF , NeriS , FerranteM , Oliveri ContiG , et al. Propionyl-L-carnitine therapy: effects on endothelin-1 and homocysteine levels in patients with peripheral arterial disease and end-stage renal disease. Kidney &amp; Blood Pressure Research2006;29(2):100-7. ">Signorelli 2006b</a>). All studies were RCTs comparing propionyl‐L‐carnitine (PLC) with placebo or another treatment. In most cases, the comparator was placebo. In one trial, PLC was compared against L‐carnitine (<a href="./references#CD010117-bbs2-0002" title="BrevettiG , PernaS , SabbaC , RossiniA , Scotto di UccioV , BerardiE , et al. Superiority of L-propionylcarnitine vs L-carnitine in improving walking capacity in patients with peripheral vascular disease: an acute, intravenous, double-blind, cross-over study. European Heart Journal1992;13(2):251-5. ">Brevetti 1992</a>). Studies comparing PLC against other interventions such as exercise, other medications, endovascular intervention, or surgery were not identified. </p> <p>The 12 included studies randomized a total of 1423 participants: PLC versus placebo: 1395 participants; and PLC versus other: 28 participants. For the primary outcome ACD, a total of 1257 participants were included (ITT), dropping to 1121 participants after dropouts were taken into account (PP population, 10.8% dropouts). For the secondary outcome ICD, a total of 1287 participants were included (ITT), dropping to 1151 participants after dropouts were taken into account (10.6% dropouts). The number of participants in these studies ranged from 19 in <a href="./references#CD010117-bbs2-0006" title="Dal LagoA , De MartiniD , FloreR , GaetaniE , GasbarriniA , GerardinoL , et al. Effects of propionyl-L-carnitine on peripheral arterial obliterative disease of the lower limbs: a double-blind clinical trial. Drugs under Experimental and Clinical Research1999;25(1):29-36. ">Dal Lago 1999</a> and <a href="./references#CD010117-bbs2-0007" title="GrecoAV , MingroneG , BianchiM , GhirlandaG . Effect of propionyl-L-carnitine in the treatment of diabetic angiopathy: controlled double-blind trial versus placebo. Drugs under Experimental and Clinical Research1992;18(2):69-80. ">Greco 1992</a> to 282 in <a href="./references#CD010117-bbs2-0010" title="LuoT , LiJ , LiL , YangB , LiuC , ZhengQ , et al. A study on the efficacy and safety assessment of propionyl-L-carnitine tablets in treatment of intermittent claudication. Thrombosis Research2013;132(4):427-32. NCT00809497. A clinical study on efficacy &amp; safety profile of propionyl-L-carnitine tablets for peripheral arterial diseases. clinicaltrialsgov/show/NCT00809497 (first received December 17, 2008). ">Luo 2013</a>. <a href="./references#CD010117-bbs2-0011" title="SignorelliSS , NeriS , Di PinoL , MarcheseG , FerranteM , OliveriCG , et al. Effect of PLC on functional parameters and oxidative profile in type 2 diabetes-associated PAD. Diabetes Research and Clinical Practice2006;72(3):231-7. ">Signorelli 2006a</a> reported ICD and ABI as primary outcomes. <a href="./references#CD010117-bbs2-0001" title="AndreozziGM , LeoneA , LaudaniR , MartiniR , DeiniteG , CataldiV . Levo-propionyl-carnitine improves the effectiveness of supervised physical training on the absolute claudication distance in patients with intermittent claudication. Angiology2008;59(1):84-9. ">Andreozzi 2008</a> reported only ACD as an outcome parameter. Most trials were performed in Italy (<a href="./references#CD010117-bbs2-0001" title="AndreozziGM , LeoneA , LaudaniR , MartiniR , DeiniteG , CataldiV . Levo-propionyl-carnitine improves the effectiveness of supervised physical training on the absolute claudication distance in patients with intermittent claudication. Angiology2008;59(1):84-9. ">Andreozzi 2008</a>; <a href="./references#CD010117-bbs2-0002" title="BrevettiG , PernaS , SabbaC , RossiniA , Scotto di UccioV , BerardiE , et al. Superiority of L-propionylcarnitine vs L-carnitine in improving walking capacity in patients with peripheral vascular disease: an acute, intravenous, double-blind, cross-over study. European Heart Journal1992;13(2):251-5. ">Brevetti 1992</a>; <a href="./references#CD010117-bbs2-0003" title="BrevettiG , PernaS , SabbaC , MartoneVD , CondorelliM . Propionyl-L-carnitine in intermittent claudication: double-blind, placebo-controlled, dose titration, multicenter study. Journal of American College of Cardiology1995;26(6):1411-6. BrevettiG , PernaS , SabbaC , MartoneVD , Di IorioA , BarlettaG . Effect of propionyl-L-carnitine on quality of life in intermittent claudication. American Journal of Cardiology1997;79(6):777-80. ">Brevetti 1995</a>; <a href="./references#CD010117-bbs2-0005" title="CotoV , D'AlessandroL , GrattarolaG , ImparatoL , LingettiM , ManciniM , et al. Evaluation of the therapeutic efficacy and tolerability of levocarnitine propionyl in the treatment of chronic obstructive arteriopathies of the lower extremities: a multicentre controlled study vs. placebo. Drugs under Experimental and Clinical Research1992;18(1):29-36. ">Coto 1992</a>; <a href="./references#CD010117-bbs2-0006" title="Dal LagoA , De MartiniD , FloreR , GaetaniE , GasbarriniA , GerardinoL , et al. Effects of propionyl-L-carnitine on peripheral arterial obliterative disease of the lower limbs: a double-blind clinical trial. Drugs under Experimental and Clinical Research1999;25(1):29-36. ">Dal Lago 1999</a>; <a href="./references#CD010117-bbs2-0007" title="GrecoAV , MingroneG , BianchiM , GhirlandaG . Effect of propionyl-L-carnitine in the treatment of diabetic angiopathy: controlled double-blind trial versus placebo. Drugs under Experimental and Clinical Research1992;18(2):69-80. ">Greco 1992</a>; <a href="./references#CD010117-bbs2-0011" title="SignorelliSS , NeriS , Di PinoL , MarcheseG , FerranteM , OliveriCG , et al. Effect of PLC on functional parameters and oxidative profile in type 2 diabetes-associated PAD. Diabetes Research and Clinical Practice2006;72(3):231-7. ">Signorelli 2006a</a>; <a href="./references#CD010117-bbs2-0012" title="SignorelliSS , FatuzzoP , RapisardaF , NeriS , FerranteM , Oliveri ContiG , et al. A randomised, controlled clinical trial evaluating changes in therapeutic efficacy and oxidative parameters after treatment with propionyl-L-carnitine in patients with peripheral arterial disease requiring hemodialysis. Drugs and Aging2006;23(3):263-70. SignorelliSS , FatuzzoP , RapisardaF , NeriS , FerranteM , Oliveri ContiG , et al. Propionyl-L-carnitine therapy: effects on endothelin-1 and homocysteine levels in patients with peripheral arterial disease and end-stage renal disease. Kidney &amp; Blood Pressure Research2006;29(2):100-7. ">Signorelli 2006b</a>); the other trials were performed in the United States ‐ <a href="./references#CD010117-bbs2-0008" title="HiattWR , RegensteinerJG , CreagerMA , HirschAT , CookeJP , OlinJW , et al. Propionyl-L-carnitine improves exercise performance and functional status in patients with claudication. American Journal of Medicine2001;110(8):616-22. ">Hiatt 2001</a>; <a href="./references#CD010117-bbs2-0009" title="HiattWR , CreagerMA , AmatoA , BrassEP . Effect of propionyl-L-carnitine on a background of monitored exercise in patients with claudication secondary to peripheral arterial disease. Journal Cardiopulmonary Rehabilitation Prevention2011;31(2):125-32. [NCT00399919]">Hiatt 2011</a> ‐ and in China ‐ <a href="./references#CD010117-bbs2-0010" title="LuoT , LiJ , LiL , YangB , LiuC , ZhengQ , et al. A study on the efficacy and safety assessment of propionyl-L-carnitine tablets in treatment of intermittent claudication. Thrombosis Research2013;132(4):427-32. NCT00809497. A clinical study on efficacy &amp; safety profile of propionyl-L-carnitine tablets for peripheral arterial diseases. clinicaltrialsgov/show/NCT00809497 (first received December 17, 2008). ">Luo 2013</a>. </p> <p>PLC treatment was similar across trials, most often 1 gram or 2 grams PLC daily. In three trials, PLC was given intravenously (<a href="./references#CD010117-bbs2-0001" title="AndreozziGM , LeoneA , LaudaniR , MartiniR , DeiniteG , CataldiV . Levo-propionyl-carnitine improves the effectiveness of supervised physical training on the absolute claudication distance in patients with intermittent claudication. Angiology2008;59(1):84-9. ">Andreozzi 2008</a>; <a href="./references#CD010117-bbs2-0002" title="BrevettiG , PernaS , SabbaC , RossiniA , Scotto di UccioV , BerardiE , et al. Superiority of L-propionylcarnitine vs L-carnitine in improving walking capacity in patients with peripheral vascular disease: an acute, intravenous, double-blind, cross-over study. European Heart Journal1992;13(2):251-5. ">Brevetti 1992</a>; <a href="./references#CD010117-bbs2-0012" title="SignorelliSS , FatuzzoP , RapisardaF , NeriS , FerranteM , Oliveri ContiG , et al. A randomised, controlled clinical trial evaluating changes in therapeutic efficacy and oxidative parameters after treatment with propionyl-L-carnitine in patients with peripheral arterial disease requiring hemodialysis. Drugs and Aging2006;23(3):263-70. SignorelliSS , FatuzzoP , RapisardaF , NeriS , FerranteM , Oliveri ContiG , et al. Propionyl-L-carnitine therapy: effects on endothelin-1 and homocysteine levels in patients with peripheral arterial disease and end-stage renal disease. Kidney &amp; Blood Pressure Research2006;29(2):100-7. ">Signorelli 2006b</a>), and in nine trials, PLC was taken orally (<a href="./references#CD010117-bbs2-0003" title="BrevettiG , PernaS , SabbaC , MartoneVD , CondorelliM . Propionyl-L-carnitine in intermittent claudication: double-blind, placebo-controlled, dose titration, multicenter study. Journal of American College of Cardiology1995;26(6):1411-6. BrevettiG , PernaS , SabbaC , MartoneVD , Di IorioA , BarlettaG . Effect of propionyl-L-carnitine on quality of life in intermittent claudication. American Journal of Cardiology1997;79(6):777-80. ">Brevetti 1995</a>; <a href="./references#CD010117-bbs2-0004" title="BrevettiG , DiehmC , LambertD . European multicenter study on propionyl-l-carnitine in intermittent claudication. Journal of American College of Cardiology1999;34(5):1618-24. ">Brevetti 1999</a>; <a href="./references#CD010117-bbs2-0005" title="CotoV , D'AlessandroL , GrattarolaG , ImparatoL , LingettiM , ManciniM , et al. Evaluation of the therapeutic efficacy and tolerability of levocarnitine propionyl in the treatment of chronic obstructive arteriopathies of the lower extremities: a multicentre controlled study vs. placebo. Drugs under Experimental and Clinical Research1992;18(1):29-36. ">Coto 1992</a>; <a href="./references#CD010117-bbs2-0006" title="Dal LagoA , De MartiniD , FloreR , GaetaniE , GasbarriniA , GerardinoL , et al. Effects of propionyl-L-carnitine on peripheral arterial obliterative disease of the lower limbs: a double-blind clinical trial. Drugs under Experimental and Clinical Research1999;25(1):29-36. ">Dal Lago 1999</a>; <a href="./references#CD010117-bbs2-0007" title="GrecoAV , MingroneG , BianchiM , GhirlandaG . Effect of propionyl-L-carnitine in the treatment of diabetic angiopathy: controlled double-blind trial versus placebo. Drugs under Experimental and Clinical Research1992;18(2):69-80. ">Greco 1992</a>; <a href="./references#CD010117-bbs2-0008" title="HiattWR , RegensteinerJG , CreagerMA , HirschAT , CookeJP , OlinJW , et al. Propionyl-L-carnitine improves exercise performance and functional status in patients with claudication. American Journal of Medicine2001;110(8):616-22. ">Hiatt 2001</a>; <a href="./references#CD010117-bbs2-0009" title="HiattWR , CreagerMA , AmatoA , BrassEP . Effect of propionyl-L-carnitine on a background of monitored exercise in patients with claudication secondary to peripheral arterial disease. Journal Cardiopulmonary Rehabilitation Prevention2011;31(2):125-32. [NCT00399919]">Hiatt 2011</a>; <a href="./references#CD010117-bbs2-0010" title="LuoT , LiJ , LiL , YangB , LiuC , ZhengQ , et al. A study on the efficacy and safety assessment of propionyl-L-carnitine tablets in treatment of intermittent claudication. Thrombosis Research2013;132(4):427-32. NCT00809497. A clinical study on efficacy &amp; safety profile of propionyl-L-carnitine tablets for peripheral arterial diseases. clinicaltrialsgov/show/NCT00809497 (first received December 17, 2008). ">Luo 2013</a>; <a href="./references#CD010117-bbs2-0011" title="SignorelliSS , NeriS , Di PinoL , MarcheseG , FerranteM , OliveriCG , et al. Effect of PLC on functional parameters and oxidative profile in type 2 diabetes-associated PAD. Diabetes Research and Clinical Practice2006;72(3):231-7. ">Signorelli 2006a</a>). Follow‐up in most studies was six months to one year. Evaluation of walking parameters was performed on a treadmill, but characteristics of testing varied because of different slopes and speeds of the treadmill. </p> <p><a href="./references#CD010117-bbs2-0001" title="AndreozziGM , LeoneA , LaudaniR , MartiniR , DeiniteG , CataldiV . Levo-propionyl-carnitine improves the effectiveness of supervised physical training on the absolute claudication distance in patients with intermittent claudication. Angiology2008;59(1):84-9. ">Andreozzi 2008</a> ‐ This placebo‐controlled RCT included 44 people (22 intervention participants, 22 control participants) with IC. Half of the participants suffered from severe claudication (MWD &lt; 100 m) and half suffered from moderate claudication (MWD &lt; 200 m), resulting in four equal subgroups of 11 participants each, based on intervention, control, and severity of claudication. The intervention consisted of physical training three times weekly for six weeks + intravenous (iv) saline solution + iv 600 mg PLC three times weekly during the last three weeks of training. Control participants received physical training three times weekly for six weeks + iv saline solution three times weekly during the last three weeks of training. MWD on a treadmill (speed 2.5 km/h, slope 15%) was the outcome of this study. Measurements were performed at baseline, and after three and six weeks. </p> <p><a href="./references#CD010117-bbs2-0002" title="BrevettiG , PernaS , SabbaC , RossiniA , Scotto di UccioV , BerardiE , et al. Superiority of L-propionylcarnitine vs L-carnitine in improving walking capacity in patients with peripheral vascular disease: an acute, intravenous, double-blind, cross-over study. European Heart Journal1992;13(2):251-5. ">Brevetti 1992</a> ‐ This cross‐over study is a double‐blind RCT comparing PLC with L‐carnitine (LC). Twelve people with IC were enrolled in the preliminary dose‐finding study and 14 people with IC in the comparative study (iv 600 mg PLC versus iv 500 mg LC, which is an equimolar dose). Participants were referred to the outpatient clinic of the study authors. In the preliminary study, all participants first received iv placebo, followed, four days later, by intervention: iv 300 mg PLC or 600 mg PLC (cross‐over after four days between 300 mg PLC and 600 mg PLC arms, following a washout period). In the comparative study, all participants first received iv placebo, four days later followed by intervention: iv 600 mg PLC or iv 500 mg LC (cross‐over after four days between the two intervention arms) without a washout period. Outcomes were MWD (meters) and PFWD (meters) on the treadmill (2.5 mph, slope 7%) and a hemodynamic assessment (ABI, cross‐sectional area (CSA) of the common femoral artery, blood flow velocity (cm/s), blood flow rate (mL/min), pulsatility index (PI), and resistance index (RI)). In this study, it should be noted that study duration and follow‐up were remarkably short (four days) and the number of participants low. Funding was provided by the pharmaceutical company Sigma Tau. </p> <p><a href="./references#CD010117-bbs2-0003" title="BrevettiG , PernaS , SabbaC , MartoneVD , CondorelliM . Propionyl-L-carnitine in intermittent claudication: double-blind, placebo-controlled, dose titration, multicenter study. Journal of American College of Cardiology1995;26(6):1411-6. BrevettiG , PernaS , SabbaC , MartoneVD , Di IorioA , BarlettaG . Effect of propionyl-L-carnitine on quality of life in intermittent claudication. American Journal of Cardiology1997;79(6):777-80. ">Brevetti 1995</a> ‐ Randomized placebo‐controlled double‐blind trial with a dose‐titration design performed at 13 centers. 245 (ITT) (214 (PP)) people with IC underwent a two‐week washout phase in which they were familiarized with the treadmill. 31 dropouts from the study were reported (14 due to various adverse events, 17 due to poor compliance). Intervention participants (n = 99) received oral PLC 1/2/3 g/d for six months, and controls (n = 115) received oral placebo 1/2/3 g/d for six months. The initial dose of 2 × 500 mg daily was increased at two‐monthly intervals to 2 grams daily, then to 3 grams daily, for participants with improvement in treadmill performance less than 30% over baseline; participants showing improvement of 30% or greater continued with the same dose as in the previous two months. Study outcomes were MWD and PFWD on the treadmill (speed 4 km/h, slope 7%) and analysis of the titration course: probability of obtaining an increase in MWD of 30% or greater with a specific dose. Funding by Sigma Tau. Quality of life was measured using the McMaster Health Index Questionnaire at the end of the run‐in period and at the last control visit. This is a self‐administered generic questionnaire of 59 health‐related statements covering physical, social, and emotional dimensions. QoL results were reported by <a href="./references#CD010117-bbs2-0030" title="BrevettiG , FaninM , De AmicisV , CarrozzoR , Di LelloF , MartoneVD , et al. Changes in skeletal muscle histology and metabolism in patients undergoing exercise deconditioning: effect of propionyl-L-carnitine. Muscle and Nerve1997;20(9):1115-20.">Brevetti 1997</a>. </p> <p><a href="./references#CD010117-bbs2-0004" title="BrevettiG , DiehmC , LambertD . European multicenter study on propionyl-l-carnitine in intermittent claudication. Journal of American College of Cardiology1999;34(5):1618-24. ">Brevetti 1999</a> ‐ This double‐blind, randomized, placebo‐controlled trial included 485 (ITT) (328 (PP)) participants with IC for a minimum of one year. 157 dropouts were observed: 10 participants died, 57 dropped out due to adverse events, 61 dropped out because of protocol violation, and 29 participants were lost to follow‐up. Dropout ratios were balanced between the two treatment arms. Participants were stratified on the basis of MWD at baseline (cutoff point 250 m) and MWD variability at baseline (cutoff point 25%) into four groups (S1 to S4). 485 participants were considered in the ITT protocol, and 328 completed the one‐year protocol. Participants taking less than 75% of prescribed dosis were considered as dropouts. Intervention participants (n = 162) received oral PLC 1 gram twice daily for one year; the control group (n = 166) received placebo oral 1 gram twice daily for one year. Study outcomes were MWD and PFWD on the treadmill (slope 7%, speed 3 km/h), QoL, and adverse events. Measurements were performed every two months. Funding was provided by Sigma Tau. For results of walking distance, only the S1 group (MWD &lt; 250 m, variability &lt; 25%) was considered; for adverse events reporting, all four groups were included. </p> <p><a href="./references#CD010117-bbs2-0005" title="CotoV , D'AlessandroL , GrattarolaG , ImparatoL , LingettiM , ManciniM , et al. Evaluation of the therapeutic efficacy and tolerability of levocarnitine propionyl in the treatment of chronic obstructive arteriopathies of the lower extremities: a multicentre controlled study vs. placebo. Drugs under Experimental and Clinical Research1992;18(1):29-36. ">Coto 1992</a> ‐ This double‐blind, randomized, placebo‐controlled trial was conducted with participants from seven centers: 300 (ITT) (282 (PP)) participants with IC for a minimum of one year, randomized in two groups. 18 dropouts were reported (due to adverse events or poor collaboration). Intervention participants (n = 140) received oral PLC 2 × 1 g/d for six months; control participants (n = 142) received oral placebo 2 × 1 g/d for six months. Primary outcomes were MWD and PFWD on the treadmill (speed 3 km/h, slope 7%). </p> <p><a href="./references#CD010117-bbs2-0006" title="Dal LagoA , De MartiniD , FloreR , GaetaniE , GasbarriniA , GerardinoL , et al. Effects of propionyl-L-carnitine on peripheral arterial obliterative disease of the lower limbs: a double-blind clinical trial. Drugs under Experimental and Clinical Research1999;25(1):29-36. ">Dal Lago 1999</a> ‐ A double‐blind, randomized, placebo‐controlled trial with 22 (ITT) (19 (PP)) participants with IC for a minimum of one year, baseline MWD between 150 and 400 meters, and ABI less than 0.80. The intervention arm received oral PLC 1 g/d for 90 days; the control arm received oral placebo 1 g/d for 90 days. MWD and PFWD on the treadmill (speed 4 km/h, slope 4%) were the study outcomes. </p> <p><a href="./references#CD010117-bbs2-0007" title="GrecoAV , MingroneG , BianchiM , GhirlandaG . Effect of propionyl-L-carnitine in the treatment of diabetic angiopathy: controlled double-blind trial versus placebo. Drugs under Experimental and Clinical Research1992;18(2):69-80. ">Greco 1992</a> ‐ This RCT was performed double‐blind on 20 diabetic individuals with IC for a minimum of one year, ABI less than 0.75, MWD from 100 to 500 meters, and less than 20% variation in ACD during the washout period. 20 participants were randomized into two groups of 10 participants. One dropout from the placebo group was reported. The intervention (n = 10) consisted of oral PLC 1.5 g/d for six months; the control (n = 10) consisted of oral placebo 1.5 g/d for six months. Main outcomes were MWD and PFWD measured on the treadmill (slope 10%, speed 2.5 km/h). Funding was provided by Sigma Tau. </p> <p><a href="./references#CD010117-bbs2-0008" title="HiattWR , RegensteinerJG , CreagerMA , HirschAT , CookeJP , OlinJW , et al. Propionyl-L-carnitine improves exercise performance and functional status in patients with claudication. American Journal of Medicine2001;110(8):616-22. ">Hiatt 2001</a> ‐ This double‐blind, randomized, placebo‐controlled trial contains 161 (ITT) (155 (PP)) participants with IC recruited from 10 centers in the United States (six centers) and Russia (four centers). There were six dropouts due to losses to follow‐up. The intervention group (n = 82) received oral PLC 2 g/d for six months; the control group (n = 73) received oral placebo 2 g/d for six months. Peak walking time (PWT) and claudication onset time (COT) were recorded on the treadmill (speed 2 mph, slope 12%). Funding was provided by Sigma Tau. </p> <p><a href="./references#CD010117-bbs2-0009" title="HiattWR , CreagerMA , AmatoA , BrassEP . Effect of propionyl-L-carnitine on a background of monitored exercise in patients with claudication secondary to peripheral arterial disease. Journal Cardiopulmonary Rehabilitation Prevention2011;31(2):125-32. [NCT00399919]">Hiatt 2011</a> ‐ A double‐blind, randomized, placebo‐controlled multi‐center trial with 69 randomized participants between 40 and 80 years old with IC for a minimum of one year and PWT between 90 and 360 seconds at baseline (modified ITT analysis on 62 participants who underwent at least one post‐randomization treadmill test, seven dropouts due to adverse events and study withdrawal). The intervention (n = 32) consisted of oral PLC 2 g/d + instruction on home‐based physical exercise three times weekly, for a duration of six months. Control (n = 30) consisted of oral placebo 2 g/d + instruction on home‐based physical exercise three times weekly for six months. Study outcomes were PWT and COT on the treadmill (speed 2 mph, slope increase 2%/2 min). Home‐based physical exercise was checked with a Stepwatch activity monitor. Funding was provided by Sigma Tau. </p> <p><a href="./references#CD010117-bbs2-0010" title="LuoT , LiJ , LiL , YangB , LiuC , ZhengQ , et al. A study on the efficacy and safety assessment of propionyl-L-carnitine tablets in treatment of intermittent claudication. Thrombosis Research2013;132(4):427-32. NCT00809497. A clinical study on efficacy &amp; safety profile of propionyl-L-carnitine tablets for peripheral arterial diseases. clinicaltrialsgov/show/NCT00809497 (first received December 17, 2008). ">Luo 2013</a> ‐ This is a double‐blind, randomized, multi‐center, phase 3, parallel‐group study with 239 (full analysis set: all participants with at least one post‐baseline assessment) (212 (PP set: all participants who completed the trial, dropouts due to adverse events in both groups)) participants with IC with a baseline MWD between 50 and 250 meters and baseline ABI less than 0.90. Intervention participants received oral PLC 2 g/d for four months (n = 103), control participants received oral placebo 2 g/d for four months (n = 109). ABI, PWT, and COT were the study outcomes, treadmill speed and slope were not given, and speed of 2 mph was assumed (as used in eligibility tests for MWD). Funding was provided by the Lee pharmaceutical company. </p> <p><a href="./references#CD010117-bbs2-0011" title="SignorelliSS , NeriS , Di PinoL , MarcheseG , FerranteM , OliveriCG , et al. Effect of PLC on functional parameters and oxidative profile in type 2 diabetes-associated PAD. Diabetes Research and Clinical Practice2006;72(3):231-7. ">Signorelli 2006a</a> ‐ This study is a double‐blind, randomized, placebo‐controlled clinical trial with 74 participants with non‐insulin‐dependent diabetes mellitus (NIDDM)‐associated PAD (stage 2 Leriche classification). Intervention (n = 37) consisted of oral PLC 2 g/d for one year; control (n = 37) consisted of oral placebo 2 g/d for one year. ABI and PFWD were evaluated on the treadmill (speed 3.5 km/h, slope 7.5%). These measurements were performed at baseline and at 6 and 12 months. </p> <p><a href="./references#CD010117-bbs2-0012" title="SignorelliSS , FatuzzoP , RapisardaF , NeriS , FerranteM , Oliveri ContiG , et al. A randomised, controlled clinical trial evaluating changes in therapeutic efficacy and oxidative parameters after treatment with propionyl-L-carnitine in patients with peripheral arterial disease requiring hemodialysis. Drugs and Aging2006;23(3):263-70. SignorelliSS , FatuzzoP , RapisardaF , NeriS , FerranteM , Oliveri ContiG , et al. Propionyl-L-carnitine therapy: effects on endothelin-1 and homocysteine levels in patients with peripheral arterial disease and end-stage renal disease. Kidney &amp; Blood Pressure Research2006;29(2):100-7. ">Signorelli 2006b</a> ‐ This trial is a randomized, placebo‐controlled, double‐blind clinical trial of 64 participants with IC on hemodialysis (chronic kidney insufficiency). The intervention group (n = 32) received iv PLC 600 mg in saline solution three times/week for one year; the control group (n = 32) received placebo (only iv saline solution infusion) three times/week for one year. No walking distances were reported in this study; the only outcome of interest for this review was ABI. </p> <p>Studies comparing PLC against other interventions such as exercise were not identified.</p> </section> <section id="CD010117-sec-0043"> <h4 class="title">Excluded studies</h4> <p>See <a href="./references#CD010117-sec-0084" title="">Characteristics of excluded studies</a>. </p> <p>In total, we excluded 14 studies for these reasons (<a href="./references#CD010117-bbs2-0013" title="AllegraC , AntignaniPL , SchachterI , KoverechA , MessanoM , VirmaniA . Propionyl-L-carnitine in Leriche-Fontaine stage II peripheral arterial obstructive disease. Annals of Vascular Surgery2008;22(4):552-8. ">Allegra 2008</a>; <a href="./references#CD010117-bbs2-0014" title="BarkerGA , GreenS , AskewCD , GreenAA , WalterPJ . Effect of propionyl-L-carnitine on exercise performance in peripheral arterial disease. Medicine and Science in Sports and Exercise2001;33:1415-22. ">Barker 2001</a>; <a href="./references#CD010117-bbs2-0015" title="BrevettiG , ChiarielloM , PolicicchioA , RossiniA , CavallaroC , CondorelliM . L-carnitine increases walking distance in patients with peripheral arterial disease (Abstract). European Heart Journal1984;5(Suppl 1):138. ">Brevetti 1984</a>; <a href="./references#CD010117-bbs2-0016" title="BrevettiG , ChiarelloM , FerulanoG , PolicicchioA , NevolaE , RossiniA , et al. Increases in walking distance in patients with peripheral vascular disease treated with L-carnitine: a double-blind, cross-over study. Circulation1988;77(4):767-73. ">Brevetti 1988</a>; <a href="./references#CD010117-bbs2-0017" title="BrevettiG , AttisanoT , PernaS , RossiniA , PolicicchioA , CorsiM . Effects of L-carnitine on the reactive hyperemia in patients affected by peripheral vascular disease: a double-blind, cross-over study. Angiology1989;40:857-62. ">Brevetti 1989</a>; <a href="./references#CD010117-bbs2-0018" title="BrevettiG , di LisaF , PernaS , MenabóR , BarbatoR , MartoneVD , et al. Carnitine-related alternations in patients with intermittent claudication: indication for a focused carnitine therapy. Circulation1996;93(9):1685-9. ">Brevetti 1996</a>; <a href="./references#CD010117-bbs2-0019" title="GoldenbergNA , KrantzMJ , HiattWR . L-carnitine plus cilostazol verus cilostazol alone for the treatment of claudication in patients with peripheral arterial disease: a multicenter, randomized, double-blind, placebo-controlled trial. Vascular Medicine2012;17(3):145-54. ">Goldenberg 2006</a>; <a href="./references#CD010117-bbs2-0020" title="JPRN-UMIN000016267. The effect of carnitine for intermittent claudication of peripheral arterial disease patient with sarcopenia and carnitine deficiency. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000016267 (first received January 26, 2015). ">JPRN‐UMIN000016267</a>; <a href="./references#CD010117-bbs2-0021" title="LoffredoL , PignatelliP , CangemiR , AndreozziP , PanicoMA , MeloniV , et al. Imbalance between nitric oxide generation and oxidative stress in patients with peripheral arterial disease: effect on antioxidant treatment. Journal of Vascular Surgery2006;44(3):525-30. ">Loffredo 2006</a>; <a href="./references#CD010117-bbs2-0022" title="LoffredoL , CarnevaleR , CangemiR , AngelicoF , AugellettiT , DiSS , et al. NOX2 up-regulation is associated with artery dysfunction in patients with peripheral artery disease. International Journal of Cardiology2013;165(1):184-92. ">Loffredo 2013</a>; <a href="./references#CD010117-bbs2-0023" title="RagozzinoG , MatteraE , MadridE , SalomoneP , FasanoC , GioiaF , et al. Effects of propionyl-carnitine in patients with type 2 diabetes and peripheral vascular disease: results of a pilot trial. Drugs in Research and Development2004;5(4):185-90. ">Ragozzino 2004</a>; <a href="./references#CD010117-bbs2-0024" title="RiccioniC , SarcinellaR , PalermoG , IzzoA , LiguoriM , KoverechA , et al. Evaluation of the efficacy of propionyl-L-carnitine versus pulsed muscular compressions in diabetic and non-diabetic patients affected by obliterating arteriopathy Leriche stage II. International Angiology2008;27(3):253-9. ">Riccioni 2008</a>; <a href="./references#CD010117-bbs2-0025" title="StranoA , Italian Propionyl-L-Carnitine Working Group. Propionyl-L-carnitine versus pentoxifylline: improvement in walking capacity in patients with intermittent claudication. Clinical Drug Investigation2002;22(Suppl 1):1-6. ">Strano 2002</a>; <a href="./references#CD010117-bbs2-0026" title="TaylorDJ , AmatoA , HandsLJ , KempGJ , RamaswamiG , NicolaidesA , et al, MRC Biochemical and Clinical Magnetic Resonance Unit, Oxford Radcliffe Hospital Trust, UK. Changes in energy metabolism of calf muscle in patients with intermittent claudication assessed by 31P magnetic resonance spectroscopy: a phase II open study. Vascular Medicine (London, England)1996;1(4):241-5. ">Taylor 1996</a>). </p> <p> <ul id="CD010117-list-0016"> <li> <p>Study was not an RCT: <a href="./references#CD010117-bbs2-0013" title="AllegraC , AntignaniPL , SchachterI , KoverechA , MessanoM , VirmaniA . Propionyl-L-carnitine in Leriche-Fontaine stage II peripheral arterial obstructive disease. Annals of Vascular Surgery2008;22(4):552-8. ">Allegra 2008</a>, <a href="./references#CD010117-bbs2-0020" title="JPRN-UMIN000016267. The effect of carnitine for intermittent claudication of peripheral arterial disease patient with sarcopenia and carnitine deficiency. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000016267 (first received January 26, 2015). ">JPRN‐UMIN000016267</a>, <a href="./references#CD010117-bbs2-0023" title="RagozzinoG , MatteraE , MadridE , SalomoneP , FasanoC , GioiaF , et al. Effects of propionyl-carnitine in patients with type 2 diabetes and peripheral vascular disease: results of a pilot trial. Drugs in Research and Development2004;5(4):185-90. ">Ragozzino 2004</a>, and <a href="./references#CD010117-bbs2-0026" title="TaylorDJ , AmatoA , HandsLJ , KempGJ , RamaswamiG , NicolaidesA , et al, MRC Biochemical and Clinical Magnetic Resonance Unit, Oxford Radcliffe Hospital Trust, UK. Changes in energy metabolism of calf muscle in patients with intermittent claudication assessed by 31P magnetic resonance spectroscopy: a phase II open study. Vascular Medicine (London, England)1996;1(4):241-5. ">Taylor 1996</a>. </p> </li> <li> <p>No double‐blinding was noted: studies were not double‐blind (<a href="./references#CD010117-bbs2-0024" title="RiccioniC , SarcinellaR , PalermoG , IzzoA , LiguoriM , KoverechA , et al. Evaluation of the efficacy of propionyl-L-carnitine versus pulsed muscular compressions in diabetic and non-diabetic patients affected by obliterating arteriopathy Leriche stage II. International Angiology2008;27(3):253-9. ">Riccioni 2008</a> and <a href="./references#CD010117-bbs2-0025" title="StranoA , Italian Propionyl-L-Carnitine Working Group. Propionyl-L-carnitine versus pentoxifylline: improvement in walking capacity in patients with intermittent claudication. Clinical Drug Investigation2002;22(Suppl 1):1-6. ">Strano 2002</a>), or it is unclear if they were double‐blind (<a href="./references#CD010117-bbs2-0014" title="BarkerGA , GreenS , AskewCD , GreenAA , WalterPJ . Effect of propionyl-L-carnitine on exercise performance in peripheral arterial disease. Medicine and Science in Sports and Exercise2001;33:1415-22. ">Barker 2001</a>). </p> </li> <li> <p>Intervention drug in the study (L‐carnitine) was not the intervention in this review (propionyl‐L‐carnitine): <a href="./references#CD010117-bbs2-0015" title="BrevettiG , ChiarielloM , PolicicchioA , RossiniA , CavallaroC , CondorelliM . L-carnitine increases walking distance in patients with peripheral arterial disease (Abstract). European Heart Journal1984;5(Suppl 1):138. ">Brevetti 1984</a>, <a href="./references#CD010117-bbs2-0016" title="BrevettiG , ChiarelloM , FerulanoG , PolicicchioA , NevolaE , RossiniA , et al. Increases in walking distance in patients with peripheral vascular disease treated with L-carnitine: a double-blind, cross-over study. Circulation1988;77(4):767-73. ">Brevetti 1988</a>, <a href="./references#CD010117-bbs2-0017" title="BrevettiG , AttisanoT , PernaS , RossiniA , PolicicchioA , CorsiM . Effects of L-carnitine on the reactive hyperemia in patients affected by peripheral vascular disease: a double-blind, cross-over study. Angiology1989;40:857-62. ">Brevetti 1989</a>, and <a href="./references#CD010117-bbs2-0019" title="GoldenbergNA , KrantzMJ , HiattWR . L-carnitine plus cilostazol verus cilostazol alone for the treatment of claudication in patients with peripheral arterial disease: a multicenter, randomized, double-blind, placebo-controlled trial. Vascular Medicine2012;17(3):145-54. ">Goldenberg 2006</a>. </p> </li> <li> <p>Outcome parameter was not a primary or secondary outcome as set for this review: <a href="./references#CD010117-bbs2-0018" title="BrevettiG , di LisaF , PernaS , MenabóR , BarbatoR , MartoneVD , et al. Carnitine-related alternations in patients with intermittent claudication: indication for a focused carnitine therapy. Circulation1996;93(9):1685-9. ">Brevetti 1996</a> (metabolic blood markers), <a href="./references#CD010117-bbs2-0022" title="LoffredoL , CarnevaleR , CangemiR , AngelicoF , AugellettiT , DiSS , et al. NOX2 up-regulation is associated with artery dysfunction in patients with peripheral artery disease. International Journal of Cardiology2013;165(1):184-92. ">Loffredo 2013</a> (flow‐mediated dilation). </p> </li> <li> <p>Study failed on the risk of bias assessment: <a href="./references#CD010117-bbs2-0014" title="BarkerGA , GreenS , AskewCD , GreenAA , WalterPJ . Effect of propionyl-L-carnitine on exercise performance in peripheral arterial disease. Medicine and Science in Sports and Exercise2001;33:1415-22. ">Barker 2001</a>, <a href="./references#CD010117-bbs2-0021" title="LoffredoL , PignatelliP , CangemiR , AndreozziP , PanicoMA , MeloniV , et al. Imbalance between nitric oxide generation and oxidative stress in patients with peripheral arterial disease: effect on antioxidant treatment. Journal of Vascular Surgery2006;44(3):525-30. ">Loffredo 2006</a>, <a href="./references#CD010117-bbs2-0024" title="RiccioniC , SarcinellaR , PalermoG , IzzoA , LiguoriM , KoverechA , et al. Evaluation of the efficacy of propionyl-L-carnitine versus pulsed muscular compressions in diabetic and non-diabetic patients affected by obliterating arteriopathy Leriche stage II. International Angiology2008;27(3):253-9. ">Riccioni 2008</a>, and <a href="./references#CD010117-bbs2-0025" title="StranoA , Italian Propionyl-L-Carnitine Working Group. Propionyl-L-carnitine versus pentoxifylline: improvement in walking capacity in patients with intermittent claudication. Clinical Drug Investigation2002;22(Suppl 1):1-6. ">Strano 2002</a>. Also, <a href="./references#CD010117-bbs2-0014" title="BarkerGA , GreenS , AskewCD , GreenAA , WalterPJ . Effect of propionyl-L-carnitine on exercise performance in peripheral arterial disease. Medicine and Science in Sports and Exercise2001;33:1415-22. ">Barker 2001</a>, <a href="./references#CD010117-bbs2-0024" title="RiccioniC , SarcinellaR , PalermoG , IzzoA , LiguoriM , KoverechA , et al. Evaluation of the efficacy of propionyl-L-carnitine versus pulsed muscular compressions in diabetic and non-diabetic patients affected by obliterating arteriopathy Leriche stage II. International Angiology2008;27(3):253-9. ">Riccioni 2008</a>, and <a href="./references#CD010117-bbs2-0025" title="StranoA , Italian Propionyl-L-Carnitine Working Group. Propionyl-L-carnitine versus pentoxifylline: improvement in walking capacity in patients with intermittent claudication. Clinical Drug Investigation2002;22(Suppl 1):1-6. ">Strano 2002</a> have either no blinding or unclear blinding of investigators as listed above. </p> </li> </ul> </p> <p>Reasons for failing the risk of bias assessment include the following.</p> <p> <ul id="CD010117-list-0017"> <li> <p><a href="./references#CD010117-bbs2-0014" title="BarkerGA , GreenS , AskewCD , GreenAA , WalterPJ . Effect of propionyl-L-carnitine on exercise performance in peripheral arterial disease. Medicine and Science in Sports and Exercise2001;33:1415-22. ">Barker 2001</a>: incomplete outcome data (high risk: no P values for walking results), selective reporting (high risk: no further reporting on ABI; walking distances reported as coefficients of variation, which was not prespecified), blinding (unclear risk: unclear whether there was blinding on the investigators' side), other bias (high risk: very small population (six participants)). </p> </li> <li> <p><a href="./references#CD010117-bbs2-0021" title="LoffredoL , PignatelliP , CangemiR , AndreozziP , PanicoMA , MeloniV , et al. Imbalance between nitric oxide generation and oxidative stress in patients with peripheral arterial disease: effect on antioxidant treatment. Journal of Vascular Surgery2006;44(3):525-30. ">Loffredo 2006</a>: incomplete data (high risk: no P values comparing PLC and placebo), selective reporting (unclear risk: focus of this study on oxidative stress, less on walking capacity), other bias (unclear risk: very low number of participants (10), short follow‐up/treatment (7 days' treatment iv), cross‐over study: 3 days placebo ‐ 3 days PLC). Given the high risk of bias, the cross‐over design with short washout period, and the low number of participants, we hypothesize that a sensitivity analysis with this study might not be relevant and will not change the results. </p> </li> <li> <p><a href="./references#CD010117-bbs2-0024" title="RiccioniC , SarcinellaR , PalermoG , IzzoA , LiguoriM , KoverechA , et al. Evaluation of the efficacy of propionyl-L-carnitine versus pulsed muscular compressions in diabetic and non-diabetic patients affected by obliterating arteriopathy Leriche stage II. International Angiology2008;27(3):253-9. ">Riccioni 2008</a>: selection bias: no reporting of random sequence generation, no reporting of allocation concealment; blinding (high risk: no blinding), incomplete outcome data (high risk: no standard deviations); PLC monotherapy regimen alone or in association with pulsed muscular compression compared to physical therapy by itself: three arms: (1) infusional PLC therapy at a dosage of 4 fl (total: 1200 mg PLC) in 250 cc of physiological solution five days a week for four weeks; (2) treatment with PLC in association with pulsed muscular compression therapy by Vascupump (five sessions a week for four weeks); and (3) submission only to Vascupump. </p> </li> <li> <p><a href="./references#CD010117-bbs2-0025" title="StranoA , Italian Propionyl-L-Carnitine Working Group. Propionyl-L-carnitine versus pentoxifylline: improvement in walking capacity in patients with intermittent claudication. Clinical Drug Investigation2002;22(Suppl 1):1-6. ">Strano 2002</a>: blinding (high risk: no blinding), incomplete outcome data (high risk: no absolute numbers given ‐ only mean differences, without standard deviations; figures do not match results for the mean difference; follow‐up ABI values not given), selective reporting (high risk: major difference between ITT and PP populations (114 versus 68), indicating that results might be valuable only for a select group of highly motivated participants). </p> </li> </ul> </p> </section> </section> <section id="CD010117-sec-0044"> <h3 class="title">Risk of bias in included studies</h3> <p>The risk of bias assessment was performed according to the Cochrane guidelines described by <a href="./references#CD010117-bbs2-0046" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>. The individual assessment for each study can be found in the risk of bias table under <a href="./references#CD010117-sec-0083" title="">Characteristics of included studies</a>. Insufficient information was the main reason for rating "unclear risk." See <a href="#CD010117-fig-0002">Figure 2</a> and <a href="#CD010117-fig-0003">Figure 3</a> for a graphical presentation of the risk of bias. </p> <div class="figure" id="CD010117-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph of the included studies: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD010117-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/image_n/nCD010117-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph of the included studies: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD010117-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD010117-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/image_n/nCD010117-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD010117-sec-0045"> <h4 class="title">Allocation</h4> <p>In four trials, the randomization method was given in sufficient detail (low risk) (<a href="./references#CD010117-bbs2-0006" title="Dal LagoA , De MartiniD , FloreR , GaetaniE , GasbarriniA , GerardinoL , et al. Effects of propionyl-L-carnitine on peripheral arterial obliterative disease of the lower limbs: a double-blind clinical trial. Drugs under Experimental and Clinical Research1999;25(1):29-36. ">Dal Lago 1999</a>; <a href="./references#CD010117-bbs2-0008" title="HiattWR , RegensteinerJG , CreagerMA , HirschAT , CookeJP , OlinJW , et al. Propionyl-L-carnitine improves exercise performance and functional status in patients with claudication. American Journal of Medicine2001;110(8):616-22. ">Hiatt 2001</a>; <a href="./references#CD010117-bbs2-0011" title="SignorelliSS , NeriS , Di PinoL , MarcheseG , FerranteM , OliveriCG , et al. Effect of PLC on functional parameters and oxidative profile in type 2 diabetes-associated PAD. Diabetes Research and Clinical Practice2006;72(3):231-7. ">Signorelli 2006a</a>; <a href="./references#CD010117-bbs2-0012" title="SignorelliSS , FatuzzoP , RapisardaF , NeriS , FerranteM , Oliveri ContiG , et al. A randomised, controlled clinical trial evaluating changes in therapeutic efficacy and oxidative parameters after treatment with propionyl-L-carnitine in patients with peripheral arterial disease requiring hemodialysis. Drugs and Aging2006;23(3):263-70. SignorelliSS , FatuzzoP , RapisardaF , NeriS , FerranteM , Oliveri ContiG , et al. Propionyl-L-carnitine therapy: effects on endothelin-1 and homocysteine levels in patients with peripheral arterial disease and end-stage renal disease. Kidney &amp; Blood Pressure Research2006;29(2):100-7. ">Signorelli 2006b</a>). The method used to generate allocation concealment was unclear in all trials (<a href="./references#CD010117-bbs2-0001" title="AndreozziGM , LeoneA , LaudaniR , MartiniR , DeiniteG , CataldiV . Levo-propionyl-carnitine improves the effectiveness of supervised physical training on the absolute claudication distance in patients with intermittent claudication. Angiology2008;59(1):84-9. ">Andreozzi 2008</a>; <a href="./references#CD010117-bbs2-0002" title="BrevettiG , PernaS , SabbaC , RossiniA , Scotto di UccioV , BerardiE , et al. Superiority of L-propionylcarnitine vs L-carnitine in improving walking capacity in patients with peripheral vascular disease: an acute, intravenous, double-blind, cross-over study. European Heart Journal1992;13(2):251-5. ">Brevetti 1992</a>; <a href="./references#CD010117-bbs2-0003" title="BrevettiG , PernaS , SabbaC , MartoneVD , CondorelliM . Propionyl-L-carnitine in intermittent claudication: double-blind, placebo-controlled, dose titration, multicenter study. Journal of American College of Cardiology1995;26(6):1411-6. BrevettiG , PernaS , SabbaC , MartoneVD , Di IorioA , BarlettaG . Effect of propionyl-L-carnitine on quality of life in intermittent claudication. American Journal of Cardiology1997;79(6):777-80. ">Brevetti 1995</a>; <a href="./references#CD010117-bbs2-0004" title="BrevettiG , DiehmC , LambertD . European multicenter study on propionyl-l-carnitine in intermittent claudication. Journal of American College of Cardiology1999;34(5):1618-24. ">Brevetti 1999</a>; <a href="./references#CD010117-bbs2-0005" title="CotoV , D'AlessandroL , GrattarolaG , ImparatoL , LingettiM , ManciniM , et al. Evaluation of the therapeutic efficacy and tolerability of levocarnitine propionyl in the treatment of chronic obstructive arteriopathies of the lower extremities: a multicentre controlled study vs. placebo. Drugs under Experimental and Clinical Research1992;18(1):29-36. ">Coto 1992</a>; <a href="./references#CD010117-bbs2-0006" title="Dal LagoA , De MartiniD , FloreR , GaetaniE , GasbarriniA , GerardinoL , et al. Effects of propionyl-L-carnitine on peripheral arterial obliterative disease of the lower limbs: a double-blind clinical trial. Drugs under Experimental and Clinical Research1999;25(1):29-36. ">Dal Lago 1999</a>; <a href="./references#CD010117-bbs2-0007" title="GrecoAV , MingroneG , BianchiM , GhirlandaG . Effect of propionyl-L-carnitine in the treatment of diabetic angiopathy: controlled double-blind trial versus placebo. Drugs under Experimental and Clinical Research1992;18(2):69-80. ">Greco 1992</a>; <a href="./references#CD010117-bbs2-0008" title="HiattWR , RegensteinerJG , CreagerMA , HirschAT , CookeJP , OlinJW , et al. Propionyl-L-carnitine improves exercise performance and functional status in patients with claudication. American Journal of Medicine2001;110(8):616-22. ">Hiatt 2001</a>; <a href="./references#CD010117-bbs2-0009" title="HiattWR , CreagerMA , AmatoA , BrassEP . Effect of propionyl-L-carnitine on a background of monitored exercise in patients with claudication secondary to peripheral arterial disease. Journal Cardiopulmonary Rehabilitation Prevention2011;31(2):125-32. [NCT00399919]">Hiatt 2011</a>; <a href="./references#CD010117-bbs2-0010" title="LuoT , LiJ , LiL , YangB , LiuC , ZhengQ , et al. A study on the efficacy and safety assessment of propionyl-L-carnitine tablets in treatment of intermittent claudication. Thrombosis Research2013;132(4):427-32. NCT00809497. A clinical study on efficacy &amp; safety profile of propionyl-L-carnitine tablets for peripheral arterial diseases. clinicaltrialsgov/show/NCT00809497 (first received December 17, 2008). ">Luo 2013</a>; <a href="./references#CD010117-bbs2-0011" title="SignorelliSS , NeriS , Di PinoL , MarcheseG , FerranteM , OliveriCG , et al. Effect of PLC on functional parameters and oxidative profile in type 2 diabetes-associated PAD. Diabetes Research and Clinical Practice2006;72(3):231-7. ">Signorelli 2006a</a>; <a href="./references#CD010117-bbs2-0012" title="SignorelliSS , FatuzzoP , RapisardaF , NeriS , FerranteM , Oliveri ContiG , et al. A randomised, controlled clinical trial evaluating changes in therapeutic efficacy and oxidative parameters after treatment with propionyl-L-carnitine in patients with peripheral arterial disease requiring hemodialysis. Drugs and Aging2006;23(3):263-70. SignorelliSS , FatuzzoP , RapisardaF , NeriS , FerranteM , Oliveri ContiG , et al. Propionyl-L-carnitine therapy: effects on endothelin-1 and homocysteine levels in patients with peripheral arterial disease and end-stage renal disease. Kidney &amp; Blood Pressure Research2006;29(2):100-7. ">Signorelli 2006b</a>). </p> <p>None of the 12 included studies reported on allocation concealment.</p> </section> <section id="CD010117-sec-0046"> <h4 class="title">Blinding</h4> <p>Eleven trials were at low risk for performance bias, as there was blinding of personnel and participants (<a href="./references#CD010117-bbs2-0002" title="BrevettiG , PernaS , SabbaC , RossiniA , Scotto di UccioV , BerardiE , et al. Superiority of L-propionylcarnitine vs L-carnitine in improving walking capacity in patients with peripheral vascular disease: an acute, intravenous, double-blind, cross-over study. European Heart Journal1992;13(2):251-5. ">Brevetti 1992</a>; <a href="./references#CD010117-bbs2-0003" title="BrevettiG , PernaS , SabbaC , MartoneVD , CondorelliM . Propionyl-L-carnitine in intermittent claudication: double-blind, placebo-controlled, dose titration, multicenter study. Journal of American College of Cardiology1995;26(6):1411-6. BrevettiG , PernaS , SabbaC , MartoneVD , Di IorioA , BarlettaG . Effect of propionyl-L-carnitine on quality of life in intermittent claudication. American Journal of Cardiology1997;79(6):777-80. ">Brevetti 1995</a>; <a href="./references#CD010117-bbs2-0004" title="BrevettiG , DiehmC , LambertD . European multicenter study on propionyl-l-carnitine in intermittent claudication. Journal of American College of Cardiology1999;34(5):1618-24. ">Brevetti 1999</a>; <a href="./references#CD010117-bbs2-0005" title="CotoV , D'AlessandroL , GrattarolaG , ImparatoL , LingettiM , ManciniM , et al. Evaluation of the therapeutic efficacy and tolerability of levocarnitine propionyl in the treatment of chronic obstructive arteriopathies of the lower extremities: a multicentre controlled study vs. placebo. Drugs under Experimental and Clinical Research1992;18(1):29-36. ">Coto 1992</a>; <a href="./references#CD010117-bbs2-0006" title="Dal LagoA , De MartiniD , FloreR , GaetaniE , GasbarriniA , GerardinoL , et al. Effects of propionyl-L-carnitine on peripheral arterial obliterative disease of the lower limbs: a double-blind clinical trial. Drugs under Experimental and Clinical Research1999;25(1):29-36. ">Dal Lago 1999</a>; <a href="./references#CD010117-bbs2-0007" title="GrecoAV , MingroneG , BianchiM , GhirlandaG . Effect of propionyl-L-carnitine in the treatment of diabetic angiopathy: controlled double-blind trial versus placebo. Drugs under Experimental and Clinical Research1992;18(2):69-80. ">Greco 1992</a>; <a href="./references#CD010117-bbs2-0008" title="HiattWR , RegensteinerJG , CreagerMA , HirschAT , CookeJP , OlinJW , et al. Propionyl-L-carnitine improves exercise performance and functional status in patients with claudication. American Journal of Medicine2001;110(8):616-22. ">Hiatt 2001</a>; <a href="./references#CD010117-bbs2-0009" title="HiattWR , CreagerMA , AmatoA , BrassEP . Effect of propionyl-L-carnitine on a background of monitored exercise in patients with claudication secondary to peripheral arterial disease. Journal Cardiopulmonary Rehabilitation Prevention2011;31(2):125-32. [NCT00399919]">Hiatt 2011</a>; <a href="./references#CD010117-bbs2-0010" title="LuoT , LiJ , LiL , YangB , LiuC , ZhengQ , et al. A study on the efficacy and safety assessment of propionyl-L-carnitine tablets in treatment of intermittent claudication. Thrombosis Research2013;132(4):427-32. NCT00809497. A clinical study on efficacy &amp; safety profile of propionyl-L-carnitine tablets for peripheral arterial diseases. clinicaltrialsgov/show/NCT00809497 (first received December 17, 2008). ">Luo 2013</a>; <a href="./references#CD010117-bbs2-0011" title="SignorelliSS , NeriS , Di PinoL , MarcheseG , FerranteM , OliveriCG , et al. Effect of PLC on functional parameters and oxidative profile in type 2 diabetes-associated PAD. Diabetes Research and Clinical Practice2006;72(3):231-7. ">Signorelli 2006a</a>; <a href="./references#CD010117-bbs2-0012" title="SignorelliSS , FatuzzoP , RapisardaF , NeriS , FerranteM , Oliveri ContiG , et al. A randomised, controlled clinical trial evaluating changes in therapeutic efficacy and oxidative parameters after treatment with propionyl-L-carnitine in patients with peripheral arterial disease requiring hemodialysis. Drugs and Aging2006;23(3):263-70. SignorelliSS , FatuzzoP , RapisardaF , NeriS , FerranteM , Oliveri ContiG , et al. Propionyl-L-carnitine therapy: effects on endothelin-1 and homocysteine levels in patients with peripheral arterial disease and end-stage renal disease. Kidney &amp; Blood Pressure Research2006;29(2):100-7. ">Signorelli 2006b</a>). For the same 11 studies, blinding of outcome assessment was assumed, indicating low risk for detection bias. For only one study, risk for performance and detection bias was unclear due to lack of information (<a href="./references#CD010117-bbs2-0001" title="AndreozziGM , LeoneA , LaudaniR , MartiniR , DeiniteG , CataldiV . Levo-propionyl-carnitine improves the effectiveness of supervised physical training on the absolute claudication distance in patients with intermittent claudication. Angiology2008;59(1):84-9. ">Andreozzi 2008</a>). </p> </section> <section id="CD010117-sec-0047"> <h4 class="title">Incomplete outcome data</h4> <p>All 12 included studies were at low risk for attrition bias, as all results for all (sub)groups were given (<a href="./references#CD010117-bbs2-0001" title="AndreozziGM , LeoneA , LaudaniR , MartiniR , DeiniteG , CataldiV . Levo-propionyl-carnitine improves the effectiveness of supervised physical training on the absolute claudication distance in patients with intermittent claudication. Angiology2008;59(1):84-9. ">Andreozzi 2008</a>; <a href="./references#CD010117-bbs2-0002" title="BrevettiG , PernaS , SabbaC , RossiniA , Scotto di UccioV , BerardiE , et al. Superiority of L-propionylcarnitine vs L-carnitine in improving walking capacity in patients with peripheral vascular disease: an acute, intravenous, double-blind, cross-over study. European Heart Journal1992;13(2):251-5. ">Brevetti 1992</a>; <a href="./references#CD010117-bbs2-0003" title="BrevettiG , PernaS , SabbaC , MartoneVD , CondorelliM . Propionyl-L-carnitine in intermittent claudication: double-blind, placebo-controlled, dose titration, multicenter study. Journal of American College of Cardiology1995;26(6):1411-6. BrevettiG , PernaS , SabbaC , MartoneVD , Di IorioA , BarlettaG . Effect of propionyl-L-carnitine on quality of life in intermittent claudication. American Journal of Cardiology1997;79(6):777-80. ">Brevetti 1995</a>; <a href="./references#CD010117-bbs2-0004" title="BrevettiG , DiehmC , LambertD . European multicenter study on propionyl-l-carnitine in intermittent claudication. Journal of American College of Cardiology1999;34(5):1618-24. ">Brevetti 1999</a>; <a href="./references#CD010117-bbs2-0005" title="CotoV , D'AlessandroL , GrattarolaG , ImparatoL , LingettiM , ManciniM , et al. Evaluation of the therapeutic efficacy and tolerability of levocarnitine propionyl in the treatment of chronic obstructive arteriopathies of the lower extremities: a multicentre controlled study vs. placebo. Drugs under Experimental and Clinical Research1992;18(1):29-36. ">Coto 1992</a>; <a href="./references#CD010117-bbs2-0006" title="Dal LagoA , De MartiniD , FloreR , GaetaniE , GasbarriniA , GerardinoL , et al. Effects of propionyl-L-carnitine on peripheral arterial obliterative disease of the lower limbs: a double-blind clinical trial. Drugs under Experimental and Clinical Research1999;25(1):29-36. ">Dal Lago 1999</a>; <a href="./references#CD010117-bbs2-0007" title="GrecoAV , MingroneG , BianchiM , GhirlandaG . Effect of propionyl-L-carnitine in the treatment of diabetic angiopathy: controlled double-blind trial versus placebo. Drugs under Experimental and Clinical Research1992;18(2):69-80. ">Greco 1992</a>; <a href="./references#CD010117-bbs2-0008" title="HiattWR , RegensteinerJG , CreagerMA , HirschAT , CookeJP , OlinJW , et al. Propionyl-L-carnitine improves exercise performance and functional status in patients with claudication. American Journal of Medicine2001;110(8):616-22. ">Hiatt 2001</a>; <a href="./references#CD010117-bbs2-0009" title="HiattWR , CreagerMA , AmatoA , BrassEP . Effect of propionyl-L-carnitine on a background of monitored exercise in patients with claudication secondary to peripheral arterial disease. Journal Cardiopulmonary Rehabilitation Prevention2011;31(2):125-32. [NCT00399919]">Hiatt 2011</a>; <a href="./references#CD010117-bbs2-0010" title="LuoT , LiJ , LiL , YangB , LiuC , ZhengQ , et al. A study on the efficacy and safety assessment of propionyl-L-carnitine tablets in treatment of intermittent claudication. Thrombosis Research2013;132(4):427-32. NCT00809497. A clinical study on efficacy &amp; safety profile of propionyl-L-carnitine tablets for peripheral arterial diseases. clinicaltrialsgov/show/NCT00809497 (first received December 17, 2008). ">Luo 2013</a>; <a href="./references#CD010117-bbs2-0011" title="SignorelliSS , NeriS , Di PinoL , MarcheseG , FerranteM , OliveriCG , et al. Effect of PLC on functional parameters and oxidative profile in type 2 diabetes-associated PAD. Diabetes Research and Clinical Practice2006;72(3):231-7. ">Signorelli 2006a</a>; <a href="./references#CD010117-bbs2-0012" title="SignorelliSS , FatuzzoP , RapisardaF , NeriS , FerranteM , Oliveri ContiG , et al. A randomised, controlled clinical trial evaluating changes in therapeutic efficacy and oxidative parameters after treatment with propionyl-L-carnitine in patients with peripheral arterial disease requiring hemodialysis. Drugs and Aging2006;23(3):263-70. SignorelliSS , FatuzzoP , RapisardaF , NeriS , FerranteM , Oliveri ContiG , et al. Propionyl-L-carnitine therapy: effects on endothelin-1 and homocysteine levels in patients with peripheral arterial disease and end-stage renal disease. Kidney &amp; Blood Pressure Research2006;29(2):100-7. ">Signorelli 2006b</a>). </p> </section> <section id="CD010117-sec-0048"> <h4 class="title">Selective reporting</h4> <p>Only five trials had low risk of reporting bias (<a href="./references#CD010117-bbs2-0001" title="AndreozziGM , LeoneA , LaudaniR , MartiniR , DeiniteG , CataldiV . Levo-propionyl-carnitine improves the effectiveness of supervised physical training on the absolute claudication distance in patients with intermittent claudication. Angiology2008;59(1):84-9. ">Andreozzi 2008</a>; <a href="./references#CD010117-bbs2-0007" title="GrecoAV , MingroneG , BianchiM , GhirlandaG . Effect of propionyl-L-carnitine in the treatment of diabetic angiopathy: controlled double-blind trial versus placebo. Drugs under Experimental and Clinical Research1992;18(2):69-80. ">Greco 1992</a>; <a href="./references#CD010117-bbs2-0010" title="LuoT , LiJ , LiL , YangB , LiuC , ZhengQ , et al. A study on the efficacy and safety assessment of propionyl-L-carnitine tablets in treatment of intermittent claudication. Thrombosis Research2013;132(4):427-32. NCT00809497. A clinical study on efficacy &amp; safety profile of propionyl-L-carnitine tablets for peripheral arterial diseases. clinicaltrialsgov/show/NCT00809497 (first received December 17, 2008). ">Luo 2013</a>; <a href="./references#CD010117-bbs2-0011" title="SignorelliSS , NeriS , Di PinoL , MarcheseG , FerranteM , OliveriCG , et al. Effect of PLC on functional parameters and oxidative profile in type 2 diabetes-associated PAD. Diabetes Research and Clinical Practice2006;72(3):231-7. ">Signorelli 2006a</a>; <a href="./references#CD010117-bbs2-0012" title="SignorelliSS , FatuzzoP , RapisardaF , NeriS , FerranteM , Oliveri ContiG , et al. A randomised, controlled clinical trial evaluating changes in therapeutic efficacy and oxidative parameters after treatment with propionyl-L-carnitine in patients with peripheral arterial disease requiring hemodialysis. Drugs and Aging2006;23(3):263-70. SignorelliSS , FatuzzoP , RapisardaF , NeriS , FerranteM , Oliveri ContiG , et al. Propionyl-L-carnitine therapy: effects on endothelin-1 and homocysteine levels in patients with peripheral arterial disease and end-stage renal disease. Kidney &amp; Blood Pressure Research2006;29(2):100-7. ">Signorelli 2006b</a>). For the other seven trials, there was a possibility of selective reporting, indicating unclear risk due to various reasons (see "Risk of bias table") (<a href="./references#CD010117-bbs2-0002" title="BrevettiG , PernaS , SabbaC , RossiniA , Scotto di UccioV , BerardiE , et al. Superiority of L-propionylcarnitine vs L-carnitine in improving walking capacity in patients with peripheral vascular disease: an acute, intravenous, double-blind, cross-over study. European Heart Journal1992;13(2):251-5. ">Brevetti 1992</a>; <a href="./references#CD010117-bbs2-0003" title="BrevettiG , PernaS , SabbaC , MartoneVD , CondorelliM . Propionyl-L-carnitine in intermittent claudication: double-blind, placebo-controlled, dose titration, multicenter study. Journal of American College of Cardiology1995;26(6):1411-6. BrevettiG , PernaS , SabbaC , MartoneVD , Di IorioA , BarlettaG . Effect of propionyl-L-carnitine on quality of life in intermittent claudication. American Journal of Cardiology1997;79(6):777-80. ">Brevetti 1995</a>; <a href="./references#CD010117-bbs2-0004" title="BrevettiG , DiehmC , LambertD . European multicenter study on propionyl-l-carnitine in intermittent claudication. Journal of American College of Cardiology1999;34(5):1618-24. ">Brevetti 1999</a>; <a href="./references#CD010117-bbs2-0005" title="CotoV , D'AlessandroL , GrattarolaG , ImparatoL , LingettiM , ManciniM , et al. Evaluation of the therapeutic efficacy and tolerability of levocarnitine propionyl in the treatment of chronic obstructive arteriopathies of the lower extremities: a multicentre controlled study vs. placebo. Drugs under Experimental and Clinical Research1992;18(1):29-36. ">Coto 1992</a>; <a href="./references#CD010117-bbs2-0006" title="Dal LagoA , De MartiniD , FloreR , GaetaniE , GasbarriniA , GerardinoL , et al. Effects of propionyl-L-carnitine on peripheral arterial obliterative disease of the lower limbs: a double-blind clinical trial. Drugs under Experimental and Clinical Research1999;25(1):29-36. ">Dal Lago 1999</a>; <a href="./references#CD010117-bbs2-0008" title="HiattWR , RegensteinerJG , CreagerMA , HirschAT , CookeJP , OlinJW , et al. Propionyl-L-carnitine improves exercise performance and functional status in patients with claudication. American Journal of Medicine2001;110(8):616-22. ">Hiatt 2001</a>; <a href="./references#CD010117-bbs2-0009" title="HiattWR , CreagerMA , AmatoA , BrassEP . Effect of propionyl-L-carnitine on a background of monitored exercise in patients with claudication secondary to peripheral arterial disease. Journal Cardiopulmonary Rehabilitation Prevention2011;31(2):125-32. [NCT00399919]">Hiatt 2011</a>). </p> </section> <section id="CD010117-sec-0049"> <h4 class="title">Other potential sources of bias</h4> <p>One trial reported pharmaceutical company funding and also explicitly reported the absence of conflict of interest (although there was company sponsoring) (<a href="./references#CD010117-bbs2-0010" title="LuoT , LiJ , LiL , YangB , LiuC , ZhengQ , et al. A study on the efficacy and safety assessment of propionyl-L-carnitine tablets in treatment of intermittent claudication. Thrombosis Research2013;132(4):427-32. NCT00809497. A clinical study on efficacy &amp; safety profile of propionyl-L-carnitine tablets for peripheral arterial diseases. clinicaltrialsgov/show/NCT00809497 (first received December 17, 2008). ">Luo 2013</a>). Eight trials do report on company funding and therefore might have a possible conflict of interest (unclear risk) (<a href="./references#CD010117-bbs2-0001" title="AndreozziGM , LeoneA , LaudaniR , MartiniR , DeiniteG , CataldiV . Levo-propionyl-carnitine improves the effectiveness of supervised physical training on the absolute claudication distance in patients with intermittent claudication. Angiology2008;59(1):84-9. ">Andreozzi 2008</a>; <a href="./references#CD010117-bbs2-0002" title="BrevettiG , PernaS , SabbaC , RossiniA , Scotto di UccioV , BerardiE , et al. Superiority of L-propionylcarnitine vs L-carnitine in improving walking capacity in patients with peripheral vascular disease: an acute, intravenous, double-blind, cross-over study. European Heart Journal1992;13(2):251-5. ">Brevetti 1992</a>; <a href="./references#CD010117-bbs2-0003" title="BrevettiG , PernaS , SabbaC , MartoneVD , CondorelliM . Propionyl-L-carnitine in intermittent claudication: double-blind, placebo-controlled, dose titration, multicenter study. Journal of American College of Cardiology1995;26(6):1411-6. BrevettiG , PernaS , SabbaC , MartoneVD , Di IorioA , BarlettaG . Effect of propionyl-L-carnitine on quality of life in intermittent claudication. American Journal of Cardiology1997;79(6):777-80. ">Brevetti 1995</a>; <a href="./references#CD010117-bbs2-0004" title="BrevettiG , DiehmC , LambertD . European multicenter study on propionyl-l-carnitine in intermittent claudication. Journal of American College of Cardiology1999;34(5):1618-24. ">Brevetti 1999</a>; <a href="./references#CD010117-bbs2-0006" title="Dal LagoA , De MartiniD , FloreR , GaetaniE , GasbarriniA , GerardinoL , et al. Effects of propionyl-L-carnitine on peripheral arterial obliterative disease of the lower limbs: a double-blind clinical trial. Drugs under Experimental and Clinical Research1999;25(1):29-36. ">Dal Lago 1999</a>; <a href="./references#CD010117-bbs2-0007" title="GrecoAV , MingroneG , BianchiM , GhirlandaG . Effect of propionyl-L-carnitine in the treatment of diabetic angiopathy: controlled double-blind trial versus placebo. Drugs under Experimental and Clinical Research1992;18(2):69-80. ">Greco 1992</a>; <a href="./references#CD010117-bbs2-0008" title="HiattWR , RegensteinerJG , CreagerMA , HirschAT , CookeJP , OlinJW , et al. Propionyl-L-carnitine improves exercise performance and functional status in patients with claudication. American Journal of Medicine2001;110(8):616-22. ">Hiatt 2001</a>; <a href="./references#CD010117-bbs2-0009" title="HiattWR , CreagerMA , AmatoA , BrassEP . Effect of propionyl-L-carnitine on a background of monitored exercise in patients with claudication secondary to peripheral arterial disease. Journal Cardiopulmonary Rehabilitation Prevention2011;31(2):125-32. [NCT00399919]">Hiatt 2011</a>). Three trials do not report any funding and do not provide a conflict of interest statement (<a href="./references#CD010117-bbs2-0005" title="CotoV , D'AlessandroL , GrattarolaG , ImparatoL , LingettiM , ManciniM , et al. Evaluation of the therapeutic efficacy and tolerability of levocarnitine propionyl in the treatment of chronic obstructive arteriopathies of the lower extremities: a multicentre controlled study vs. placebo. Drugs under Experimental and Clinical Research1992;18(1):29-36. ">Coto 1992</a>; <a href="./references#CD010117-bbs2-0011" title="SignorelliSS , NeriS , Di PinoL , MarcheseG , FerranteM , OliveriCG , et al. Effect of PLC on functional parameters and oxidative profile in type 2 diabetes-associated PAD. Diabetes Research and Clinical Practice2006;72(3):231-7. ">Signorelli 2006a</a>; <a href="./references#CD010117-bbs2-0012" title="SignorelliSS , FatuzzoP , RapisardaF , NeriS , FerranteM , Oliveri ContiG , et al. A randomised, controlled clinical trial evaluating changes in therapeutic efficacy and oxidative parameters after treatment with propionyl-L-carnitine in patients with peripheral arterial disease requiring hemodialysis. Drugs and Aging2006;23(3):263-70. SignorelliSS , FatuzzoP , RapisardaF , NeriS , FerranteM , Oliveri ContiG , et al. Propionyl-L-carnitine therapy: effects on endothelin-1 and homocysteine levels in patients with peripheral arterial disease and end-stage renal disease. Kidney &amp; Blood Pressure Research2006;29(2):100-7. ">Signorelli 2006b</a>). </p> <p>The main analysis of <a href="./references#CD010117-bbs2-0003" title="BrevettiG , PernaS , SabbaC , MartoneVD , CondorelliM . Propionyl-L-carnitine in intermittent claudication: double-blind, placebo-controlled, dose titration, multicenter study. Journal of American College of Cardiology1995;26(6):1411-6. BrevettiG , PernaS , SabbaC , MartoneVD , Di IorioA , BarlettaG . Effect of propionyl-L-carnitine on quality of life in intermittent claudication. American Journal of Cardiology1997;79(6):777-80. ">Brevetti 1995</a> was not split into subgroups of severe and moderate claudication, as was done in an additional publication for the same population (<a href="./references#CD010117-bbs2-0030" title="BrevettiG , FaninM , De AmicisV , CarrozzoR , Di LelloF , MartoneVD , et al. Changes in skeletal muscle histology and metabolism in patients undergoing exercise deconditioning: effect of propionyl-L-carnitine. Muscle and Nerve1997;20(9):1115-20.">Brevetti 1997</a>). A pronounced outcome discrepancy was shown between groups A (98 participants coming from 1 center) and B (116 participants coming from 12 centers). The study authors themselves state that "a marked center effect was observed because the 77 patients studied in 1 center were more severely affected than those studied in the remaining 12 centers." A conflict of interest is possible because the study was supported by Sigma Tau. </p> </section> </section> <section id="CD010117-sec-0050"> <h3 class="title" id="CD010117-sec-0050">Effects of interventions</h3> <p>See: <a href="./full#CD010117-tbl-0001"><b>Summary of findings 1</b> Propionyl‐L‐carnitine compared to placebo for intermittent claudication</a>; <a href="./full#CD010117-tbl-0002"><b>Summary of findings 2</b> Propionyl‐L‐carnitine compared to L‐carnitine for intermittent claudication</a> </p> <section id="CD010117-sec-0051"> <h4 class="title">PLC versus placebo or control</h4> <section id="CD010117-sec-0052"> <h5 class="title">Absolute claudication distance</h5> <p>In this review, under the common term "absolute claudication distance" (ACD), we unite all results from different studies that evaluate maximal walking performance. This includes all maximal walking distance (MWD) (in unit of length) results as well as all peak walking time (PWT) (in unit of time) results from the included studies. All time measurements from PWT studies were converted to absolute distances (in meters), according to treadmill testing speed. This might be subject to discussion given the fact that for example studies that use PWT on a graded treadmill are not comparable to studies that use MWD on a constant‐load treadmill. However, different treadmill protocols exist within studies measuring MWD and within those measuring PWT. Therefore, we also based the data on the treatment effect of the ratio (or percent change) of the benefit of propionyl‐L‐carnitine (PLC) relative to the benefit of placebo or control (or other active) treatment. </p> <p>Selection of relevant and reliable studies resulted in nine included studies reporting on ACD (<a href="./references#CD010117-bbs2-0001" title="AndreozziGM , LeoneA , LaudaniR , MartiniR , DeiniteG , CataldiV . Levo-propionyl-carnitine improves the effectiveness of supervised physical training on the absolute claudication distance in patients with intermittent claudication. Angiology2008;59(1):84-9. ">Andreozzi 2008</a>; <a href="./references#CD010117-bbs2-0003" title="BrevettiG , PernaS , SabbaC , MartoneVD , CondorelliM . Propionyl-L-carnitine in intermittent claudication: double-blind, placebo-controlled, dose titration, multicenter study. Journal of American College of Cardiology1995;26(6):1411-6. BrevettiG , PernaS , SabbaC , MartoneVD , Di IorioA , BarlettaG . Effect of propionyl-L-carnitine on quality of life in intermittent claudication. American Journal of Cardiology1997;79(6):777-80. ">Brevetti 1995</a>; <a href="./references#CD010117-bbs2-0004" title="BrevettiG , DiehmC , LambertD . European multicenter study on propionyl-l-carnitine in intermittent claudication. Journal of American College of Cardiology1999;34(5):1618-24. ">Brevetti 1999</a>; <a href="./references#CD010117-bbs2-0005" title="CotoV , D'AlessandroL , GrattarolaG , ImparatoL , LingettiM , ManciniM , et al. Evaluation of the therapeutic efficacy and tolerability of levocarnitine propionyl in the treatment of chronic obstructive arteriopathies of the lower extremities: a multicentre controlled study vs. placebo. Drugs under Experimental and Clinical Research1992;18(1):29-36. ">Coto 1992</a>; <a href="./references#CD010117-bbs2-0006" title="Dal LagoA , De MartiniD , FloreR , GaetaniE , GasbarriniA , GerardinoL , et al. Effects of propionyl-L-carnitine on peripheral arterial obliterative disease of the lower limbs: a double-blind clinical trial. Drugs under Experimental and Clinical Research1999;25(1):29-36. ">Dal Lago 1999</a>; <a href="./references#CD010117-bbs2-0007" title="GrecoAV , MingroneG , BianchiM , GhirlandaG . Effect of propionyl-L-carnitine in the treatment of diabetic angiopathy: controlled double-blind trial versus placebo. Drugs under Experimental and Clinical Research1992;18(2):69-80. ">Greco 1992</a>; <a href="./references#CD010117-bbs2-0008" title="HiattWR , RegensteinerJG , CreagerMA , HirschAT , CookeJP , OlinJW , et al. Propionyl-L-carnitine improves exercise performance and functional status in patients with claudication. American Journal of Medicine2001;110(8):616-22. ">Hiatt 2001</a>; <a href="./references#CD010117-bbs2-0009" title="HiattWR , CreagerMA , AmatoA , BrassEP . Effect of propionyl-L-carnitine on a background of monitored exercise in patients with claudication secondary to peripheral arterial disease. Journal Cardiopulmonary Rehabilitation Prevention2011;31(2):125-32. [NCT00399919]">Hiatt 2011</a>; <a href="./references#CD010117-bbs2-0010" title="LuoT , LiJ , LiL , YangB , LiuC , ZhengQ , et al. A study on the efficacy and safety assessment of propionyl-L-carnitine tablets in treatment of intermittent claudication. Thrombosis Research2013;132(4):427-32. NCT00809497. A clinical study on efficacy &amp; safety profile of propionyl-L-carnitine tablets for peripheral arterial diseases. clinicaltrialsgov/show/NCT00809497 (first received December 17, 2008). ">Luo 2013</a>). In total, this participant pool contained 1257 participants (627 PLC participants, 630 placebo control participants) who were randomized for supplementation (intention‐to‐treat (ITT) population). 1121 participants or 89.2% completed the trials and could be administered for further full analysis (per‐protocol (PP) population). In light of this participant pool, randomization in the studies created two balanced groups that were comparable in number, age, and sex. The following baseline clinical parameters matched well: baseline ACD 186 meters for the PLC group, 191 meters for the placebo group, and baseline ankle brachial index (ABI) mean equal to 0.63 in both intervention arms. The dropout ratio differed (12.1% versus 9.5%); however, this results mainly from inequalities in the <a href="./references#CD010117-bbs2-0003" title="BrevettiG , PernaS , SabbaC , MartoneVD , CondorelliM . Propionyl-L-carnitine in intermittent claudication: double-blind, placebo-controlled, dose titration, multicenter study. Journal of American College of Cardiology1995;26(6):1411-6. BrevettiG , PernaS , SabbaC , MartoneVD , Di IorioA , BarlettaG . Effect of propionyl-L-carnitine on quality of life in intermittent claudication. American Journal of Cardiology1997;79(6):777-80. ">Brevetti 1995</a> and <a href="./references#CD010117-bbs2-0010" title="LuoT , LiJ , LiL , YangB , LiuC , ZhengQ , et al. A study on the efficacy and safety assessment of propionyl-L-carnitine tablets in treatment of intermittent claudication. Thrombosis Research2013;132(4):427-32. NCT00809497. A clinical study on efficacy &amp; safety profile of propionyl-L-carnitine tablets for peripheral arterial diseases. clinicaltrialsgov/show/NCT00809497 (first received December 17, 2008). ">Luo 2013</a> studies. Reasons for dropout in these studies are given; dropout is likely to be due to coincidence. </p> <p>Detailed results can be found under <a href="./references#CD010117-fig-0010" title="">Analysis 1.1</a>. Analysis was performed on 1121 participants from nine different studies. As mentioned above, time measurements in PWT were converted to units of length. In the PLC group, participants walked 122.7 meters more at the end of the study compared to baseline, versus 59.7‐meter improvement in the control group versus baseline. Considering the relative weight of each study, this resulted in a mean difference of 50.86 meters (95% confidence interval (CI) ranging from 50.34 to 51.38) favoring PLC (moderate‐certainty evidence). (See <a href="#CD010117-fig-0004">Figure 4</a>.) In this analysis, <a href="./references#CD010117-bbs2-0003" title="BrevettiG , PernaS , SabbaC , MartoneVD , CondorelliM . Propionyl-L-carnitine in intermittent claudication: double-blind, placebo-controlled, dose titration, multicenter study. Journal of American College of Cardiology1995;26(6):1411-6. BrevettiG , PernaS , SabbaC , MartoneVD , Di IorioA , BarlettaG . Effect of propionyl-L-carnitine on quality of life in intermittent claudication. American Journal of Cardiology1997;79(6):777-80. ">Brevetti 1995</a> is very prominent in determining the outcome of this comparison. Due to its small confidence intervals, it has a relative weight of 75%. This gives other large studies such as <a href="./references#CD010117-bbs2-0005" title="CotoV , D'AlessandroL , GrattarolaG , ImparatoL , LingettiM , ManciniM , et al. Evaluation of the therapeutic efficacy and tolerability of levocarnitine propionyl in the treatment of chronic obstructive arteriopathies of the lower extremities: a multicentre controlled study vs. placebo. Drugs under Experimental and Clinical Research1992;18(1):29-36. ">Coto 1992</a> and <a href="./references#CD010117-bbs2-0008" title="HiattWR , RegensteinerJG , CreagerMA , HirschAT , CookeJP , OlinJW , et al. Propionyl-L-carnitine improves exercise performance and functional status in patients with claudication. American Journal of Medicine2001;110(8):616-22. ">Hiatt 2001</a> less weight in the review. This trend is seen in all analyses. </p> <div class="figure" id="CD010117-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Propionyl‐L‐carnitine versus placebo or control, outcome: 1.1 Absolute claudication distance (MWD + PWT)." data-id="CD010117-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/image_n/nCD010117-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Propionyl‐L‐carnitine versus placebo or control, outcome: 1.1 Absolute claudication distance (MWD + PWT). </p> </div> </div> </div> <p>Due to slight differences in treadmill testing protocols (slope, speed), baseline walking performances are heterogeneous. To cope with these diverse results, not only absolute but also relative improvements in walking distance were calculated (in odds ratios). For each intervention arm, relative improvement in walking distance versus baseline was calculated. (See <a href="./references#CD010117-fig-0011" title="">Analysis 1.2</a>.) PLC participants showed a mean improvement of 1.61, and placebo control participants showed a mean improvement of 1.29; this means that PLC participants walked 1.61 times better (61% more distance) at the end of the studies than at baseline and placebo/control participants walked 1.29 times better (29% more distance) at the end of the study than at baseline. After the weight of each study is considered again, the mean difference results in a significant advantage of 0.26 for PLC (95% CI 0.23 to 0.28) or 26% more improvement compared with the control arm. Again <a href="./references#CD010117-bbs2-0003" title="BrevettiG , PernaS , SabbaC , MartoneVD , CondorelliM . Propionyl-L-carnitine in intermittent claudication: double-blind, placebo-controlled, dose titration, multicenter study. Journal of American College of Cardiology1995;26(6):1411-6. BrevettiG , PernaS , SabbaC , MartoneVD , Di IorioA , BarlettaG . Effect of propionyl-L-carnitine on quality of life in intermittent claudication. American Journal of Cardiology1997;79(6):777-80. ">Brevetti 1995</a> is very prominent in the outcome of this comparison (<a href="#CD010117-fig-0005">Figure 5</a>). </p> <div class="figure" id="CD010117-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Propionyl‐L‐carnitine versus placebo or control, outcome: 1.2 ACD (odds ratio)." data-id="CD010117-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/image_n/nCD010117-FIG-05.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Propionyl‐L‐carnitine versus placebo or control, outcome: 1.2 ACD (odds ratio). </p> </div> </div> </div> <p>We note that heterogeneity/I² (percentage of total variation across studies that is due to heterogeneity rather than to chance) for all outcomes is very high (&gt; 85% for all studies that have pooled data). </p> </section> <section id="CD010117-sec-0053"> <h5 class="title">Initial claudication distance</h5> <p>Similar to the analysis process for ACD, under the common term "initial claudication distance" (ICD), we unite all results from the different studies that evaluate pain‐free walking performance. This includes all pain‐free walking distances (in unit of length) results, as well as all claudication onset time (in unit of time) results, from the included studies. All time measurements from COT studies were converted to absolute distances (in meters), according to treadmill testing speed. </p> <p>For this analysis, again nine studies were included (<a href="./references#CD010117-bbs2-0003" title="BrevettiG , PernaS , SabbaC , MartoneVD , CondorelliM . Propionyl-L-carnitine in intermittent claudication: double-blind, placebo-controlled, dose titration, multicenter study. Journal of American College of Cardiology1995;26(6):1411-6. BrevettiG , PernaS , SabbaC , MartoneVD , Di IorioA , BarlettaG . Effect of propionyl-L-carnitine on quality of life in intermittent claudication. American Journal of Cardiology1997;79(6):777-80. ">Brevetti 1995</a>; <a href="./references#CD010117-bbs2-0004" title="BrevettiG , DiehmC , LambertD . European multicenter study on propionyl-l-carnitine in intermittent claudication. Journal of American College of Cardiology1999;34(5):1618-24. ">Brevetti 1999</a>; <a href="./references#CD010117-bbs2-0005" title="CotoV , D'AlessandroL , GrattarolaG , ImparatoL , LingettiM , ManciniM , et al. Evaluation of the therapeutic efficacy and tolerability of levocarnitine propionyl in the treatment of chronic obstructive arteriopathies of the lower extremities: a multicentre controlled study vs. placebo. Drugs under Experimental and Clinical Research1992;18(1):29-36. ">Coto 1992</a>; <a href="./references#CD010117-bbs2-0006" title="Dal LagoA , De MartiniD , FloreR , GaetaniE , GasbarriniA , GerardinoL , et al. Effects of propionyl-L-carnitine on peripheral arterial obliterative disease of the lower limbs: a double-blind clinical trial. Drugs under Experimental and Clinical Research1999;25(1):29-36. ">Dal Lago 1999</a>; <a href="./references#CD010117-bbs2-0007" title="GrecoAV , MingroneG , BianchiM , GhirlandaG . Effect of propionyl-L-carnitine in the treatment of diabetic angiopathy: controlled double-blind trial versus placebo. Drugs under Experimental and Clinical Research1992;18(2):69-80. ">Greco 1992</a>; <a href="./references#CD010117-bbs2-0008" title="HiattWR , RegensteinerJG , CreagerMA , HirschAT , CookeJP , OlinJW , et al. Propionyl-L-carnitine improves exercise performance and functional status in patients with claudication. American Journal of Medicine2001;110(8):616-22. ">Hiatt 2001</a>; <a href="./references#CD010117-bbs2-0009" title="HiattWR , CreagerMA , AmatoA , BrassEP . Effect of propionyl-L-carnitine on a background of monitored exercise in patients with claudication secondary to peripheral arterial disease. Journal Cardiopulmonary Rehabilitation Prevention2011;31(2):125-32. [NCT00399919]">Hiatt 2011</a>; <a href="./references#CD010117-bbs2-0010" title="LuoT , LiJ , LiL , YangB , LiuC , ZhengQ , et al. A study on the efficacy and safety assessment of propionyl-L-carnitine tablets in treatment of intermittent claudication. Thrombosis Research2013;132(4):427-32. NCT00809497. A clinical study on efficacy &amp; safety profile of propionyl-L-carnitine tablets for peripheral arterial diseases. clinicaltrialsgov/show/NCT00809497 (first received December 17, 2008). ">Luo 2013</a>; <a href="./references#CD010117-bbs2-0011" title="SignorelliSS , NeriS , Di PinoL , MarcheseG , FerranteM , OliveriCG , et al. Effect of PLC on functional parameters and oxidative profile in type 2 diabetes-associated PAD. Diabetes Research and Clinical Practice2006;72(3):231-7. ">Signorelli 2006a</a>). Compared to the ACD analysis, one study was removed ‐ <a href="./references#CD010117-bbs2-0001" title="AndreozziGM , LeoneA , LaudaniR , MartiniR , DeiniteG , CataldiV . Levo-propionyl-carnitine improves the effectiveness of supervised physical training on the absolute claudication distance in patients with intermittent claudication. Angiology2008;59(1):84-9. ">Andreozzi 2008</a> ‐ and one study was added ‐ <a href="./references#CD010117-bbs2-0011" title="SignorelliSS , NeriS , Di PinoL , MarcheseG , FerranteM , OliveriCG , et al. Effect of PLC on functional parameters and oxidative profile in type 2 diabetes-associated PAD. Diabetes Research and Clinical Practice2006;72(3):231-7. ">Signorelli 2006a</a>. The participant pool contained 1287 ITT participants and was well balanced between intervention arms (642 in the PLC group, 645 in the placebo group). No major differences between the two groups could be found in demographic and clinical parameters. Mean baseline ICDs were 120.3 meters (PLC) versus 120.8 meters (placebo). </p> <p>Detailed results can be found under <a href="./references#CD010117-fig-0015" title="">Analysis 1.6</a> (<a href="#CD010117-fig-0006">Figure 6</a>). Per‐protocol analysis was performed on 1151 participants, excluding 136 dropout participants. As mentioned above, time measurements in COT were converted to distances in units of length. The improvement in walking performance in absolute numbers for PLC participants was 75.7 meters; for control participants in the placebo arm, mean improvement was 36.6 meters. Weighing the impact of the studies revealed a mean difference of 32.98 meters (95% CI 32.60 to 33.37) favoring PLC (moderate‐certainty evidence). In keeping with the same methods used for ACD, relative changes were calculated (<a href="./references#CD010117-fig-0016" title="">Analysis 1.7</a>). This resulted in a relative improvement of 1.67 for PLC participants versus 1.32 for control participants. Mean difference between intervention arms is 0.31 (95% CI 0.28 to 0.34), or 31% more improvement in favor of PLC participants. These numbers favoring PLC over placebo confirm results from the ACD analysis. See also <a href="#CD010117-fig-0007">Figure 7</a>. </p> <div class="figure" id="CD010117-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Propionyl‐L‐carnitine versus placebo or control, outcome: 1.6 Initial claudication distance (PFWD + COT)." data-id="CD010117-fig-0006" src="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/image_n/nCD010117-FIG-06.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Propionyl‐L‐carnitine versus placebo or control, outcome: 1.6 Initial claudication distance (PFWD + COT). </p> </div> </div> </div> <div class="figure" id="CD010117-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Propionyl‐L‐carnitine versus placebo, outcome: 1.8 ICD (odds ratio) with subgroup." data-id="CD010117-fig-0007" src="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/image_n/nCD010117-FIG-07.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Propionyl‐L‐carnitine versus placebo, outcome: 1.8 ICD (odds ratio) with subgroup. </p> </div> </div> </div> <p>However, large heterogeneity is also present here.</p> <p>As two trials in this analysis contain only participants with diabetes (<a href="./references#CD010117-bbs2-0007" title="GrecoAV , MingroneG , BianchiM , GhirlandaG . Effect of propionyl-L-carnitine in the treatment of diabetic angiopathy: controlled double-blind trial versus placebo. Drugs under Experimental and Clinical Research1992;18(2):69-80. ">Greco 1992</a>; <a href="./references#CD010117-bbs2-0011" title="SignorelliSS , NeriS , Di PinoL , MarcheseG , FerranteM , OliveriCG , et al. Effect of PLC on functional parameters and oxidative profile in type 2 diabetes-associated PAD. Diabetes Research and Clinical Practice2006;72(3):231-7. ">Signorelli 2006a</a>), we investigated whether PLC could have different efficacy in these participants. This small pool with only diabetes participants contained 93 participants and showed a mean relative improvement for ICD of 0.47 (95% CI 0.39 to 0.56) in favor of PLC. In the absence of individual data, the comparator is the pool of all other studies, which contains a mixed group of diabetic and non‐diabetic individuals. This group of the seven remaining studies covered 1058 PP participants and showed a relative improvement of 0.29 (95% CI 0.26 to 0.32) favoring PLC. Differences between subgroups showed a statistically significant difference in treatment effect between subgroups (P &lt; 0.0001) (<a href="./references#CD010117-fig-0016" title="">Analysis 1.7</a>). Obviously, this subgroup analysis using a mixed group as a comparator is not ideal; however this result suggests that PLC could have greater effect in diabetes participants, and this should be further researched. </p> </section> <section id="CD010117-sec-0054"> <h5 class="title">Quality of life</h5> <p>For people with intermittent claudication (IC), quality of life is an important issue, as pain and the impossibility to walk long distances can severely restrict their daily activities and daily quality of life. In two studies by Brevetti (<a href="./references#CD010117-bbs2-0003" title="BrevettiG , PernaS , SabbaC , MartoneVD , CondorelliM . Propionyl-L-carnitine in intermittent claudication: double-blind, placebo-controlled, dose titration, multicenter study. Journal of American College of Cardiology1995;26(6):1411-6. BrevettiG , PernaS , SabbaC , MartoneVD , Di IorioA , BarlettaG . Effect of propionyl-L-carnitine on quality of life in intermittent claudication. American Journal of Cardiology1997;79(6):777-80. ">Brevetti 1995</a>; <a href="./references#CD010117-bbs2-0004" title="BrevettiG , DiehmC , LambertD . European multicenter study on propionyl-l-carnitine in intermittent claudication. Journal of American College of Cardiology1999;34(5):1618-24. ">Brevetti 1999</a>), this item was evaluated. Standardized questionnaires designed to measure quality of life were used to obtain a valuable evaluation. <a href="./references#CD010117-bbs2-0003" title="BrevettiG , PernaS , SabbaC , MartoneVD , CondorelliM . Propionyl-L-carnitine in intermittent claudication: double-blind, placebo-controlled, dose titration, multicenter study. Journal of American College of Cardiology1995;26(6):1411-6. BrevettiG , PernaS , SabbaC , MartoneVD , Di IorioA , BarlettaG . Effect of propionyl-L-carnitine on quality of life in intermittent claudication. American Journal of Cardiology1997;79(6):777-80. ">Brevetti 1995</a> used the McMaster Health Index Questionnaire, containing 59 health‐related statements that investigate the person's psychological, social, and emotional status. Global score improved for PLC participants from 0.59 to 0.64, whereas placebo participants experienced a reduced quality of life, from 0.64 to 0.63. Mean difference was 0.06 (95% CI 0.05 to 0.07) (moderate‐certainty evidence). These results can be found in <a href="./references#CD010117-fig-0020" title="">Analysis 1.11</a> and in <a href="#CD010117-fig-0008">Figure 8</a>. </p> <div class="figure" id="CD010117-fig-0008"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 8</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Propionyl‐L‐carnitine versus placebo or control, outcome: 1.11 Quality of life (QoL)." data-id="CD010117-fig-0008" src="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/image_n/nCD010117-FIG-08.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Propionyl‐L‐carnitine versus placebo or control, outcome: 1.11 Quality of life (QoL). </p> </div> </div> </div> <p>The other study, <a href="./references#CD010117-bbs2-0004" title="BrevettiG , DiehmC , LambertD . European multicenter study on propionyl-l-carnitine in intermittent claudication. Journal of American College of Cardiology1999;34(5):1618-24. ">Brevetti 1999</a>, was not included in this participant pool, as scores are calculated differently from <a href="./references#CD010117-bbs2-0003" title="BrevettiG , PernaS , SabbaC , MartoneVD , CondorelliM . Propionyl-L-carnitine in intermittent claudication: double-blind, placebo-controlled, dose titration, multicenter study. Journal of American College of Cardiology1995;26(6):1411-6. BrevettiG , PernaS , SabbaC , MartoneVD , Di IorioA , BarlettaG . Effect of propionyl-L-carnitine on quality of life in intermittent claudication. American Journal of Cardiology1997;79(6):777-80. ">Brevetti 1995</a>, as published in <a href="./references#CD010117-bbs2-0030" title="BrevettiG , FaninM , De AmicisV , CarrozzoR , Di LelloF , MartoneVD , et al. Changes in skeletal muscle histology and metabolism in patients undergoing exercise deconditioning: effect of propionyl-L-carnitine. Muscle and Nerve1997;20(9):1115-20.">Brevetti 1997</a>; as such, these scores were not convertible. <a href="./references#CD010117-bbs2-0004" title="BrevettiG , DiehmC , LambertD . European multicenter study on propionyl-l-carnitine in intermittent claudication. Journal of American College of Cardiology1999;34(5):1618-24. ">Brevetti 1999</a> used the questionnaire of Jaeschke and Guyatt to interrogate 114 participants about multiple life domains. In terms of pain and psychological function, a significantly better result was achieved for PLC participants, but for the social function, the difference was not significant. </p> <p>In light of the two studies, quality of life appears to improve after PLC supplementation. This is related to improved walking performance. </p> </section> <section id="CD010117-sec-0055"> <h5 class="title">Progression of disease (to Fontaine stage III or IV or necessity for intervention (endovascular or surgery)) </h5> <p>PLC efficacy can also be evaluated by the evolution of peripheral arterial disease (PAD). Only one study checked this (<a href="./references#CD010117-bbs2-0004" title="BrevettiG , DiehmC , LambertD . European multicenter study on propionyl-l-carnitine in intermittent claudication. Journal of American College of Cardiology1999;34(5):1618-24. ">Brevetti 1999</a>). Five participants in the PLC group (2%) evolved from Fontaine stage II to stage III (rest pain) versus 10 participants (4%) in the placebo group. However, two PLC participants evolved to stage IV (critical ischemia) versus none of the placebo participants. Larger participant pools and longer follow‐up periods are needed to determine the true difference. </p> </section> <section id="CD010117-sec-0056"> <h5 class="title">Side effects of the propionyl‐L‐carnitine regimen</h5> <p>In <a href="./references#CD010117-bbs2-0003" title="BrevettiG , PernaS , SabbaC , MartoneVD , CondorelliM . Propionyl-L-carnitine in intermittent claudication: double-blind, placebo-controlled, dose titration, multicenter study. Journal of American College of Cardiology1995;26(6):1411-6. BrevettiG , PernaS , SabbaC , MartoneVD , Di IorioA , BarlettaG . Effect of propionyl-L-carnitine on quality of life in intermittent claudication. American Journal of Cardiology1997;79(6):777-80. ">Brevetti 1995</a>, seven adverse events were reported in the placebo group and five adverse events in the PLC group not requiring drug discontinuation. Nausea and gastric pain were the most frequent side effects. In this trial, 11 adverse events resulting in drug discontinuation occurred in the PLC group and three in the placebo group. However, the medical problems requiring drug discontinuation in the PLC group were unrelated to study medication, according to the study authors. </p> <p> <ul id="CD010117-list-0018"> <li> <p>7/127 participants in the control group experienced adverse events.</p> </li> <li> <p>5/118 participants in the PLC group experienced adverse events.</p> </li> </ul> </p> <p>In <a href="./references#CD010117-bbs2-0004" title="BrevettiG , DiehmC , LambertD . European multicenter study on propionyl-l-carnitine in intermittent claudication. Journal of American College of Cardiology1999;34(5):1618-24. ">Brevetti 1999</a>, 27 PLC participants discontinued the study because of the occurrence of serious adverse events (mainly cardiac and peripheral vascular). In the placebo group, 30 adverse events required study discontinuation. Thirty‐eight adverse events not requiring drug discontinuation occurred in the PLC group, and 98 occurred in the placebo group; flu syndrome was the most frequent adverse effect without a difference of occurrence between arms. </p> <p> <ul id="CD010117-list-0019"> <li> <p>30/246 participants in the control group experienced adverse events requiring study discontinuation (5 cardiac, 2 cerebral, 13 peripheral, 10 for other reasons), and 98/246 participants experienced adverse events not requiring study discontinuation. </p> </li> <li> <p>27/239 participants in the PLC group experienced adverse events requiring study discontinuation (5 cardiac, 3 cerebral, 12 peripheral, 7 for other reasons), and 38/239 participants experienced adverse events not requiring study discontinuation. </p> </li> </ul> </p> <p><a href="./references#CD010117-bbs2-0005" title="CotoV , D'AlessandroL , GrattarolaG , ImparatoL , LingettiM , ManciniM , et al. Evaluation of the therapeutic efficacy and tolerability of levocarnitine propionyl in the treatment of chronic obstructive arteriopathies of the lower extremities: a multicentre controlled study vs. placebo. Drugs under Experimental and Clinical Research1992;18(1):29-36. ">Coto 1992</a> saw three adverse events requiring study interruption in the PLC group and six in the placebo group. The most common adverse event was abdominal pain. </p> <p> <ul id="CD010117-list-0020"> <li> <p>6/140 participants in the control group experienced adverse events requiring study discontinuation (2 for cardiac reasons, 4 for gastro‐enterological reasons). </p> </li> <li> <p>3/142 participants in the PLC group experienced adverse events (3 for gastro‐enterological reasons). </p> </li> </ul> </p> <p>Both trials from Hiatt do not mention important differences in side effects between the two intervention arms: 70% of PLC participants and 68% of placebo participants experienced one or more adverse events (<a href="./references#CD010117-bbs2-0008" title="HiattWR , RegensteinerJG , CreagerMA , HirschAT , CookeJP , OlinJW , et al. Propionyl-L-carnitine improves exercise performance and functional status in patients with claudication. American Journal of Medicine2001;110(8):616-22. ">Hiatt 2001</a>; <a href="./references#CD010117-bbs2-0009" title="HiattWR , CreagerMA , AmatoA , BrassEP . Effect of propionyl-L-carnitine on a background of monitored exercise in patients with claudication secondary to peripheral arterial disease. Journal Cardiopulmonary Rehabilitation Prevention2011;31(2):125-32. [NCT00399919]">Hiatt 2011</a>). In these studies, adverse events that affected more than 5% of participants in either group with a ratio greater than 1.5 PLC versus placebo included nausea, diarrhea, bronchitis, and back pain. </p> <p><a href="./references#CD010117-bbs2-0012" title="SignorelliSS , FatuzzoP , RapisardaF , NeriS , FerranteM , Oliveri ContiG , et al. A randomised, controlled clinical trial evaluating changes in therapeutic efficacy and oxidative parameters after treatment with propionyl-L-carnitine in patients with peripheral arterial disease requiring hemodialysis. Drugs and Aging2006;23(3):263-70. SignorelliSS , FatuzzoP , RapisardaF , NeriS , FerranteM , Oliveri ContiG , et al. Propionyl-L-carnitine therapy: effects on endothelin-1 and homocysteine levels in patients with peripheral arterial disease and end-stage renal disease. Kidney &amp; Blood Pressure Research2006;29(2):100-7. ">Signorelli 2006b</a> did not find any adverse events in the study population. </p> <p>The six remaining studies did not report adverse events.</p> <p>Checking the database of the European Medicines Agency (EMA) and the database of the individual patient experience (DIPEx) registry did not reveal any matched documents. </p> <p>PLC appears to be a safe and well‐tolerated drug, as no significant differences from placebo can be found in studies with follow‐up from six months to one year. </p> </section> <section id="CD010117-sec-0057"> <h5 class="title">Ankle brachial index</h5> <p>Four of the included studies investigate the efficacy of PLC for ABI evolution (<a href="./references#CD010117-bbs2-0007" title="GrecoAV , MingroneG , BianchiM , GhirlandaG . Effect of propionyl-L-carnitine in the treatment of diabetic angiopathy: controlled double-blind trial versus placebo. Drugs under Experimental and Clinical Research1992;18(2):69-80. ">Greco 1992</a>; <a href="./references#CD010117-bbs2-0010" title="LuoT , LiJ , LiL , YangB , LiuC , ZhengQ , et al. A study on the efficacy and safety assessment of propionyl-L-carnitine tablets in treatment of intermittent claudication. Thrombosis Research2013;132(4):427-32. NCT00809497. A clinical study on efficacy &amp; safety profile of propionyl-L-carnitine tablets for peripheral arterial diseases. clinicaltrialsgov/show/NCT00809497 (first received December 17, 2008). ">Luo 2013</a>; <a href="./references#CD010117-bbs2-0011" title="SignorelliSS , NeriS , Di PinoL , MarcheseG , FerranteM , OliveriCG , et al. Effect of PLC on functional parameters and oxidative profile in type 2 diabetes-associated PAD. Diabetes Research and Clinical Practice2006;72(3):231-7. ">Signorelli 2006a</a>; <a href="./references#CD010117-bbs2-0012" title="SignorelliSS , FatuzzoP , RapisardaF , NeriS , FerranteM , Oliveri ContiG , et al. A randomised, controlled clinical trial evaluating changes in therapeutic efficacy and oxidative parameters after treatment with propionyl-L-carnitine in patients with peripheral arterial disease requiring hemodialysis. Drugs and Aging2006;23(3):263-70. SignorelliSS , FatuzzoP , RapisardaF , NeriS , FerranteM , Oliveri ContiG , et al. Propionyl-L-carnitine therapy: effects on endothelin-1 and homocysteine levels in patients with peripheral arterial disease and end-stage renal disease. Kidney &amp; Blood Pressure Research2006;29(2):100-7. ">Signorelli 2006b</a>). <a href="./references#CD010117-bbs2-0012" title="SignorelliSS , FatuzzoP , RapisardaF , NeriS , FerranteM , Oliveri ContiG , et al. A randomised, controlled clinical trial evaluating changes in therapeutic efficacy and oxidative parameters after treatment with propionyl-L-carnitine in patients with peripheral arterial disease requiring hemodialysis. Drugs and Aging2006;23(3):263-70. SignorelliSS , FatuzzoP , RapisardaF , NeriS , FerranteM , Oliveri ContiG , et al. Propionyl-L-carnitine therapy: effects on endothelin-1 and homocysteine levels in patients with peripheral arterial disease and end-stage renal disease. Kidney &amp; Blood Pressure Research2006;29(2):100-7. ">Signorelli 2006b</a> focused only on the ABI, as it is the only outcome parameter in this study. The participant pool for this analysis contains 397 participants with an average baseline ABI of 0.69 (placebo group 0.70, PLC group 0.69). There were 28 dropouts, and PP analysis was performed on 369 participants. Results can be found in <a href="./references#CD010117-fig-0021" title="">Analysis 1.12</a> and <a href="#CD010117-fig-0009">Figure 9</a>. Apart from <a href="./references#CD010117-bbs2-0007" title="GrecoAV , MingroneG , BianchiM , GhirlandaG . Effect of propionyl-L-carnitine in the treatment of diabetic angiopathy: controlled double-blind trial versus placebo. Drugs under Experimental and Clinical Research1992;18(2):69-80. ">Greco 1992</a>, with a relative weight of only 0.6%, the impact of the other three studies appears more balanced than in ACD and ICD analyses in which domination of one study was found. For PLC participants, ABI has risen 0.06 at the end of the study compared to the baseline value. The control group experienced a negligible difference of 0.007 at the end versus at baseline. In all four studies, the PLC population experienced an increase in mean ABI compared to the baseline ABI. In all but one study, ABI of control participants worsened during follow‐up (<a href="./references#CD010117-bbs2-0010" title="LuoT , LiJ , LiL , YangB , LiuC , ZhengQ , et al. A study on the efficacy and safety assessment of propionyl-L-carnitine tablets in treatment of intermittent claudication. Thrombosis Research2013;132(4):427-32. NCT00809497. A clinical study on efficacy &amp; safety profile of propionyl-L-carnitine tablets for peripheral arterial diseases. clinicaltrialsgov/show/NCT00809497 (first received December 17, 2008). ">Luo 2013</a>). Only in <a href="./references#CD010117-bbs2-0010" title="LuoT , LiJ , LiL , YangB , LiuC , ZhengQ , et al. A study on the efficacy and safety assessment of propionyl-L-carnitine tablets in treatment of intermittent claudication. Thrombosis Research2013;132(4):427-32. NCT00809497. A clinical study on efficacy &amp; safety profile of propionyl-L-carnitine tablets for peripheral arterial diseases. clinicaltrialsgov/show/NCT00809497 (first received December 17, 2008). ">Luo 2013</a>, the control population also showed improvement in ABI. The mean difference between the two intervention arms was 0.09 (95% CI 0.08 to 0.09) (moderate‐certainty evidence), favoring PLC. </p> <div class="figure" id="CD010117-fig-0009"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 9</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Propionyl‐L‐carnitine versus placebo or control, outcome: 1.12 Ankle brachial index (ABI)." data-id="CD010117-fig-0009" src="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/image_n/nCD010117-FIG-09.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Propionyl‐L‐carnitine versus placebo or control, outcome: 1.12 Ankle brachial index (ABI). </p> </div> </div> </div> </section> </section> <section id="CD010117-sec-0058"> <h4 class="title">PLC versus L‐carnitine</h4> <p>Only <a href="./references#CD010117-bbs2-0002" title="BrevettiG , PernaS , SabbaC , RossiniA , Scotto di UccioV , BerardiE , et al. Superiority of L-propionylcarnitine vs L-carnitine in improving walking capacity in patients with peripheral vascular disease: an acute, intravenous, double-blind, cross-over study. European Heart Journal1992;13(2):251-5. ">Brevetti 1992</a>, with a total of 28 participants, has compared the efficacy of PLC and an equimolar dose of L‐carnitine. Investigation of ACD favored PLC supplementation over L‐carnitine (ACD 20.00 m, 95% CI 0.47 to 39.53; 28 participants, 1 study; low‐certainty evidence), with a significance level of 0.04 (see <a href="./references#CD010117-fig-0022" title="">Analysis 2.1</a>). ICD assessment also showed greater improvement among PLC participants, but this difference was not significant (ICD 4.00 m, 95% CI ‐9.86 to 17.86; 28 participants, 1 study; P = 0.57; low‐certainty evidence) (<a href="./references#CD010117-fig-0023" title="">Analysis 2.2</a>). </p> <p><a href="./references#CD010117-bbs2-0002" title="BrevettiG , PernaS , SabbaC , RossiniA , Scotto di UccioV , BerardiE , et al. Superiority of L-propionylcarnitine vs L-carnitine in improving walking capacity in patients with peripheral vascular disease: an acute, intravenous, double-blind, cross-over study. European Heart Journal1992;13(2):251-5. ">Brevetti 1992</a> reported that the ABI index remained unchanged. </p> <p>Remaining outcomes of the review were not measured by <a href="./references#CD010117-bbs2-0002" title="BrevettiG , PernaS , SabbaC , RossiniA , Scotto di UccioV , BerardiE , et al. Superiority of L-propionylcarnitine vs L-carnitine in improving walking capacity in patients with peripheral vascular disease: an acute, intravenous, double-blind, cross-over study. European Heart Journal1992;13(2):251-5. ">Brevetti 1992</a>. </p> </section> <section id="CD010117-sec-0059"> <h4 class="title">Subgroup and sensitivity analysis</h4> <p>We performed subgroup analysis according to the participant characteristic diabetes versus non‐diabetes, as described above. </p> <p>We did not perform subgroup analysis based on route of administration (orally or intravenously) because there were only three iv trials (<a href="./references#CD010117-bbs2-0001" title="AndreozziGM , LeoneA , LaudaniR , MartiniR , DeiniteG , CataldiV . Levo-propionyl-carnitine improves the effectiveness of supervised physical training on the absolute claudication distance in patients with intermittent claudication. Angiology2008;59(1):84-9. ">Andreozzi 2008</a>: PLC versus placebo, outcome: ACD; <a href="./references#CD010117-bbs2-0012" title="SignorelliSS , FatuzzoP , RapisardaF , NeriS , FerranteM , Oliveri ContiG , et al. A randomised, controlled clinical trial evaluating changes in therapeutic efficacy and oxidative parameters after treatment with propionyl-L-carnitine in patients with peripheral arterial disease requiring hemodialysis. Drugs and Aging2006;23(3):263-70. SignorelliSS , FatuzzoP , RapisardaF , NeriS , FerranteM , Oliveri ContiG , et al. Propionyl-L-carnitine therapy: effects on endothelin-1 and homocysteine levels in patients with peripheral arterial disease and end-stage renal disease. Kidney &amp; Blood Pressure Research2006;29(2):100-7. ">Signorelli 2006b</a>: PLC versus placebo, outcome: ABI; <a href="./references#CD010117-bbs2-0002" title="BrevettiG , PernaS , SabbaC , RossiniA , Scotto di UccioV , BerardiE , et al. Superiority of L-propionylcarnitine vs L-carnitine in improving walking capacity in patients with peripheral vascular disease: an acute, intravenous, double-blind, cross-over study. European Heart Journal1992;13(2):251-5. ">Brevetti 1992</a>: PLC versus LC, outcome: ICD, ACD and ABI) compared to nine oral PLC trials. </p> <p>In most trials, dose range was small and was similar at 1 to 2 g/d; therefore we did not perform subgroup analysis based on dose range. </p> <p>If in future reviews sufficient data are available, we will also carry out subgroup analyses for treatment duration, dose (for propionyl‐L‐carnitine, a wide dose range exists, ranging from 1 g daily to 4 g daily), and route of administration. </p> <p>We also performed sensitivity analyses including the three studies with the biggest weight in the fixed‐effect model; however effect sizes were similar and heterogeneity did not change. </p> <p>We did not assess funnel plots because of the insufficient number of included studies.</p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD010117-sec-0060" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD010117-sec-0060"></div> <section id="CD010117-sec-0061"> <h3 class="title" id="CD010117-sec-0061">Summary of main results</h3> <p>Individuals with intermittent claudication (IC) should in the first place be treated with conservative interventions such as exercise and management of cardiovascular risk. This Cochrane Review was set up to investigate whether propionyl‐L‐carnitine (PLC) could be an effective adjuvant treatment. All but one of the included studies compared PLC to placebo. </p> <p>For maximal walking performance (absolute claudication distance ‐ ACD), IC participants on PLC showed 26% more improvement than control participants who received placebo. For pain‐free walking performance (initial claudication distance ‐ ICD), participants on PLC showed 31% more improvement than participants on placebo. These differences between the two intervention arms were significant in absolute distances as well as in relative improvement (as shown using odds ratios (ORs)). For a disease such as IC, the primary goal should be improving functional capacities. Improvement in walking performance can contribute to this by putting less restriction on social and professional activities. Walking outcomes are therefore essential parameters for the IC patient. Two trials showed significant improvement in the outcome parameter quality of life (QoL) with PLC (<a href="./references#CD010117-bbs2-0003" title="BrevettiG , PernaS , SabbaC , MartoneVD , CondorelliM . Propionyl-L-carnitine in intermittent claudication: double-blind, placebo-controlled, dose titration, multicenter study. Journal of American College of Cardiology1995;26(6):1411-6. BrevettiG , PernaS , SabbaC , MartoneVD , Di IorioA , BarlettaG . Effect of propionyl-L-carnitine on quality of life in intermittent claudication. American Journal of Cardiology1997;79(6):777-80. ">Brevetti 1995</a>; <a href="./references#CD010117-bbs2-0004" title="BrevettiG , DiehmC , LambertD . European multicenter study on propionyl-l-carnitine in intermittent claudication. Journal of American College of Cardiology1999;34(5):1618-24. ">Brevetti 1999</a>). Ankle brachial index (ABI) increased on PLC therapy and decreased on placebo, showing small but statistical significance. For "progression of disease," evidence was insufficient to permit a clear statement. </p> <p>In terms of adverse events, overall no remarkable differences were seen between intervention arms. Mainly gastric and intestinal problems were observed, occurring evenly in both arms. Tolerance and safety of this drug appear to be acceptable. </p> </section> <section id="CD010117-sec-0062"> <h3 class="title" id="CD010117-sec-0062">Overall completeness and applicability of evidence</h3> <p>Participants with intermittent claudication who were included in these trials were a representative sample of people with this disease. With a mean baseline ACD of 189 meters, the average participant in this review is at an advanced stage of IC (Fontaine stage IIb), indicating that this group might be the target population for PLC use. Only one study also includes participants with a baseline MWD greater than 250 meters, but the results of this subgroup were not analyzed in the ACD participant pool for this review (<a href="./references#CD010117-bbs2-0004" title="BrevettiG , DiehmC , LambertD . European multicenter study on propionyl-l-carnitine in intermittent claudication. Journal of American College of Cardiology1999;34(5):1618-24. ">Brevetti 1999</a>). Primary and secondary outcomes in this review are relevant parameters for following‐up on the evolution of the disease. </p> <p>We contacted the company Sigma Tau to ask for potential additional data; the company responded that in relation to our request, there were no supplemental data. On our request, they sent us the publication of <a href="./references#CD010117-bbs2-0034" title="DeckertJ . Propionyl-L-carnitine for intermittent claudication. Journal of Family Practice1997;44(6):533-4.">Deckert 1997</a>, which refers to the <a href="./references#CD010117-bbs2-0030" title="BrevettiG , FaninM , De AmicisV , CarrozzoR , Di LelloF , MartoneVD , et al. Changes in skeletal muscle histology and metabolism in patients undergoing exercise deconditioning: effect of propionyl-L-carnitine. Muscle and Nerve1997;20(9):1115-20.">Brevetti 1997</a> publication, which is an additional publication of the included study <a href="./references#CD010117-bbs2-0003" title="BrevettiG , PernaS , SabbaC , MartoneVD , CondorelliM . Propionyl-L-carnitine in intermittent claudication: double-blind, placebo-controlled, dose titration, multicenter study. Journal of American College of Cardiology1995;26(6):1411-6. BrevettiG , PernaS , SabbaC , MartoneVD , Di IorioA , BarlettaG . Effect of propionyl-L-carnitine on quality of life in intermittent claudication. American Journal of Cardiology1997;79(6):777-80. ">Brevetti 1995</a>. </p> <p>Only one small study compared PLC with treatments other than placebo or control: PLC versus L‐carnitine (<a href="./references#CD010117-bbs2-0002" title="BrevettiG , PernaS , SabbaC , RossiniA , Scotto di UccioV , BerardiE , et al. Superiority of L-propionylcarnitine vs L-carnitine in improving walking capacity in patients with peripheral vascular disease: an acute, intravenous, double-blind, cross-over study. European Heart Journal1992;13(2):251-5. ">Brevetti 1992</a>). </p> <p>Most studies do not report on the outcomes QoL, progression of disease, side effects, and ABI. </p> <p>Although all results revealed significant differences, a pronounced placebo effect of over 50% was often observed. This phenomenon could be attributed to a tendency towards improved exercise tolerance on repeated examinations (training effect). Moreover, it is conceivable that an outcome such as walking performance is strongly influenced by participants' enhanced motivation in response to the intense follow‐up (Hawthorne effect). Anyhow, confounding factors are hard to fully avoid when studying and following up on patients. </p> <p>Generally, in studies on treatment for IC, there is a large range of treatment durations ‐ from four days to one year. Trials on treatment in IC recommend treatment duration of at least three months. In this review, treatment duration of the included studies was between six months and one year. </p> <p>Based on current price indications, PLC supplementation of 1 to 2 g/d would cost around one Euro a day. </p> </section> <section id="CD010117-sec-0063"> <h3 class="title" id="CD010117-sec-0063">Quality of the evidence</h3> <p>See <a href="./full#CD010117-tbl-0001">summary of findings Table 1</a> and <a href="./full#CD010117-tbl-0002">summary of findings Table 2</a>. </p> <p>For this review, we included only double‐blind randomized controlled trials. Most studies were double‐blind ‐ for one study, this is not clearly stated but the double‐blind character is assumed (<a href="./references#CD010117-bbs2-0001" title="AndreozziGM , LeoneA , LaudaniR , MartiniR , DeiniteG , CataldiV . Levo-propionyl-carnitine improves the effectiveness of supervised physical training on the absolute claudication distance in patients with intermittent claudication. Angiology2008;59(1):84-9. ">Andreozzi 2008</a>). Studies had to fulfill quality criteria and underwent a detailed risk of bias assessment; studies were included in the review only if none of the risk of bias domains were judged to be at high risk of bias. </p> <p>With all data taken into account, the overall certainty of evidence for the comparison between PLC and placebo/control is considered moderate. There is heterogeneity due to study size (some studies have large participant numbers (282); other trials include only 19 participants), participants coming from different countries and centers, the combination of participants with and without diabetes, and use of different treadmill protocols. To cope with these differences in characteristics of participant pools, weight was given to each trial. Outcomes were similar in all studies and were assessed by standardized testing methods. To deal with differences in treadmill speed and slope and a wide range of baseline values, relative improvements were also calculated (odds ratios) and analyzed. </p> <p>Besides clinical heterogeneity, there is also substantial statistical heterogeneity throughout the current review. To deal with this heterogeneity, we performed similar analyses using standardized effect size. However, heterogeneity even increased with this approach. Furthermore, we performed the same analyses with a random‐effects model (instead of the fixed‐effect model), but overall results were largely similar to those of the fixed‐effect model, as well as similar heterogeneity for both approaches. Due to the number of smaller studies, a random‐effects model is not the optimal solution, which is why we opted for the fixed‐effect model. Finally, post‐hoc sensitivity analyses, which retained only the three studies contributing the largest weight to the fixed‐effect model, had no effect on reducing or explaining this heterogeneity. </p> <p>The comparison between PLC and L‐carnitine in a single study with few participants and a short follow‐up period should be interpreted with caution (<a href="./references#CD010117-bbs2-0002" title="BrevettiG , PernaS , SabbaC , RossiniA , Scotto di UccioV , BerardiE , et al. Superiority of L-propionylcarnitine vs L-carnitine in improving walking capacity in patients with peripheral vascular disease: an acute, intravenous, double-blind, cross-over study. European Heart Journal1992;13(2):251-5. ">Brevetti 1992</a>). We judged the certainty of evidence to be low. </p> </section> <section id="CD010117-sec-0064"> <h3 class="title" id="CD010117-sec-0064">Potential biases in the review process</h3> <p>The studies included in this review generally have low to moderate participant numbers. In ACD and ICD analyses, nine included studies created participant pools of over 1000 participants. This should be sufficient to generate a reliable outcome when the efficacy of the study drug is evaluated. </p> <p>As already mentioned, the weight of studies was calculated according to participant numbers and standard deviations. In all analyses, <a href="./references#CD010117-bbs2-0003" title="BrevettiG , PernaS , SabbaC , MartoneVD , CondorelliM . Propionyl-L-carnitine in intermittent claudication: double-blind, placebo-controlled, dose titration, multicenter study. Journal of American College of Cardiology1995;26(6):1411-6. BrevettiG , PernaS , SabbaC , MartoneVD , Di IorioA , BarlettaG . Effect of propionyl-L-carnitine on quality of life in intermittent claudication. American Journal of Cardiology1997;79(6):777-80. ">Brevetti 1995</a> has a major impact up to 80%, leaving the other large trials of minor weight. It can then be questioned whether the results of <a href="./references#CD010117-bbs2-0003" title="BrevettiG , PernaS , SabbaC , MartoneVD , CondorelliM . Propionyl-L-carnitine in intermittent claudication: double-blind, placebo-controlled, dose titration, multicenter study. Journal of American College of Cardiology1995;26(6):1411-6. BrevettiG , PernaS , SabbaC , MartoneVD , Di IorioA , BarlettaG . Effect of propionyl-L-carnitine on quality of life in intermittent claudication. American Journal of Cardiology1997;79(6):777-80. ">Brevetti 1995</a> are indeed reliable, and if there was no selective reporting or participant recruitment. However, after assessment, overall this study seems to be well conducted. We performed a sensitivity analysis by excluding <a href="./references#CD010117-bbs2-0003" title="BrevettiG , PernaS , SabbaC , MartoneVD , CondorelliM . Propionyl-L-carnitine in intermittent claudication: double-blind, placebo-controlled, dose titration, multicenter study. Journal of American College of Cardiology1995;26(6):1411-6. BrevettiG , PernaS , SabbaC , MartoneVD , Di IorioA , BarlettaG . Effect of propionyl-L-carnitine on quality of life in intermittent claudication. American Journal of Cardiology1997;79(6):777-80. ">Brevetti 1995</a>. This did not change the overall outcome. After <a href="./references#CD010117-bbs2-0003" title="BrevettiG , PernaS , SabbaC , MartoneVD , CondorelliM . Propionyl-L-carnitine in intermittent claudication: double-blind, placebo-controlled, dose titration, multicenter study. Journal of American College of Cardiology1995;26(6):1411-6. BrevettiG , PernaS , SabbaC , MartoneVD , Di IorioA , BarlettaG . Effect of propionyl-L-carnitine on quality of life in intermittent claudication. American Journal of Cardiology1997;79(6):777-80. ">Brevetti 1995</a> was excluded, a moderate although statistically significant difference of 55 meters (versus 50 meters) for ACD and of 39 meters (versus 33 meters) for ICD remained. </p> <p>All time measurements from PWT studies were converted to absolute distances (in meters), according to treadmill testing speed. This might be subject to discussion, given the fact that for example studies that use PWT on a graded treadmill are not comparable to those using MWD on a constant‐load treadmill. However, different treadmill protocols exist within studies measuring MWD and within those measuring PWT. Therefore, we also based the data on the treatment effect of the ratio (or per cent change) for the benefit of propionyl‐L‐carnitine relative to the benefit of placebo or control (or other active) treatment. For <a href="./references#CD010117-bbs2-0004" title="BrevettiG , DiehmC , LambertD . European multicenter study on propionyl-l-carnitine in intermittent claudication. Journal of American College of Cardiology1999;34(5):1618-24. ">Brevetti 1999</a>, only the S1 group (variability &lt; 25% and MWD &lt; 250 m) was analyzed. </p> </section> <section id="CD010117-sec-0065"> <h3 class="title" id="CD010117-sec-0065">Agreements and disagreements with other studies or reviews</h3> <p>Results from this Cochrane Review are similar to the results of the <a href="./references#CD010117-bbs2-0029" title="BrassEP , KosterD , HiattWR , AmatoA . A systematic review and meta-analysis of propionyl-l-carnitine effects on exercise performance in patients with claudication. Vascular Medicine2013;18(1):3-12.">Brass 2013</a> review on the same topic. Most of the studies used in <a href="./references#CD010117-bbs2-0029" title="BrassEP , KosterD , HiattWR , AmatoA . A systematic review and meta-analysis of propionyl-l-carnitine effects on exercise performance in patients with claudication. Vascular Medicine2013;18(1):3-12.">Brass 2013</a> were also included in the present review (Brass also included the study of <a href="./references#CD010117-bbs2-0025" title="StranoA , Italian Propionyl-L-Carnitine Working Group. Propionyl-L-carnitine versus pentoxifylline: improvement in walking capacity in patients with intermittent claudication. Clinical Drug Investigation2002;22(Suppl 1):1-6. ">Strano 2002</a>, which was excluded from this review). <a href="./references#CD010117-bbs2-0035" title="DelaneyCL , SparkJI , ThomasJ , WongYT , ChanLT , MillerMD . A systematic review to evaluate the effectiveness of carnitine supplementation in improving walking performance among individuals with intermittent claudication. Atherosclerosis2013;229(1):1-9.">Delaney 2013</a> observed the same trend in a review comparing carnitine derivatives with placebo, favoring carnitine derivatives over placebo; however, results are less specific for PLC. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD010117-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/urn:x-wiley:14651858:media:CD010117:CD010117-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD010117-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/image_n/nCD010117-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/image_t/tCD010117-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/full#CD010117-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/image_n/nCD010117-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010117-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/urn:x-wiley:14651858:media:CD010117:CD010117-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph of the included studies: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD010117-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/image_n/nCD010117-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/image_t/tCD010117-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph of the included studies: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/full#CD010117-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/image_n/nCD010117-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010117-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/urn:x-wiley:14651858:media:CD010117:CD010117-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD010117-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/image_n/nCD010117-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/image_t/tCD010117-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/full#CD010117-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/image_n/nCD010117-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010117-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/urn:x-wiley:14651858:media:CD010117:CD010117-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Propionyl‐L‐carnitine versus placebo or control, outcome: 1.1 Absolute claudication distance (MWD + PWT)." data-id="CD010117-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/image_n/nCD010117-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/image_t/tCD010117-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Propionyl‐L‐carnitine versus placebo or control, outcome: 1.1 Absolute claudication distance (MWD + PWT). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/full#CD010117-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/image_n/nCD010117-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010117-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/urn:x-wiley:14651858:media:CD010117:CD010117-FIG-05" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Propionyl‐L‐carnitine versus placebo or control, outcome: 1.2 ACD (odds ratio)." data-id="CD010117-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/image_n/nCD010117-FIG-05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/image_t/tCD010117-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Propionyl‐L‐carnitine versus placebo or control, outcome: 1.2 ACD (odds ratio). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/full#CD010117-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/image_n/nCD010117-FIG-05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010117-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/urn:x-wiley:14651858:media:CD010117:CD010117-FIG-06" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Propionyl‐L‐carnitine versus placebo or control, outcome: 1.6 Initial claudication distance (PFWD + COT)." data-id="CD010117-fig-0006" src="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/image_n/nCD010117-FIG-06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/image_t/tCD010117-FIG-06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Propionyl‐L‐carnitine versus placebo or control, outcome: 1.6 Initial claudication distance (PFWD + COT). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/full#CD010117-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/image_n/nCD010117-FIG-06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010117-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/urn:x-wiley:14651858:media:CD010117:CD010117-FIG-07" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Propionyl‐L‐carnitine versus placebo, outcome: 1.8 ICD (odds ratio) with subgroup." data-id="CD010117-fig-0007" src="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/image_n/nCD010117-FIG-07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/image_t/tCD010117-FIG-07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Propionyl‐L‐carnitine versus placebo, outcome: 1.8 ICD (odds ratio) with subgroup. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/full#CD010117-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/image_n/nCD010117-FIG-07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010117-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/urn:x-wiley:14651858:media:CD010117:CD010117-FIG-08" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Propionyl‐L‐carnitine versus placebo or control, outcome: 1.11 Quality of life (QoL)." data-id="CD010117-fig-0008" src="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/image_n/nCD010117-FIG-08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/image_t/tCD010117-FIG-08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 8</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Propionyl‐L‐carnitine versus placebo or control, outcome: 1.11 Quality of life (QoL). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/full#CD010117-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/image_n/nCD010117-FIG-08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010117-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/urn:x-wiley:14651858:media:CD010117:CD010117-FIG-09" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Propionyl‐L‐carnitine versus placebo or control, outcome: 1.12 Ankle brachial index (ABI)." data-id="CD010117-fig-0009" src="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/image_n/nCD010117-FIG-09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/image_t/tCD010117-FIG-09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 9</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Propionyl‐L‐carnitine versus placebo or control, outcome: 1.12 Ankle brachial index (ABI). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/full#CD010117-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/image_n/nCD010117-FIG-09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010117-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/urn:x-wiley:14651858:media:CD010117:CD010117-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Propionyl‐L‐carnitine versus placebo or control, Outcome 1: Absolute claudication distance (MWD + PWT)" data-id="CD010117-fig-0010" src="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/image_n/nCD010117-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/image_t/tCD010117-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Propionyl‐L‐carnitine versus placebo or control, Outcome 1: Absolute claudication distance (MWD + PWT) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/references#CD010117-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/image_n/nCD010117-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010117-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/urn:x-wiley:14651858:media:CD010117:CD010117-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Propionyl‐L‐carnitine versus placebo or control, Outcome 2: ACD (odds ratio)" data-id="CD010117-fig-0011" src="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/image_n/nCD010117-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/image_t/tCD010117-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Propionyl‐L‐carnitine versus placebo or control, Outcome 2: ACD (odds ratio) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/references#CD010117-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/image_n/nCD010117-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010117-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/urn:x-wiley:14651858:media:CD010117:CD010117-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Propionyl‐L‐carnitine versus placebo or control, Outcome 3: Maximal walking distance (MWD)" data-id="CD010117-fig-0012" src="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/image_n/nCD010117-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/image_t/tCD010117-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Propionyl‐L‐carnitine versus placebo or control, Outcome 3: Maximal walking distance (MWD) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/references#CD010117-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/image_n/nCD010117-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010117-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/urn:x-wiley:14651858:media:CD010117:CD010117-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Propionyl‐L‐carnitine versus placebo or control, Outcome 4: Peak walking time (PWT)" data-id="CD010117-fig-0013" src="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/image_n/nCD010117-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/image_t/tCD010117-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Propionyl‐L‐carnitine versus placebo or control, Outcome 4: Peak walking time (PWT) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/references#CD010117-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/image_n/nCD010117-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010117-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/urn:x-wiley:14651858:media:CD010117:CD010117-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Propionyl‐L‐carnitine versus placebo or control, Outcome 5: ACD without Brevetti 1995 (sensitivity analysis)" data-id="CD010117-fig-0014" src="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/image_n/nCD010117-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/image_t/tCD010117-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Propionyl‐L‐carnitine versus placebo or control, Outcome 5: ACD without Brevetti 1995 (sensitivity analysis) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/references#CD010117-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/image_n/nCD010117-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010117-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/urn:x-wiley:14651858:media:CD010117:CD010117-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Propionyl‐L‐carnitine versus placebo or control, Outcome 6: Initial claudication distance (PFWD + COT)" data-id="CD010117-fig-0015" src="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/image_n/nCD010117-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/image_t/tCD010117-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Propionyl‐L‐carnitine versus placebo or control, Outcome 6: Initial claudication distance (PFWD + COT) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/references#CD010117-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/image_n/nCD010117-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010117-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/urn:x-wiley:14651858:media:CD010117:CD010117-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Propionyl‐L‐carnitine versus placebo or control, Outcome 7: ICD (odds ratio)" data-id="CD010117-fig-0016" src="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/image_n/nCD010117-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/image_t/tCD010117-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Propionyl‐L‐carnitine versus placebo or control, Outcome 7: ICD (odds ratio) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/references#CD010117-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/image_n/nCD010117-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010117-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/urn:x-wiley:14651858:media:CD010117:CD010117-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Propionyl‐L‐carnitine versus placebo or control, Outcome 8: Pain‐free walking distance (PFWD)" data-id="CD010117-fig-0017" src="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/image_n/nCD010117-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/image_t/tCD010117-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Propionyl‐L‐carnitine versus placebo or control, Outcome 8: Pain‐free walking distance (PFWD) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/references#CD010117-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/image_n/nCD010117-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010117-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/urn:x-wiley:14651858:media:CD010117:CD010117-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Propionyl‐L‐carnitine versus placebo or control, Outcome 9: Claudication onset time (COT)" data-id="CD010117-fig-0018" src="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/image_n/nCD010117-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/image_t/tCD010117-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Propionyl‐L‐carnitine versus placebo or control, Outcome 9: Claudication onset time (COT) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/references#CD010117-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/image_n/nCD010117-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010117-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/urn:x-wiley:14651858:media:CD010117:CD010117-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Propionyl‐L‐carnitine versus placebo or control, Outcome 10: ICD without Brevetti 1995 (sensitivity analysis)" data-id="CD010117-fig-0019" src="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/image_n/nCD010117-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/image_t/tCD010117-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Propionyl‐L‐carnitine versus placebo or control, Outcome 10: ICD without Brevetti 1995 (sensitivity analysis) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/references#CD010117-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/image_n/nCD010117-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010117-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/urn:x-wiley:14651858:media:CD010117:CD010117-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Propionyl‐L‐carnitine versus placebo or control, Outcome 11: Quality of life (QoL)" data-id="CD010117-fig-0020" src="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/image_n/nCD010117-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/image_t/tCD010117-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Propionyl‐L‐carnitine versus placebo or control, Outcome 11: Quality of life (QoL) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/references#CD010117-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/image_n/nCD010117-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010117-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/urn:x-wiley:14651858:media:CD010117:CD010117-CMP-001.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Propionyl‐L‐carnitine versus placebo or control, Outcome 12: Ankle brachial index (ABI)" data-id="CD010117-fig-0021" src="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/image_n/nCD010117-CMP-001.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/image_t/tCD010117-CMP-001.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1: Propionyl‐L‐carnitine versus placebo or control, Outcome 12: Ankle brachial index (ABI) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/references#CD010117-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/image_n/nCD010117-CMP-001.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010117-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/urn:x-wiley:14651858:media:CD010117:CD010117-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Propionyl‐L‐carnitine versus L‐carnitine, Outcome 1: Maximal walking distance" data-id="CD010117-fig-0022" src="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/image_n/nCD010117-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/image_t/tCD010117-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Propionyl‐L‐carnitine versus L‐carnitine, Outcome 1: Maximal walking distance </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/references#CD010117-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/image_n/nCD010117-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010117-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/urn:x-wiley:14651858:media:CD010117:CD010117-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Propionyl‐L‐carnitine versus L‐carnitine, Outcome 2: Initial claudication distance" data-id="CD010117-fig-0023" src="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/image_n/nCD010117-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/image_t/tCD010117-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Propionyl‐L‐carnitine versus L‐carnitine, Outcome 2: Initial claudication distance </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/references#CD010117-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/media/CDSR/CD010117/image_n/nCD010117-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD010117-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Propionyl‐L‐carnitine compared to placebo for intermittent claudication</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Propionyl‐L‐carnitine compared to placebo for intermittent claudication</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with intermittent claudication<br/><b>Setting:</b> outpatient setting<br/><b>Intervention:</b> propionyl‐L‐carnitine<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo/control</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with propionyl‐L‐carnitine</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute claudication distance (MWD + PWT) (in meters)</p> <p>Follow‐up: 3 weeks to 1 year</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean change in ACD in placebo group was 59.89 m</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 50.86 m higher<br/>(50.34 higher to 51.38 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1121<br/>(9 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Initial claudication distance (PFWD + COT) (in meters)</p> <p>Follow‐up: 90 days to 1 year</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean change in ICD in placebo group was 32.24 m</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 32.98 m higher<br/>(32.6 higher to 33.37 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1151<br/>(9 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean change in QoL score in placebo group was 0.01</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.06 higher<br/>(0.05 higher to 0.07 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Progression of disease (to Fontaine stage III or IV, or necessity for intervention (endovascular or surgery)) </p> <p>Follow‐up: 1 year</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>1 study evaluated progression of disease: 5/242 (2%) PLC participants evolved from Fontaine stage II to stage III (rest pain) vs 10/243 (4%) placebo participants; 2/242 (0.8%) PLC participants evolved to Fontaine stage IV (critical ischemia) vs 0/243 (0%) placebo participants </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>485</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low</b><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Side effects of propionyl‐L‐carnitine regimen</p> <p>Follow‐up: 6 months to 1 year</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><a href="./references#CD010117-bbs2-0003" title="BrevettiG , PernaS , SabbaC , MartoneVD , CondorelliM . Propionyl-L-carnitine in intermittent claudication: double-blind, placebo-controlled, dose titration, multicenter study. Journal of American College of Cardiology1995;26(6):1411-6. BrevettiG , PernaS , SabbaC , MartoneVD , Di IorioA , BarlettaG . Effect of propionyl-L-carnitine on quality of life in intermittent claudication. American Journal of Cardiology1997;79(6):777-80. ">Brevetti 1995</a>: 7 AEs in placebo group and 5 AEs in PLC group not requiring drug discontinuation. Nausea and gastric pain were the most frequent side effects; 11 AEs resulting in drug discontinuation occurred in the PLC group, and 3 in the placebo group. According to study authors, medical problems requiring drug discontinuation in the PLC group were unrelated to study medication </p> <p><a href="./references#CD010117-bbs2-0004" title="BrevettiG , DiehmC , LambertD . European multicenter study on propionyl-l-carnitine in intermittent claudication. Journal of American College of Cardiology1999;34(5):1618-24. ">Brevetti 1999</a>: 27 PLC participants discontinued the study because of the occurrence of serious AEs (mainly cardiac and peripheral vascular). In the placebo group, 30 AEs required study discontinuation. 38 AEs not requiring drug discontinuation occurred in the PLC group vs 98 in the placebo group; flu syndrome was the most frequent AE without a difference in occurrence between arms </p> <p><a href="./references#CD010117-bbs2-0005" title="CotoV , D'AlessandroL , GrattarolaG , ImparatoL , LingettiM , ManciniM , et al. Evaluation of the therapeutic efficacy and tolerability of levocarnitine propionyl in the treatment of chronic obstructive arteriopathies of the lower extremities: a multicentre controlled study vs. placebo. Drugs under Experimental and Clinical Research1992;18(1):29-36. ">Coto 1992</a>: 3 AEs requiring study interruption in the PLC group and 6 in the placebo group. The most common AE was abdominal pain </p> <p><a href="./references#CD010117-bbs2-0008" title="HiattWR , RegensteinerJG , CreagerMA , HirschAT , CookeJP , OlinJW , et al. Propionyl-L-carnitine improves exercise performance and functional status in patients with claudication. American Journal of Medicine2001;110(8):616-22. ">Hiatt 2001</a> and <a href="./references#CD010117-bbs2-0009" title="HiattWR , CreagerMA , AmatoA , BrassEP . Effect of propionyl-L-carnitine on a background of monitored exercise in patients with claudication secondary to peripheral arterial disease. Journal Cardiopulmonary Rehabilitation Prevention2011;31(2):125-32. [NCT00399919]">Hiatt 2011</a>: no mention of important differences in side effects between 2 intervention arms: 70% of PLC participants and 68% of placebo participants experienced 1 or more AEs; AEs that affected more than 5% of participants in either group with a ratio &gt; 1.5 PLC vs placebo included nausea, diarrhea, bronchitis, and back pain </p> <p><a href="./references#CD010117-bbs2-0012" title="SignorelliSS , FatuzzoP , RapisardaF , NeriS , FerranteM , Oliveri ContiG , et al. A randomised, controlled clinical trial evaluating changes in therapeutic efficacy and oxidative parameters after treatment with propionyl-L-carnitine in patients with peripheral arterial disease requiring hemodialysis. Drugs and Aging2006;23(3):263-70. SignorelliSS , FatuzzoP , RapisardaF , NeriS , FerranteM , Oliveri ContiG , et al. Propionyl-L-carnitine therapy: effects on endothelin-1 and homocysteine levels in patients with peripheral arterial disease and end-stage renal disease. Kidney &amp; Blood Pressure Research2006;29(2):100-7. ">Signorelli 2006b</a>: no AEs </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1303</p> <p>(6 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p><b>moderate</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall, PLC appears to be a safe and well‐tolerated drug, as no significant differences with placebo can be found in studies with follow‐up from 6 months to 1 year </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ankle brachial index (ABI)</p> <p>Follow‐up: 4 months to 1 year</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Mean ABI in control group was ‐0.02</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>MD 0.09 higher<br/>(0.08 higher to 0.09 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>369<br/>(4 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p><b>moderate</b><sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>ABI:</b> ankle brachial index; <b>ACD:</b> absolute claudication distance; <b>AE:</b> adverse event; <b>CI:</b> confidence interval; <b>COT:</b> claudication onset time; <b>ICD:</b> initial claudication distance; <b>MD:</b> mean difference; <b>MWD:</b> maximum waking distance; <b>PFWD:</b> pain‐free walking distance; <b>PLC:</b> propionyl‐L‐carnitine; <b>PWT:</b> peak walking time; <b>QoL:</b> quality of life. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by one level due to high heterogeneity between studies. Furthermore, the overall estimate of effect reflects mainly results of the studies of Brevetti (largest numbers of participants); however in these studies, subgroups were not reported (?publication bias) and there was a marked center effect. Overall results were relatively consistent among studies. The same remarks apply for all outcomes.<br/><sup>b</sup>Downgraded by one level because this was investigated in only one study.<br/><sup>c</sup>Downgraded by two levels because this outcome was investigated in only one study and the absolute number of events in this study was low.<br/><sup>d</sup>Downgraded by one level because causal relationship of different adverse events was not fully explained.<br/><sup>e</sup>Downgraded by one level because this outcome was investigated in a small number of studies (four studies). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Propionyl‐L‐carnitine compared to placebo for intermittent claudication</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/full#CD010117-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010117-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Propionyl‐L‐carnitine compared to L‐carnitine for intermittent claudication</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Propionyl‐L‐carnitine compared to L‐carnitine for intermittent claudication</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with intermittent claudication<br/><b>Setting:</b> outpatient setting<br/><b>Intervention:</b> propionyl‐L‐carnitine<br/><b>Comparison:</b> L‐carnitine </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with L‐carnitine</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with propionyl‐L‐carnitine</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute claudication distance (in meters)</p> <p>Follow‐up: 4 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean ACD in control group was 36.00 m</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 20 m higher<br/>(0.47 higher to 39.53 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Initial claudication distance (in meters)</p> <p>Follow‐up: 4 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean ICD in control group was 23.00 m</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 4 m higher<br/>(9.86 lower to 17.86 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>See comments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The single included study in this comparison did not report this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Progression of disease (to Fontaine stage III or IV or necessity for intervention (endovascular or surgery)) </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>See comments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The single included study in this comparison did not report this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Side effects of propionyl‐L‐carnitine regimen</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>See comments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The single included study in this comparison did not report this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ankle brachial index</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>See comments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The single included study in this comparison did not report this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>ACD:</b> absolute claudication distance; <b>CI:</b> confidence interval; <b>ICD:</b> initial claudication distance; <b>MD:</b> mean difference. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by two levels because results are based on a single study with borderline or no statistically significant results. Moreover, this study is a cross‐over study with few participants and limited follow‐up time (four days), as well as several risk of bias issues. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Propionyl‐L‐carnitine compared to L‐carnitine for intermittent claudication</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/full#CD010117-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010117-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Propionyl‐L‐carnitine versus placebo or control</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Absolute claudication distance (MWD + PWT) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>50.86 [50.34, 51.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 ACD (odds ratio) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [0.23, 0.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Maximal walking distance (MWD) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>692</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>50.43 [49.91, 50.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Peak walking time (PWT) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>429</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>84.04 [79.57, 88.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 ACD without Brevetti 1995 (sensitivity analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>907</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>55.90 [54.85, 56.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Initial claudication distance (PFWD + COT) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>32.98 [32.60, 33.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 ICD (odds ratio) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.28, 0.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.1 Mixed group of diabetic and non‐diabetic patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1058</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.26, 0.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.2 Diabetic patients only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.39, 0.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Pain‐free walking distance (PFWD) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>722</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>33.19 [32.80, 33.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Claudication onset time (COT) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>429</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>27.76 [25.05, 30.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 ICD without Brevetti 1995 (sensitivity analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>937</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>39.24 [38.52, 39.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Quality of life (QoL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.12 Ankle brachial index (ABI) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>369</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [0.08, 0.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Propionyl‐L‐carnitine versus placebo or control</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/references#CD010117-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010117-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Propionyl‐L‐carnitine versus L‐carnitine</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Maximal walking distance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Initial claudication distance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Propionyl‐L‐carnitine versus L‐carnitine</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010117.pub2/references#CD010117-tbl-0004">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD010117.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD010117-note-0010">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD010117-note-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD010117-note-0008">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD010117-note-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD010117-note-0005">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD010117-note-0006">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010117\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010117\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010117\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010117\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010117\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010117\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010117\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010117\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010117\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010117\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010117\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010117\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010117\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010117\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010117\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010117\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010117\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010117\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=afU96cMv&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010117.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010117.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD010117.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD010117.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010117.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740715729456"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010117.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740715729460"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010117.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d8e2fef52f55f',t:'MTc0MDcxNTczMC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 